1
Status: Approved ,  Date: 14February 2018Janssen Research & Development*
Clinical Protocol
A Phase 3, Randomized, Controlled, Open- label Study of VELCADE (Bortezomib) 
Melphalan -Prednisone (VMP) Compared to Daratumumab in Combination with VMP 
(D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are I neligible for 
High -dose Therapy
Protocol 54767414MMY3007; Phase 3
Amendment 5
JNJ-54767414   Daratumumab
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Produ cts, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen 
Sciences Ireland UC ;or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact Information 
page that accompanies the protocol.
EudraCT NUMBER: 2014 -002272 -88
Status: Approved
Date: 14 February 2018
Prepared by: Janssen Research & Development, LLC
EDMS number: EDMS- ERI-83878417, 10.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed 
by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
2
Approved , Date: 14 February 2018TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 5
LIST OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 6
PROTOCOL A MENDMENTS ....................................................................................................................... 7
SYNOPSIS .................................................................................................................................................. 28
TIME AND EVENTS SCHE DULE .............................................................................................................. 34
TIME AND EVENTS SCHE DULE FOR STUDY TREAT MENT, CYCLE 1 (VMP TREA TMENT 
PHASE)....................................................................................................................................................... 37
TIME AND EVENTS SCHE DULE FOR STUDY TREAT MENT, CYCLE 2 TO 9 (VMP 
TREA TMENT PHA SE)............................................................................................................................... 38
TIME AND EVENTS SCHE DULE FOR STUDY TREAT MENT, CYCLE 10+ (D ARA 
TREA TMENT PHA SE, A RMB ONLY) ...................................................................................................... 40
ABBREVIA TIONS ...................................................................................................................................... 41
1. INTRODUCTION ................................................................................................................................ 43
1.1. Background .................................................................................................................................... 43
1.1.1. Multiple Myeloma ........................................................................................................................ 43
1.1.2. Treatment Options for Multiple Myeloma .................................................................................... 43
1.1.3. Transplant -ineligible Population ................................................................................................ .44
1.1.4. Treatment Until Progression in Transplant -ineligible Patients .................................................... 44
1.2. Daratumumab ................................................................................................................................ 45
1.2.1. Nonclinical Studies ..................................................................................................................... 45
1.2.2. Clinical Studies ........................................................................................................................... 47
1.2.2.1. Single -Agent Daratumumab Studies (GEN501 and MMY2002) ............................................. 47
1.2.2.2. Combination Daratumumab Studies ....................................................................................... 48
1.3. Overall Rationale for the Study ...................................................................................................... 50
2. OBJECTIVES A ND HYPOTHESIS ................................................................................................... 51
2.1. Objectives ...................................................................................................................................... 51
2.2. Hypothesis ..................................................................................................................................... 51
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .52
3.1. Overview of Study Design .............................................................................................................. 52
3.2. Study Design Rationale .................................................................................................................. 54
4. SUBJECT POPUL ATION.................................................................................................................. 58
4.1. Inclusion Criteria ............................................................................................................................ 58
4.2. Exclusion Criteria ........................................................................................................................... 60
4.3. Prohibitions and Restrictions ......................................................................................................... 63
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 63
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 64
6.1. Daratumumab (Arm B Only) .......................................................................................................... 65
6.1.1. Daratumumab Preparation ......................................................................................................... 65
6.1.2. Daratumumab Administrati on..................................................................................................... 65
6.1.3. Guidelines for Prevention of Infusion Reactions ........................................................................ 66
6.1.3.1. Pre-infusion Medication ........................................................................................................... 66
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
3
Approved , Date: 14 February 20186.1.3.2. Post- Infusion Medication ......................................................................................................... 66
6.1.4. Management of Infusion -related Reactions ................................................................................ 67
6.1.4.1. Infusion -Related Events of Grade 1 or Grade 2 ...................................................................... 67
6.1.4.2. Infusion -Related Reactions of Grade 3 or Higher ................................................................... 68
6.2. VELCADE, Melphalan, and Prednisone (Arm A and Arm B) ......................................................... 68
6.2.1. Dose Calculation of VELCADE, Melphalan, and Prednisone ..................................................... 68
6.2.2. VELCADE Administration ........................................................................................................... 68
6.2.3. Melphalan and Prednisone Administration ................................................................................. 69
6.3. Dose Delay s and Dose Modification .............................................................................................. 69
6.3.1. Daratumumab Dose Modification ............................................................................................... 69
6.3.1.1. Daratumumab -Related Toxicity Management ......................................................................... 70
6.3.1.2. Daratumumab Interruption or Missed Doses ........................................................................... 71
6.3.2. Dose Reductions (VELCADE, Melphalan, a nd Prednisone) ...................................................... 71
6.3.3. Dose Modification Guidelines for VELCADE, Melphalan, and Prednisone Related 
Toxicities ..................................................................................................................................... 71
7. TREA TMENT COMPLIA NCE ............................................................................................................ 77
8. CONCOMIT ANT THERA PY.............................................................................................................. 77
8.1. Recommended Therapies .............................................................................................................. 77
8.1.1. Bisphosphonate Therapy ............................................................................................................ 77
8.1.2. Therapy for Tumor Ly sis Syndrome ........................................................................................... 77
8.1.3. Prophylaxis for Pneumocy stis carinii .......................................................................................... 78
8.1.4. Prophylaxis for Herpes Zoster Reactivation ............................................................................... 78
8.1.5. Prevention of Hemorrhagic Cystitis ............................................................................................ 78
8.2. Permitted Therapies ....................................................................................................................... 78
8.3. Prohibited Therapies ...................................................................................................................... 78
8.4. Subsequent Therapies ................................................................................................................... 79
9. STUDY EVA LUATIONS .................................................................................................................... 80
9.1. Study Procedures ........................................................................................................................... 80
9.1.1. Overview ..................................................................................................................................... 80
9.1.2. Screening Phase ........................................................................................................................ 80
9.1.3. Treatment Phase ........................................................................................................................ 81
9.1.4. Follow -up Phase ......................................................................................................................... 82
9.1.5. Assessments Following the Positive Second Interim Analysis of PFS ...................................... 82
9.1.6. Assessments Following the OS I nterim Analysis ....................................................................... 83
9.2. Efficacy ........................................................................................................................................... 83
9.2.1. Evaluations ................................................................................................................................ .83
9.2.1.1. Response Categories .............................................................................................................. 83
9.2.1.2. Myeloma Protein Measurements in Serum and Urine ............................................................ 86
9.2.1.3. Serum Calcium Corrected for Albumin .................................................................................... 87
9.2.1.4. β2-microglobulin and Albumin ................................................................................................ .87
9.2.1.5. Bone Marrow Examination ...................................................................................................... 87
9.2.1.6. Minimal Residual Disease Assessment .................................................................................. 89
9.2.1.7. Assessment of Lytic Disease ................................................................................................... 89
9.2.1.8. Documentation of Extramedullar y Plasmacy tomas ................................................................ .89
9.2.2. Endpoints .................................................................................................................................... 90
9.3. Pharmacokinetics and Immunogenicity ......................................................................................... 92
9.3.1. Evaluations ................................................................................................................................ .92
9.3.2. Analytical Procedures ................................................................................................................. 92
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 92
9.3.4. Immunogenicity Assessments (Antibodies to daratumumab) .................................................... 93
9.4. Pharmacokinetic/Pharmacodynamic Evaluations .......................................................................... 93
9.5. Biom arkers ..................................................................................................................................... 93
9.6. Patient- reported Outcomes ............................................................................................................ 94
9.7. Medical Resource Utilization .......................................................................................................... 95
9.8. Safety Evaluations ......................................................................................................................... 95
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
4
Approved , Date: 14 February 20189.9. Sample Collection and Handling .................................................................................................... 98
10. SUBJECT COMPLETION/W ITHDRA WAL....................................................................................... 98
10.1. Completion ..................................................................................................................................... 98
10.2. Discontinuation of Study Treatment ............................................................................................... 99
10.3. Withdrawal From the Study .......................................................................................................... 100
11. STATISTICA L METHODS ............................................................................................................... 100
11.1. Subject Information ...................................................................................................................... 100
11.2. Sample Size Determination ......................................................................................................... 101
11.3. Efficacy  Analyses ......................................................................................................................... 101
11.4. Pharmacokinetic Analy ses........................................................................................................... 102
11.5. Immunogenicity Analyses ............................................................................................................ 102
11.6. Pharmacokinetic/Pharmacodynamic Analyses ............................................................................ 102
11.7. Biom arker Analyses ..................................................................................................................... 102
11.8. Patient- reported Outcomes .......................................................................................................... 103
11.9. Safety Analyses ........................................................................................................................... 103
11.10. Interim Analysis ............................................................................................................................ 104
11.11. Data Monitoring Committee ......................................................................................................... 105
12. ADVERSE EVENT REPORT ING.................................................................................................... 105
12.1. Definitions .................................................................................................................................... 105
12.1.1. Adverse Event Definitions and Classifications ......................................................................... 105
12.1.2. Attribution Definitions ................................................................................................................ 106
12.1.3. Severity Criteria ........................................................................................................................ 107
12.2. Special Reporting Situations ........................................................................................................ 107
12.3. Procedures ................................................................................................................................... 108
12.3.1. All Adverse Events .................................................................................................................... 108
12.3.2. Serious Adverse Events ........................................................................................................... 109
12.3.3. Pregnancy ................................................................................................................................ .110
12.4. Reporting, Monitoring, and Review of Safety Events in Japanese Subjects in Arm B 
(Japanese Sites Only) .................................................................................................................. 110
12.5. Contacting Sponsor Regarding Safety ......................................................................................... 111
13. PRODUCT QUA LITY COMP LAINT HA NDLING ............................................................................ 111
13.1. Procedures ................................................................................................................................... 111
13.2. Contacting Sponsor Regarding Product Quality .......................................................................... 111
14. STUDY DRUG INFORM ATION....................................................................................................... 111
14.1. Physical Description of Study Drug .............................................................................................. 111
14.2. Packaging .................................................................................................................................... 111
14.3. Labeling ........................................................................................................................................ 112
14.4. Preparation, Handling, and Storage ............................................................................................. 112
14.5. Drug Accountability ...................................................................................................................... 112
15. STUDY -SPECIFIC M ATERIA LS..................................................................................................... 112
16. ETHICA L ASPECTS ....................................................................................................................... 113
16.1. Study-Specific Design Considerations ......................................................................................... 113
16.2. Regulatory Ethics Compliance ..................................................................................................... 114
16.2.1. Investigator Responsibilities ..................................................................................................... 114
16.2.2. Independent Ethics Committee or Institutional Review Board ................................................. 114
16.2.3. Informed Consent ..................................................................................................................... 115
16.2.4. Privacy of Personal Data .......................................................................................................... 116
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 117
16.2.6. Countr y Selection ..................................................................................................................... 117
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 117
17.1. Protocol Amendments .................................................................................................................. 117
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
5
Approved , Date: 14 February 201817.2. Regulatory Documentation .......................................................................................................... 118
17.2.1. Regulatory Approval/Notification .............................................................................................. 118
17.2.2. Required Pre -Study Documentation ......................................................................................... 118
17.3. Subject Identif ication, Enrollment, and Screening Logs .............................................................. 119
17.4. Source Documentation ................................................................................................................. 119
17.5. Case Report Form Completion .................................................................................................... 120
17.6. Data Quality Assurance/Quality Control ...................................................................................... 121
17.7. Record Retention ......................................................................................................................... 121
17.8. Monitoring .................................................................................................................................... 122
17.9. Study Com pletion/Termination ..................................................................................................... 122
17.9.1. Study Com pletion ..................................................................................................................... 122
17.9.2. Study Termination ..................................................................................................................... 122
17.10. On-Site Audits .............................................................................................................................. 123
17.11. Use of Information and Publication .............................................................................................. 123
REFERENCES .......................................................................................................................................... 125
INVESTIGA TOR A GREEME NT............................................................................................................... 141
LIST OF A TTACHMENTS
Attachment 1: Modified IM WGDiagnostic Criteria for Multiple Myeloma ........................................ 128
Attachment 2: ECOG Performance Status Scale ............................................................................ 129
Attachment 3: Serum Calcium Corrected for Albumin ..................................................................... 130
Attachment 4: Guideline for Asthma Eligibility Criteria .................................................................... 131
Attachment 5: Antihistamine Medications ........................................................................................ 135
Attachment 6: Conversion Table for Glucocorticosteroid Dose ....................................................... 136
Attachment 7: Body Surface Area Nom ogram ................................................................................ 137
Attachment 8: Reporting, Monitoring, and Evaluating Safety Events in Japanese Subjects in 
Arm B (Japanese Sites Only) ................................................................................... 138
Attachment 9: International Staging System (ISS) Staging ............................................................. 139
Attachment 10: Anticipated Adverse Ev ents...................................................................................... 140
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
6
Approved , Date: 14 February 2018LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Daratumumab Single -Agent Studies GEN501 and MMY2002 ................................................. 48
Table 2: Daratumumab Combination Studies GEN503 and MMY1001 ................................................. 49
Table 3: Complete responses, prog ression -free survival and peripheral neuropathy in all 
patients and in those who received weekly infusion of VELCADE ........................................... 55
Table 4: Daratumumab -Related Toxicity Manag ement .......................................................................... 70
Table 5: Dose Reduction for VELCADE ................................................................................................ .71
Table 6: Dose Reduction for Melphalan ................................................................................................ .71
Table 7: Dose Reduction for Prednisone ................................................................................................ 71
Table 8: Dose modification Guidelines for VELCADE, Melphalan, and Prednisone .............................. 72
Table 9: International Uniform Response Criteria Consensus Recommendations ................................ 85
Table 10: Bone Marrow Testing ................................................................................................................ 88
FIGURES
Figure 1: Daratumumab -Enhanced Multiple Myeloma Cell Killing by Key Multiple Myeloma 
Chemotherapeutic Agents ........................................................................................................ 46
Figure 2: Dose -dependent Lysis of Multiple Myeloma cells in Triple Chemotherapy Treatments ........... 47
Figure 3: Schematic Overview of the Study ............................................................................................. 52
Figure 4: Daratumumab Maximal Target Suppression ............................................................................ 57
Figure 5: Study Treatment Administration ............................................................................................... 65
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
7
Approved , Date: 14 February 2018PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 26 June 2014
Amendment 1 24 November 2014
Amendment 2 05November 2015
Amendment 3 26July 2016
Amendment 4 11 November 2016
Amendment 5 14February 2018
Amendments are listed beginning with the most recent amendment.
Amendment 5 (14February 2018 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: Based on the Independent Data Monitoring Committee (IDMC)
recommendation following review of data from the second i nterim analysis, the study is being amended to allow  
subjects in Arm A ( VELCADE [bortezomib] -melphalan -prednisone [VMP] alone) access to daratumumab after
sponsor confirmat ion of disease progression (PD) per International Myeloma Working Group criteria.
Applicable Section(s) Description of Change(s)
Rationale: Subjects randomized to Arm A (VMP )who have sponsor -confirmed disease progression may have 
theoptiontoreceive daratumumab provided by the sponsor (in any subsequent line of therapy) if recommended 
by the investigator . Eligibility for and administration of daratumumab must be in accordance w ith local 
prescribing information and local regulations. 
8.4. Sub sequent 
TherapiesA new section has been added.
Rationale: To update statistical text following positive findings for the second i nterim analysis.
Synopsis, Overview 
of Study Design;
Synopsis, Statistical 
Methods;
3.1. Overview  of 
Study Design;
9.2.2. EndpointsDetails of IDMC reviews have been removed from the Synopsis, Overview of Study 
Design.
Details of IDMC reviews , the 2 planned interim analyses, and the primary 
progression -free survival ( PFS)analysis have been incorporated w ithin the Synopsis, 
Statistical Methods.
It is explained that the interim PFS analysis will function as the primary analysis of this 
endpoint, as the superiority of daratumumab plus VMP (D-VMP )over VMP alone is 
established at the second interim analysis.
Synopsis, Overview 
of Study Design;
Synopsis, Statistical 
Methods;
Time and Events 
Schedule;
3.1. Overview  of 
Study DesignRemoved text which referred to reduced data collection as described in Section 9.1.4. 
Where appropriate, added references to subject monitoring as described in the ne w 
Sections 9.1.5 (follow ing positive second interim analysis of PFS) and 9.1.6 (following 
overall survival [ OS]interim analysis).
Synopsis, Overview 
of Study Design ;
3.1. Overview  of 
Study DesignAdded a statement that a sthe superiority of daratumumab combined with VMP over 
VMP alone w ith respect to PFS w as established at the second interim analysis, the 
interim PFS analysis will serve as the primary PFS analysis.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
8
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Synopsis, Overview 
of Study Design;
3.1. Overview  of 
Study Design; 
11.10. Interim 
AnalysisDescribed that an interim analysis of OS is now planned to be conducted when 
200deaths (60% of all planned events) have been accumulated , withthe final analysis of 
OS to be conducted when 330 deaths are accumulated.
Time and Events 
Schedule;
9.2.2. EndpointsRemoved text which referred to disease evaluations not being required after the clinical 
cutoff date.
9.1.4. Follow -up 
PhaseRemoved the following text:
A clinical cut -off will be established after the primary PFS analysis (360 PFS 
events). Following the clinical cut -off date, disease assessments will no longer be 
required and data collection will be limited to the following:
•For subjects still receiving study treatment: study treatment administration, AEs, 
SAEs, laboratory data associated w ith SAEs
•For all subjects: all subsequent anticancer treatment, PFS2 (per investigator 
judgment), second primary malignancies, and survival follow -up
9.1.5. Assessments 
Follow ing the 
Positive Second 
Interim Analysis of 
PFSA new section has been added.
9.1.6. Assessments 
Follow ing the OS 
Interim AnalysisA new section has been added.
11.3. Efficacy 
AnalysesDescribed that the analysis of OS may be confounded by subjects from Arm A receiving 
daratumumab after their study treatment was stopped . Exploratory analysis may be 
performed to adjust for the effect daratumumab exposure may have on OS for the 
subjects who w ere randomized to Arm A (VMP) .
11.3. Efficacy 
AnalysesText describing secondary endpoints was revised to align with the secondary endpoints 
which were planned to be sequentially tested at the second interim analysis.
Rationale: To clarify/emphasize the requirement to wait unti l confirmed PDprior to starting subsequent 
anti-myeloma therapy.
Synopsis, Overview 
of Study Design ;
3.1. Overview  of 
Study DesignIt is emphasized that for both Arm A (VMP) and Arm B (D -VMP), subjects entering the 
Follow -up Phase ‘should not be started on subsequent anti -myeloma therapy without 
confirmed disease progression’.
8.3. Prohibited 
TherapiesClarified that the prohibition on concomitant administration of any other antineoplastic 
therapy for the intention of treating multiple myeloma applies pr ior to confirmation of 
disease progression.
Synopsis, Overview 
of Study Design;
3.1. Overview  of 
Study Design;
9.1.4. Follow -up 
Phase;
9.2.1.1. Response 
CategoriesCross -references to the new Section 8.4 Subsequent Therapies have been added.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
9
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Clarification of the IDMC’s role in data review following database lock for the primary analysis.
Synopsis, Statistical 
Methods;
3.1. Overview  of 
Study Design ;
11.11. Data 
Monitoring 
CommitteeIt is noted that the IDMC will no longer revie w study data af ter the database lock for the 
primary analysis has been completed.
Rationale: To clarify the daratumumab pharmacokinetics (PK) and immunogenicity assessments specific to Arm 
B (D -VMP).
Synopsis, 
Pharm acokinetic and 
Immunogenicity 
Evaluations;
9.3.1. Evaluations;
9.3.4. 
Immunogenicity 
Assessments
(Antibodies to 
daratumumab)Added text stating that in the Follow -up Phase, for all subjects in Arm B (D- VMP), 
samples for PK and immunogenicity assessments are to be collected 8 w eeks after the 
last dose of d aratumumab, regardless of whether there has been confirmed disease 
progression.
Time and Events 
ScheduleWithin the rows describing daratumumab PK and immunogenicity assessments, the 
‘Prior to PD’ and ‘After PD’ cells under Follow -up Phase have been merged. Samples 
are to be collected 8 w eeks after the last dose of daratumumab, regardless of whether 
there has been confirmed disease progression.
Within the rows describing daratumumab PK and immunogenicity assessments, text has 
been added to emphasize that these assessments apply only to subjects in Arm B .
Rationale: To clarify quantitative immunoglobulin (Ig)assessments.
Time and Events 
ScheduleWithin the quantitative Ig row, the ‘Cycle 10+’ text has been revised to replace ‘C12D1 
and every 3 cycles thereafter until PD’ with ‘every 4 months until PD’. It is emphasized 
that assessments of quantitative Ig for Cycle 10+ apply to Arm B (D -VMP) only. Within 
this same row, within the Follow -up Phase/Prior to PD cell, the following text has been 
added : ‘Every 3 months in Year 1, then every 4 months after Year 1 until PD’.
Rationale: To clarify that Eastern Cooperative Oncology Group (ECOG) and patient -reported outcomes (PRO) 
assessments that occur at Week 8 and Week 16 post -PD should be scheduled rela tive to the date of confirmation 
of disease progression.
9.1.4. Follow -up 
PhaseText in bold has been added: ‘Every 16 -week follow -up contacts , as well as Week 8 
post-PD and Week 16 post -PD ECOG and ePRO assessments, should be scheduled 
from the date of confirmed progression (ie, the date of the confirm atory laboratory 
assessment, not the date of confirm ation by the sponsor) .’
Rationale: Replaced time qualifier of ‘1 -3 weeks later’ because in urgent situations, a rep eat investigation may 
be needed sooner. ‘At least 1 day later’ is used to make clear that the confirmatory test cannot happen on the 
same day as the initial test.
9.2.1.2. Myeloma 
Protein 
Measurements in 
Serum and UrineText in strikethrough has been deleted, text in bold has been added: ‘Disease 
progression based on 1 of the laboratory tests alone must be confirmed by at least 1 a
repeat investigation performed at least 1 day 1 to 3 w eeks later’.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
10
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: To clarify that sites should continue to monitor extramedullary plasmacytomas for PD follow ing 
complete response (CR) .
9.2.1.8. 
Documentation of 
Extramedullary 
PlasmacytomasText in strikethrough has been deleted: ‘Assessment of measurable sites of 
extramedullary disease will be performed and evaluated locally every 6 w eeks (by 
physical examination) or every 12 w eeks by imaging (if required) for subjects with a 
history of plasmacytomas or as clini cally  indicated during treatment for other subjects, 
until development of confirmed CR or confirmed disease progression.’
Rationale: To clarify required chemistry assessments at End -of-Treatm ent.
9.8. Safety 
EvaluationsText in bold has been added: ‘Screening ,Cycles 1 -9 and E nd-of-Treatm ent’
Rationale: To clarify definitions for study end.
10.1. Completion Text added that the study end is defined as when 330 deaths have occurred or 5 years 
after the last subject is randomized, w hichever comes first .
Rationale: To clarify definitions for completion of treatment.
10.1. Completion Separate definitions are provided for treatment completion for Arm A (VMP) and Arm 
B (D -VMP).
Rationale: Alignment of text with recent protocol template changes.
Title page Added ‘Janssen Pharmaceutica NV’ to the list of legal entities.
10.3. Withdraw al 
from the StudyRevised the text related to subjects w ithdraw ing from the study.
12.3.1. All Adverse 
EventsAdded a sentence related to sponsor's responsibility for reporting anticipated events.
12.3.3. Pregnancy Deleted text related to the unknown effect of study drug on sperm, and consolidated to a 
single paragraph the guidance for all initial reports of pregnancy in female subjects or 
partners of male subjects.
17.3. Subject 
Identification ,
Enrollment, and 
Screening LogsAdded ‘(as allowed by local regulations)’ following 2 instances of ‘date of birth’.
17.11. Use of 
Information and 
PublicationAdded the text in bold: ‘key assessment parameters of the study will be used to 
determine a coordinating investigator for the study’ .
Changed the time for submitting combined results from the completed study for 
publication from ‘within 12 months of the availab ility of the final data (tables, listings, 
graphs)’ to ‘within 18months after study end date’ .
Revised the text beginning ‘Authorship of publications...’
Abbreviations ICMJE has been added to the list of abbreviations.
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Throughout the 
protocol‘anticancer’ has been replaced w ith ‘anti -myeloma’
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
11
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
6.3.1.1. 
Daratumumab -
Related Toxicity 
ManagementAdded ‘other’ to describe ‘components of the chemotherapy regimen’.
9.2.1.5. Bone Marrow  
Examination, 
Table 10 Bone 
Marrow  TestingWithin the cell that describes local testing for CR, stringent CR (sCR), the text in bold
has been added, to clarify that a separate biopsy is not needed: ‘If sCR is not met, repeat 
local testing for sCR with subsequent bone marrow  examinations will be done at the 
time of the next protocol -required bone marrow examination ’.
10.3. Withdraw al 
from the Study‘When a subject withdraws b efore completing the study’ has been revised to ‘ When a 
subject w ithdraws from the study’.
Amendment 4 (11 November 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union .
The overall reason for the amendment: The International Myeloma Working Group (IMWG) has recently defined 
new categories of MRD– negativity and has clarified several aspects of disease response assessment along with 
clinical trial endpoints (Kumar, 2016). In order for Protocol MMY3007 to be aligned with the new categories of 
MRD -negativity, the time points for collection of bone marrow  for MRD assessment must b e revised.
Applicable Section(s) Description of Change(s)
Rationale: Addition of Kumar 2016 reference to support IMWG recommendations for multiple myeloma treatment 
response criteria.
Amendment table ; 
9.2.1.1 Response 
Categories; 
References Reference added to Amendment table, Section 9.2.1.1, and References
Rationale: Clarification of the minimal residual disease ( MRD) secondary objective for cross protocol consistency. 
Synopsis, Secondary 
Objectives; 2.1 
Secondary ObjectivesText modified to clarify objective to be the assessment of MRD negativity rate. Text 
moved to clinical outcome objective and text noting time point of “after treatment” was 
deleted.
Rationale: Inclusion of objective “time to response” for cross -protocol consistency.
Synopsis, Secondary 
Objectives; 2.1 
Secondary Objectives“Time to response” included under clinical outcomes objective. 
Rationale: New  objective added to provide cross protocol consistency and to explore durability of MRD negativity .
Synopsis, Exploratory 
Objectives; 2.1 
Exploratory 
Objectives ; 9.2.2 
EndpointsExploratory objective added to assess durability of MRD negativity. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
12
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Whole blood samples for MRD assessment obtained with bone marrow  aspirates will no longer be 
collected. 
Synopsis, Overview 
of Study Design; 
Time and Event 
Schedule: Disease: 
Evaluations: Blood 
sample for MRD; 3.1 
Overvie w of Study 
Design ;9.2. 1.6 
Minimal Residual
Disease AssessmentText and requirement for whole blood samples to be obtained at 14, 20, and 26 months 
(+/-1 month) for MRD assessment deleted. 
Rationale: Revision of endpoint presentation for protocol consistency.
Synopsis, Efficacy 
Evaluation/Endpoints; 
9.2.2 EndpointsSecondary efficacy endpoint for sCR rate moved below  overall response rate endpoint. 
Rationale: Revision of the definition of MRD negativity required to align with IMWG.
Synopsis, Efficacy 
Evaluation/Endpoints; 
9.2.2 EndpointsText modified to define the MRD negativity rate as the proportion of subjects with 
negative MRD at any time point after the date of randomization. Text defining rate as 
measurement of subjects who achieve CR/sCR at 14, 20, and 26 months after first dose 
deleted.
Rationale: Text correction to include exploratory endpoints to align with exploratory endpoints in Section 9.2.2.
Synopsis, Efficacy 
Evaluation/EndpointsExploratory endpoints added to synopsis.
Rationale: Text correction to include a time to response secondary efficacy endpoint to align with secondary 
objectives.
Synopsis, Efficacy 
Evaluation/Endpoints; 
9.2.2 EndpointsTime to response, defined as the time betw een the randomization and the first efficacy 
evaluation that the subject has met all criteria for PR or better” included as secondary 
efficacy endpoint. 
Rationale: Clarification of use for collected w hole blood samples. 
Synopsis, Biomarker 
Evaluation; 9.5 
Biomarkers Text modified to indicate that whole blood samples will be collected to process to plasma 
and PBMCs. Text indicating use for assessment of MRD deleted. 
Rationale: Modification of disease evaluation prior to PD time points in the Follow -up Phase to align with 
evaluation time points in the Treatment Phase.
Time and Event s
Schedule: Follow -up 
PhaseEvery 4 -week designation for follow -up prior to PD deleted.
Rational e: Addition of ±2 weeks window  to allow for flexible scheduling for follow -up visits after PD. 
Time and Event s
Schedule: Follow -up 
PhaseVisit window  of ±2 weeks added to the every -16 w eek visit after PD in the Follow -up 
Phase.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
13
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Clarification of visit time points to e nsure consistent timing of assessments for both ECOG and ePRO.
Time and Events 
Schedule: ECOG, 
Disease Evaluations, 
PRO Text modified to define ‘every 3 months’ as ‘every 12 weeks’ in Year 1 and ‘every 
6months thereafter’ as ‘every 24 w eeks thereafter’.
Rationale: Reinstatement of the 2 -hour collection window  for the pre -infusion daratumumab PK sample for 
subjects in Arm B.
Time and Event s
Schedule: Laboratory 
Assessment: 
Daratumumab PKText added to clarify that collection of the pre -infusion daratumumab PK sample is 
allow ed up to 2 hours prior to the start of infusion.
Rationale: Align bone marrow aspirate/biopsy collection time points in the Time and Event sSchedule with new 
MRD guidelines and across darat umumab protocols.
Time and Event s
Schedule: Disease: 
Evaluations: Bone 
marrow  
aspirate/biopsyText modified to indicate that for subjects with CR/sCR, additional bone marrow samples 
will be obtained 12, 18, 24, and 30 months (+2 months) after first dose. Text added 
indicating information including time points located in Section 9.2.1.5 and Table 10 .
Rationale: Inclusion of antihistamine medication listing to align with daratumumab protocols.
Time and Event s
Schedule for Study 
Treatment, Cycle 1; 
Time and Event s
Schedule for Study 
Treatment, Cycles 2 -
9; Time and Event s
Schedule for Study 
Treatment, Cycle 
10+; 6.1.3.1 
Pre-infusion 
MedicationText indicating inclusion of new attachment included in Time and Event sSchedules and 
Section 6.1.3.1. Listing provided in Attachment 5. Previous Attachments 5 -8 renumbered 
throughou t protocol.
Rationale: Clarification that order of combination drug administration applies to subjects in Arm B only.
6 Dosage and 
AdministrationText added to clarify that the protocol -specified order of study drugs given in combination 
is applicable to subjects in Arm B only.
Rationale: Clarification that criteria required for VMP administration are applicable for Cycles 2 -9 only. Minor text 
modifications to align with VELCADE SmPC.
6 Dosage and 
AdministrationText added to clarify that criteria required for VMP administration are applicable for 
Cycles 2 -9 only. Text w ording “must” replaced w ith “should” for VELCADE SmPC 
alignment.
Rationale: Clarification that text within Table 4 is applicable to “within cycle” administration only. 
6.3.1.1 
Daratumumab -
Related Toxicity 
Management, Table 4Text added to clarify that the information for Table 4 “Daratumumab -Related Toxicity 
Management” is applicable to “within cycle” administration only and not Day 1. The dose 
on Day 1 can be delayed but may no t be skipped. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
14
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Clarification of VELCADE dose reduction. 
6.3.2 Dose 
Reductions 
(VELCADE, 
Melphalan, and 
Prednisone )Text added to clarify that VELCADE dose reduction is only required in cases of held 
doses due to VELCADE -related toxicity. 
Rationale: Clarification of text regarding re -escalation of melphalan after dose reduction post toxicity to align with 
melphalan dose -modification guidelines.
6.3.2 Dose 
Reductions 
(VELCADE, 
Melphalan, and 
Prednisone )Text added to indicate that re -escalation after dose reduction post toxicity is permitted for 
melphalan following recovery of renal function.
Rationale: Clarification of toxicity guidelines provided for the administration of VELCADE, Melphalan, and 
Predni sone.
6.3.3 Dose 
Modification 
Guidelines for 
VELCADE, 
Melphalan, and 
Prednisone Related 
Toxicities Text added to indicate that protocol provided management guidelines are applicable for 
toxicities deemed related to the administration of VELCADE, melphalan, and prednisone. 
Rationale:  Clarification of dose modification category for Grade 3 or Grade 4 neutropenia.
6.3.3 Dose 
Modification 
Guidelines for 
VELCADE, 
Melphalan, and 
Prednisone Related 
Toxicities, Table 8 
Hem atologicalText revised to emphasize that this dose modification is applicable to Grade 3 neutropenia 
with associated fever and to all Grade 4 neutropenia (w ith or w ithout associated fever).
Rationale: Dose modification for melphalan in the event of Grade 3 thromboc ytopenia should be implemented in 
the subsequent treatment cycle. 
6.3.3 Dose 
Modification 
Guidelines for 
VELCADE, 
Melphalan, and 
Prednisone Related 
Toxicities, Table 8 
Hem atologicalText indicating that reduction of melphalan by 1 dose -level for the remainder of the cycle 
has been deleted.
Rationale: Prophylaxis text revision to align with daratumumab label
8.1.4 Prophylaxis for 
Herpes Zoster 
ReactivationText providing detailed information on herpes zoster prophylaxis deleted. Prophylaxis 
recommended during Treatment Phase as per institutional guidelines. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
15
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Clarification of theuse of study drug during or after emergency orthopedic surgery or ra diotherapy.
8.3 Prohibited 
Therapies Text modified to indicate use of study drug or components of VMP regimen during or after 
emergency orthopedic surgery or radiotherapy are for conditions related to multiple 
myeloma. Text indicating “subject benefit” deleted.
Rationale: Clarification to provide additional scheduling flexibility for subject follow -up visits after PD and to 
clarify follow -up intervals for subjects not con tinuing disease evaluations after PD.
9.1.4 Follow -up 
PhaseTime points from T ime and Events schedule added.
Text added to expand the protocol -specified information collection period after PD to 
every 16 w eeks ( ±2 weeks). Clarification included indicating that in subjects not 
continuing disease evaluation, an every -16-week follow -up visit should be scheduled from 
the date of the End of Treatment visit.
Rationale: Highlight that i ncreases in serum free light chains or the FLC ratio alone do not meet IMWG criteria for 
progressive disease in patients w ith measurable disease by SPEP and/or UPEP at baseline.
9.2.1.1 Response 
Categories Text modified to indicate that for patients with measurable disease by SPEP and/or UPEP 
at baseline, increases in serum free light chains or the FLC ratio alone do not meet criteria 
for progressive disease.
Rationale: Inclusion of text for protocol consistency to Section 9.1.4 .
9.2.1.1 Response 
CategoriesText “lost to follow -up” included in 
“For subjects who discontinue study treatment before disease progression, disease 
evaluations should continue to be performed p er the Time and Events Schedule until 
confirmed disease progression, death, the start of a new treatment for multiple myeloma, 
withdrawal of consent for study participation, lost to follow -up,or the end of study, 
whichever occurs first” to be consistent w ith text in Section 9.1.4.
Rationale: Bone Marrow  Examination Table modified to align with new MRD guidelines and daratumumab 
protocols . 
9.2.1.5 Bone Marrow  
Examination, Table 
10Text modifications:
CR/sCR
Local testing: Text modified to indicate preference of 2- 4 color flow  cytom etry for 
detection of kappa/lambda ratio. Immunohistochemistry and immunofluorescence 
allow ed but a kappa/lambda ratio from ≥100 plasma cells required to confirm 
sCR. Subjects who a chieved CR but not sCR will have additional sCR 
evaluation sto coincide with MRD bone marrow time points until sCR is 
achieved. 
Central testing :For subjects with CR/sCR additional samples to be obtained at 12, 
18, 24, and 30 months after first dose. A wi ndow  of 2 m onths after the 12, 18, 24 
and 30 -month time points is allow ed.
Maintained CR/sCR :
Text deleted 
Disease Progression: 
Text modified to indicate that a bone marrow sample is requested from subjects in 
both treatment arms at disease progression to evaluate mechanism of resistance.
Rationale: Revision of time points for bone marrow  collection for MRD assessment.
9.2.1.6 Minimal 
Residual Disease 
AssessmentText indicating collection time points of baseline, CR confirmation, 14, 20 and 26 months 
(+/-1 month) deleted. Please see Table 10 for updated time points.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
16
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Clarification of collection points for the Serum Chemistry Panel.
9.8 Safety 
Evaluations: Clinical 
Laboratory TestsText added to indicate that the serum chemistry panel is to be obtained at Screening and 
Cycles 1 -9. Text added to clarify that sodium and potassium, added in Amendment 2, will 
be retrospectively evaluated from the date of subject consent if collected as part of routine 
care. Urea added to the serum chemistry panel for Cycles 10+. 
Rationale: Addition of Chapuy 2016 reference to support processes to eliminate daratumumab IAT interference .
9.8 Safety 
Evaluations :
Daratumumab 
Interference with 
Indirect Antiglobulin 
Test (IAT) Results;
ReferencesReference added to Section 9.8 and References
Rationale: Although vital signs are performed at multiple time points as specified in the Time and Events Schedule, 
only vital signs obtained at Screening or associated with an adverse event are captured in the eCRFs.
9.8 Safety 
Evaluations; 
References: Vital 
SignsText modified to indicate that only vital signs obtained at Screening or associated with an 
AE will be entered in the eCRF; all measurements will be recorded in the source 
documents.
Rationale: Clarification that subjects do not have to discontinue all components of the VMP regimen if only one 
component requires a third dose reduction for toxicity.
10.2 Discontinuation 
of Study TreatmentText modified to indicate that subjects do not have to discontinue all components of the 
VMP regimen if only one component requires a third dose reduction for toxicity. Bullet 
outlining discontinuation of study treatment if any component of VMP requires dose 
reduction for the third time deleted.
Rationale: Realignment of the testing order of the major secondary endpoints for the control of familywise type 1 
error during the second interim analysis.
11.3 Efficacy 
Analyses , Secondary 
Endpoints Text mo dification s
Major secondary endpoints revised as TTP, CR rate, MRD negativity rate, PFS2, 
and OS.
Secondary time to event efficacy endpoints: time to treatment added as endpoint .
Rationale: Changes from baseline cannot be summarized since vital signs are only captured in the eCRF at 
Screening and when associated w ith an adverse event .
11.9 Safety Analysis Text modified to indicate that descriptive statistics for baseline temperature, heart r ate, and 
blood pressure will be summarized. Text indicating providing changes from baseline for 
these parameters deleted.
Rationale: Inclusion of anticipated adverse events guidelines to align daratumumab protocols.
12.3.1 All Adverse 
Events; Attachment 
10Text added to Section 12.3.1 indicating inclusion of new attachment. New guidelines 
provided in Attachment 10. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
17
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Alignment of text with recent protocol template changes.
12.3.1 All Adverse 
EventsText modified to indicate that the sponsor w ill report incidences of suspected unexpected 
serious adverse events to the investigator. Text added to indicate that the sponsor will 
periodically evaluate the data independent of the investigator and w ill, in t he event of a 
drug-related serious anticipated event, submit appropriate documentation to the 
investigator. 
Rationale: Alignment of text with recent protocol template changes.
17.5 Case Report 
Form  Com pletionText specifying that all data related to the study must be recorded on eCRFs prepared by 
the sponsor w as deleted.
Rationale: Minor errors w ere noted .
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 3 (25 July 2016 )
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and th e Council of the European Union , in that it does not significantly 
impact the safety or physical/men tal integrity of subjects, nor th e scientific value of the study.
The overall reason for the amendment: The Safety Evaluations included in Protocol Amendment 2 (dated 
05Nov 2015) for the chemistry panel (ie, the analysis of sodium and potassium levels) will require the collection of 
results to be done retrospectively from the date of subject consent for the duration of the study, if collected as part of 
routine care. The baseline data, if available, are needed in order to effectively analyze safety with respect to changes 
in sodium/potassium levels while on treatment with respect to the investigational agent daratumumab in this 
combination with VMP in the frontline setting of treatment for multiple myeloma in an elderly population. This 
does not require any additional testing nor does it require a change to the Informed Consent Form or the request for 
additional consent from the subjects.
Applicable Section(s) Description of Change(s)
Rationale: This nonsubstantial amendment is required to include a clarification statement regarding collection of 
sodium and potassium . No changes to the text have been made .
Amendment 2(05November 2015 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: To provide updated guidance with respect to VELCADE dose 
modifications (per the Summary of Product Characteristics [SmPC] and United Sates Package Insert [USPI]) and to 
align with the VELCADE label regarding dose modifications, to incorporate investigator feedback into the protocol , 
and to revise operational asp ects of the study and provide clarifications on study procedures.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
18
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: To provide updated guidance with respect to VELCADE dose modifications (per SmPC and USPI) and 
to add a w indow  for w ithin-cycle VELCADE and daratumumab treatments for site and subject convenience
Time and Events 
Schedules for Study 
Treatment, Cycle 1
(VMP treatment 
Phase) and Cycle 2 to 
9(VMP Treatment 
Phase);
6.2.2 VELCADE 
AdministrationVELCADE doses should must be at least 72 hours apart. Doses that need to be w ithheld 
are skipped and w ill not be made up later in the cycle. Individual doses within a cycle 
have a ±1 day window. 
6 Dosage and 
Administration; 
9.1.3 Treatment PhaseText has been added or revised as follows:
Before initiating a new cycle of therapy, subjects m ust meet the following criteria:
•Platelet count ≥70 x 109/L
•ANC ≥1.0 x 109/L
•Non-hematological toxicities resolved to Grade 1 or baseline
The start of each cycle may occur within ±3 days of the scheduled day in order to 
accommodate the schedule of the site or subject. If the start of a cycle is del ayed, Day 1 
of subsequent cycles should be adjusted accordingly to maintain the 42 -day cycle 
duration. In Cycles 1 through 9, weekly or every -three- week daratumumab infusions 
may be given within ±1 day of the scheduled day in order to accommodate the 
sched ule of the site or subject. Additionally, weekly or twice weekly VELCADE doses 
may be given within ±1 day of the scheduled day in order to accommodate the 
schedule of the site or subject. Changes to within -cycle dosing should not impact 
Day 1 of the next c ycle. The start of each cycle should be scheduled relative to Cycle 1 
Day 1 and should not change if visits have shifted within the allow ed window.
6.3.2 Dose 
Reductions 
(VELCADE, 
Melphalan, and 
Prednisone)VELCADE will be reduced or discontinued according to the guidelines presented in 
Table 5. In addition to the VELCADE dose modification guidelines presented in 
Section 6.3.3, Table 8, if several VELCADE d oses in a cycle are withheld ( ≥3 doses 
during twice weekly adm inistration or ≥2 doses during weekly a dministration), 
VELCADE dose should be reduced by 1 dose level. Once reduced due to toxicity, 
doses of VELCADE, melphalan, or prednisone should not be re -escalated.
6.3.3 Dose 
Modification 
Guidelines for 
VELCADE, 
Melphalan, and 
Prednisone Moved all footnotes in Table 8 to the end of the table. 
Updated Table 8 to align with VELCADE SmPC and USPI.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
19
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale:   To allow  flexibility in the adm inistration of pre- infusion medications , to clarify allow able pre -infusion 
medications, and to be cons istent with other daratumumab protocols.
Time and Events 
Schedules for Study 
Treatment, Cycle 1
(VMP treatment 
Phase) and Cycle 2 to 
9(VMP Treatment 
Phase), and Cycle 
10+(Dara treatment 
Phase, Arm B only) Administer pre-infusion medications approximately 1 hour before daratumumab infusion . 
Pre-infusion medications given by mouth (PO) may be administered within 3 hours before 
the infusion.
Time and Events 
Schedules for Study 
Treatment, Cycle 1
(VMP treatment 
Phase) and Cycle 2 to 
9(VMP Treatment 
Phase); and Cycle 
10+(Dara treatment 
Phase, Arm B only) ;
6.1.3.1 Pre-infusion 
MedicationBecause it is acceptable to give dexamethasone PO or intravenously ( IV)regardless of 
availability of IV dexamethasone, text was revised for clarity : Dexam ethasone 20 mg IV 
or PO .
To specify that only equivalent H1 blockers are acceptable , clarified: An antihistamine 
(diphenhydramine 25 -50 mg IV or PO, or equivalent H1 blocker )
Time and Events 
Schedules for Study 
Treatment, Cycle 1
(VMP Treatment 
Phase);
6.1.3.1 Pre-infusion 
MedicationAdded allow ance of administration of leukotriene inhibitor, montelukast 10 mg PO or 
equivalent, at C1D1 approximately 1 hour or less before the daratumumab infusion.
6.1.3.2 Post -Infusion 
MedicationAdded leukotrien e inhibitor (montelukast or equivalent) as allow able post -infusion 
medication
Attach ment 5 
Conversion Table for 
Gluc ocorticosteroid 
DoseRevised table to rem ove hydrocortisone, as it’s a short acting corticosteroid and should not 
be used as a pre- infusion medication substitute for dexamethasone. Added the allow ance 
of bethamethasone (0.6 mg), which can be used as a s ubstitute for dexamethasone 
pre-infusion medication. 
Rationale: To provide additional guidance as to acceptable methods of bone marrow  preparation and indicate that 
flow cytometry is also an acceptable method of confirming multiple myeloma diagnosis.
Time and Events 
ScheduleFor screening (up to 42 days before random ization) fresh aspirate or biopsy preferred. If 
not available, obtain non -decalcified slides (bone m arrow aspirate, touch preparation 
or clot selection) or FFPE block (clot section only, no bone m arrow biopsy ).
9.2.1.5 Bone Marrow  
ExaminationUpdated Table 10 to provide additional guidance onthe acceptable methods of bone 
marrow  preparation .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
20
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: To clarify assessments and procedures, and timing thereof, and allow  flexibility, as applicable, for some 
assessments and procedures, in relation to S creening.
Time and Events 
Schedule ;
9.1.2 Screening 
Phase ;
9.2.1.8 
Documentation of 
Extramedullary 
PlasmacytomasDisease evaluations, including chest X -ray (or full chest CT scan), 12-lead ECG, lytic 
disease assessment, and extramedullary plasmacytomas are performed as part of SOC, are 
acceptable to be used for screening, as long as the assessments are done w ithin 42 days 
before randomization. 
For subjects w ith history of plasmacyto masassessed by physical exam, a repeat 
assessment should be performed on C1D1 if not done within 14 days prior to 
randomization
Time and Events 
Schedule12-lead ECG assessments can be performed within ±7 days of the planned assessment 
date.
Hem atology and chemistry values are acceptable for screening to meet CRAB criteria, if 
performed as part of SOC within 42 days before randomization but must be performed 
within 21 days before randomization for other eligibility requirements .  
Clarifi cation for an alysis of daratumumab PK. For Arm B only, on daratumumab infusion 
days, 1 sample is to be collected before the start of infusion, and 1 sample is to be 
collected after the end of infusion (up to 2 hours after the end of infusion).  
Clarified that for SPEP and IFE, 24 -hour UPEP and IFE; serum FLC; and calcium and 
albumin that the time frame is based on when the samples were collected, not w hen results 
were received.
Clarified timing of assessments for Quantitative Ig to indicate that during Cycles 1 -9, 
assessments are at C3D1, C5D1, C7D1, and C9D1.  For Cycles 10+, assessments are at 
C12D1 and every 3 cycles thereafter until PD. 
Rationale: Modified language and guidance pertaining to the indirect antiglobulin test (IAT) .
Time and Events 
ScheduleAdded text indicating that a wallet card is to be given to all subjects (in Arm A and in 
ArmB) at C1D1.
4.3 Prohibitions and 
RestrictionsRemoved the Blood Type IAT results language, as this is now limited to Section 9.8 Safety 
Evaluations.
9.8 Safety 
EvaluationsUpdated the daratumumab IAT results text to align with other daratumumab protocols. 
12.3.1 All Adverse 
EventsAdded text specifying that wallet cards must be carried for the duration of the study by 
subjects in Arm A and for at least 6 months after the study treatment is discontinued for 
subjects in Arm B.
Rationale: To clarify inclusion and exclusion criteria.
Synopsis, Subject 
Population; 
4.1 Inclusion Criteria, 
Criterion #2. 2Eligible subjects must satisfy the calcium elevation, renal insufficiency, anemia, and 
bone abnorm alities (CRAB) diagnostic criteria, monoclonal plasm a cells in the bone 
marrow ≥10% or presence of a biopsy proven plasm acytom as, and m easurable 
secretory disease ,as assessed by the central laboratory .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
21
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
4.2 Exclusion 
Criteria, Criterion 
12.2Because subjects w ith pacemakers, which is classified as NCI CTCAE Grade 3 atrial 
fibrillation, are eligible for the study, criterion was revised to clarify: “ Subjects are to be 
excluded if they have uncontrolled cardiac arrhythmia (NCI CTCAE Version 4 Grade ≥2 )
or clinically significant ECG abnormalities ”, because subjects with pacemakers, which is 
classified as NCI -CTCAE Grade 3 atrial fibrillation, are allowed to be enrolled in the 
study.
As the intent is to exclude any subjects with prolonged QT and not to have sites converting 
ECG output using different correction formulas, criterion was revised to state “screening 
12-lead ECG showing a baseline corrected QT interval as corrected by Fridericia’s 
formula (QTcF) (QTc) >470 msec .
Rationale: To align w ith updated Investigator’s Brochure (IB) and risk language wording, updated the timeframe 
associated with birth control use.
4.2 Exclusion 
Criteria ,Criterion 
#16.1Subject is a w oman who is pregnant, or breast -feeding, or planning to become pregnant 
while enrolled in this study or within 3 months 4 months after the last dose of any 
component of the treatment regimen. Or, subject is a man who plans to father a child while 
enrolled in this study or within 3 months 4 months after the last dose of any component of 
the treatment regimen.
4.3 Prohibitions and 
Restrictions, #1 and 
#21. For w omen of childbearing potential, adequate contraception as specified in Section 4.1 
must continue during the Treatment Phase, during any dose interruptions, and for 3 
months 4 months after the last dose of daratumumab. In addi tion, w omen must not donate 
ova during the study and for 3 months 4 months after the last dose of daratumumab.
2. A man who is sexually active with a w oman of childbearing potential must always use a 
latex or synthetic condom during the study and for 3 m onths 4 months after discontinuing 
daratumumab. All men must not donate sperm during the study and for 3 months
4months after the last dose of daratumumab. 
Rationale: Toclarify if assessments are to be analyzed by the local or central laboratory and to provide the 
reference for determination of ISS Stage .
Synopsis, Overview 
of the Study Design; 
Time and Events 
Schedule;
5 Treatment 
Allocation and 
Blinding; 
9.2.1.4 β2 
Microglobulin and 
AlbuminEligible subjects w ill be stratified by International Stagi ng System (I vs II vs III based on 
central laboratory results at Screening ).
Time and Events 
ScheduleIndirect Antiglobulin Test (IAT) isto be assessed locally .
Randomization based on SPEP and IFE and 24 -hour UPEP and IFE is based on central 
laboratory values . 
NewAttachment 8
International Staging 
System  (ISS) Staging
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
22
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: To update recommended and prohibited therapies.
8.1 Recommended 
TherapiesRemoved Section 8.1.1 Prevention of Deep Vein Thrombosis because none of the study 
treatments are associated with increased incidence of veno -thromboembolic disease.
8.1.1 Bisphosphonate 
TherapyAfter Cycle 1, investigators should not prescribe bisphosphonates to subjects who have not 
received them  before as this would be considered a s ign of disease progression , unless 
approved by the sponsor after confirm ing that the subject does not have disease 
progression at the tim e of bisphosphonate initiation .
8.3 Prohibited 
Therapies Nonsteroidal anti -inflammatory agents should be used with caution avoided in order to 
prevent myeloma -related kidney disease.
Rationale: To update serum chemistry panel assessments to allow urea to be performed instead of BUN as some 
centers do not assess BUN; to add sodium and potassium to the chemistry panel; and to clarify that direct bilirubin 
assessment is only necessary if total bilirubin is >1.5xULN.
9.8 Safety 
EvaluationsCycles 1 -9
Blood urea nitrogen (BUN) or urea
total bilirubin (direct bilirubin if total bilirubin >1.5xULN)
sodium
potassium
Cycle 10+
Sodium
Potassium
Rationale: Clarify procedure for management of infusion -related reactions.
6.1.4 Management of 
Infusion -related 
ReactionsSubjects in Arm B should be carefully observed during daratumumab infusions. Trained 
study staff at the clinic should be prepared to intervene in case of any infusion -related 
reactions occurring, and resources necessary for resuscitation (eg, agents such a s 
epinephrine and aerosolized bronchodilator, also medical equipment such as oxygen tanks, 
tracheostomy equipment, and a defibrillator) must be available at the bedside . Attention to 
staffing should be considered when multiple subjects will be dosed at the same time. 
If an infusion -related reaction develops, then the infusion should be temporarily 
interrupted or slow ed down .
If an infusion is paused or the infusion rate is decreased , then a longer -than-anticipated 
infusion time may occur.
Rationale: To align w ith updated protocol template language .
4 Subject Population Specified that “…the investigator must consult with the appropriate sponsor representative 
and resolve any issues before enrolling a subject in the study.  Waivers are not allowed.”
Rationale: Miscellaneous updates and clarifications made throughout the protocol. 
Synopsis, Objectives 
and Hypothesis;
2.1 Objectives;
9.2.2 EndpointsClarified that ORR includes all subjects with PR or better (not just those with CR and PR).
Synopsis, Objectives 
and Hypothesis;
2.1 ObjectivesClarified secondary objective as “very good partial response (VGPR) or better rate.
Synopsis, Overview 
of Study Design;
3.1 Overview  of 
Study DesignMeasures to prevent infusion -related reactions cytokine release syndrome will include...
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
23
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Synopsis, Overview 
of Study Design ;
3.1 Overview  of 
Study Design;
9.3.3 Pharmacokinetic 
ParametersBlood samples will be drawn for assessment of pharmacokinetic sand immunogenicity 
parameters .
Changes were made to further clarif y the pharmacokinetic data analysis plans .
Synopsis, Efficacy 
Evaluations and 
Endpoints;
9.2.1.2 Myeloma 
Protein Measurements 
in Serum and Urine;
9.2.2 EndpointsUpdated the DIRA interference language to specify “For those subjects with negative or 
low SPEP ( ≤0.2 g/L) and suspected daratumumab interference on immunofixation, a 
reflex assay using anti -idiotype antibody will be utilized…”
For subjects w ith suspected daratumumab interference on SPEP and/or serum IFE…
Time and Events 
Schedule ; 
9.8 Safety 
EvaluationsRemoved asthma as a condition for measurement of FEV1, as subjects with asthma are 
excluded from study participatio n. 
Time and Events 
ScheduleAdded that it is allowable to accept results of a FEV1 assessment that was done as part of 
SOC wit hin 42 days before randomization and not require repeat assessment within 
21days before randomization. Also, clarified the timing of the ECOG assessments in 
year 1.
Time and Events 
Schedules for Study 
Treatment, Cycle 1
(VMP treatment 
Phase) and Cycle 2 to 
9(VMP Treatment 
Phase)Clarified that hematology and chemistry assessments are required for subjects in both 
treatment arms. Testing may be performed for up to 2 days before other treatment days, 
and results of hematology tests must be evaluated before treatment. 
Vital signs assessments are required for subjects in both treatment arms; additional vital 
sign assessments before, during, and after the daratumumab infusion are required for 
subjects in Arm B only.
3.1 Overview  of 
Study DesignUpdated Figur e 3 to accurately reflect that in the Follow -up Phase, prior to PD, disease 
evaluations will be conducted as per the T&E schedule (rather than q4wks).
6.1.3.2 Post -Infusion 
MedicationControl medications for lung disease (eg, inhaled corticosteroids ± long -acting β2 
adrenergic receptor agonists for subjects w ith asthma; long -acting bronchodilators such as 
tiotropium or salmeterol salbutanol ± inhaled corticosteroids for subjects with COP D)
6.3.1.1 
Daratumumab -
Related Toxicity 
ManagementUpdated Table 4 to specifically refer to “Cycle 1” and “Cycle s 2-9”and delete “VMP” 
clarifier.
9.2.1.8 
Documentation of 
Extramedullary 
PlasmacytomasCorrect erroneous text to indicate that to quality fo r PR, the sum of products of the 
perpendicular diameters of the existing extramedullary plasmacytomas must have 
decreased by at least 50% or 25%, respectively, and new plasmacytomas must not have 
developed.
9.3.2 Analytical 
ProceduresDue to the evolving need for pharmacokinetic/immunogenicity data in this study to 
support daratumumab program decisions, it is not necessary to specif ybioanalysis timing 
in the protocol, so removed text describing the specific detailed timing of the bioanalysis.
12.3.1 All Adverse 
EventsReiterated statement that only clinically relevant laboratory abnormalities (ie, those 
causing a treatment intervention or need for concomitant therapy) should be recorded on 
the adverse event eCRF. All other laboratory abnormalities need no t be recorded as 
adverse events.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
24
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 1(24November 2014 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union .
The overall reason for the amendment: To incorporate investigator feedback into the protocol ,to further clarify 
MRD monitoring ,to clarify safety reporting requirements for sites in Japan , to incorporate updated IMWG criteria
Applicable Section(s) Description of Change(s)
Rationale: To align the definition of multiple myeloma with the updated IMWG criteria (Lancet Oncol 2014; 15: 
e538–48.
Attachment 1 Replaced contents of Attachment with new guidelines adapted from the newly published 
criteria
Rationale: To provide instructions for prevent ing interference of daratumumab in determining blood type for future 
transfusions .
Timeand Events 
Schedule , 
12.3.1 , All Adverse 
EventsBlood type and IAT results will be included on wallet card for subjects in Arm B.
4.3,Prohibitions
9.8, Safety 
EvaluationsAdded text to explain daratumumab interference and recommendations for which tests to 
perform.
Rationale: To clarify details of bone marrow collection for MRD monitoring.
Time and Events 
Schedule, 
9.2.1.5, Bone Marrow  
Examination
9.2.1.6 , MRD 
AssessmentClarified that a fresh bone marrow  aspirate or biopsy is preferred at screening, and a fresh 
aspirate or biopsy (or both) required t o confirm CR/sCR; changed timing of bone marrow  
sample and blood sample to 14, 20, and 26 months after first dose.
9.2.1.5 , Bone Marrow  
ExaminationRevised text and put it into table format.
Rationale: To clarify that the secondary objective and secondary endpoint is to assess the MRD negative rate
Synopsis, 
2.1, ObjectivesTo assess minimal residual disease (MRD) negative rate after treatment
Synopsis,
9.2.2, EndpointsAssess MRD negative rate, as measured in subjects who achieve CR/sCR, at 14, 20, and 
26 months after first dose .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
25
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: To clarify PRO and ECOG collection procedures
Time and Events 
ScheduleClarified that both PRO questionnaires and ECOG performance status must be 
administered and completed prior to any other study procedures or assessments for that 
study visit
Time and Events 
Schedule;
9.6,PRO 
15, Study -specific 
MaterialsAll PRO measures will be collected via an electronic device (ePRO ).
17.6, Data QA/QC PRO data w ill be transmitted to the ePRO vendor database and then to the sponsor’s 
database.
Rationale: Removed 2 -hr post infusion collection of vital signs on Cycle 1 Day 1, in absence of safety signal and in 
response to investigator request .  
Time and Events 
Schedule for Study 
Treatment, Cycle 1On Cycle 1 Day 1: immediately before the start of dara infusion; at 0.5, 1, 1.5, 2, 3.5 hr 
after start of infusion; at end of infusion; 0.5,1 , 2hr after end of infusion.
Rationale: Align inclusion criteria with other daratumumab protocols.
4.1, Inclusion Criteria #2: Added “without measurable disease in the serum or urine” to light chain myeloma
#5: Added cutoff for Gilbert syndrome “direct bilirubin ≤1.5xULN”
#5: Aligned creatinine clearance w ith ne w guidelines: “creatinine clearance ≥40 m L/min, 
may be calculated or measured according to local practice (if calculated, MDRD or 
CKD -EPIformulae preferred )”
#5: corrected serum calcium to “<= 14”mg/dL ( “<=3.5 ”mmo l/L); or free ionized calcium 
“<=6.5”mg/dL ( “<=1.6”mmol/L)
#7: changed screening pregnancy test to within 14 days prior to randomization
Rationale: Align exclusion criteria with other daratumumab protocols.
4.2, Exclusion 
Criteria
Attachment 4#9: revised entire criterion for subjects with COPD or asthma, and added asthma guidelines 
as Attachment 4
#10: rew rote criteria for hepatitis B and hepatitis C
#12: specified only subjects with uncontrolled cardiac arrhythmia should be excluded
#17: specified vertebroplasty not considered to be major surgery
Rationale: Improve instructions for pre -infusion medications
6.1.3.1 , Pre-infusion 
Medicationspecified administration “approximately” 1 hour before daratumumab infusion, deleted 
infusion of antihistamine 12 hours before first daratumumab infusion on C1D1, clarified 
that dexamethasone PO is only if IV not available
Rationale: Provide examples of subjects at higher risk of respiratory complications for post -infusion medications.
6.1.3.2 , Post -Infusi on 
MedicationSpecified subjects w ith higher risk of respiratory complications (eg, subjects with m ild 
asthm a, or subjects with COPD
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
26
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
Rationale: Improve guidelines for delay of daratumumab infusions
6.3.1.1 , Daratumumab 
Toxicity Managem entTo emphasize the criteria when to stop daratumumab, bolded and underlined the following 
sentence: ONLY if any of the following criteria are m et, and the event cannot be 
ascribed to components of the chem otherapy regimen , the daratum umab infusion 
must be he ld to allow for recovery from  toxicity
The follow ing changes were made to the criteria for dose delay to:
Added: Grade 4 hematologic toxicity 
Revised: Febrile neutropenia
Rationale: Clarify criteria for discontinuation of treatment after Cycle 9 due to dose delays.
6.3.1.1, Daratumumab 
Toxicity Managem ent 
6.3.1.2, Daratumumab 
Interruption
10.2, Discontinuation 
of TreatmentAdded w ording that, after Cycle 9, if a subject misses 2 consecutive planned doses (rather 
than 4 weeks) then treatment should be discontinued.
Rationale: To allow  prednisolone to substitute for prednisone in countries where prednisone is not available.
6.2.3 , Melphalan and 
Prednisone Adm inPrednisolone may be substituted for prednisone in countries where prednisone is not 
available.
Rationale: Updated investigational product characteristics and handling according to ne w guidelines
14.1, Description of 
Study Drug
14.4, Preparation, 
Handling, StorageUpdated physical description of study drug, revised instructions for preparation and  
handling to refer to Investigational Product Preparation Instructions or SIPPM
Rationale: Revisions to improve  accuracy and consistency
Time and Events 
ScheduleReorganized disease evaluations and specify window  for SPEP, UPEP, IFE, and β-2 
microglobulin to within 14 days of C1D1.
3.1, Overview  of 
Study DesignRevised definition of Treatment Phase
3.1,Overview  of 
Study Design
5, Treatment 
AllocationChanged International Scoring System to International Staging System
6.2.2 , VELCADE 
AdministrationAdded sentence that VELCADE dose may be delayed up to 48 hours, as stated in Time and 
Events Schedule.
6.3.3 , Dose 
Modification 
GuidelinesRemoved hepatic criteria from guidelines for melphalan dose adjustment for renal 
impairm ent
8.3, Prohibited 
TherapiesAdded interferon and clarithromycin as prohibited therapies
9.1.2 , Screening 
PhaseAdded provision that Sponsor will review eligibility, specified assessments that do not 
need to be repeated on Cycle 1 Day 1 if done within the prior 14 days, extended window  
for pregnancy test to 14 days, provided instruction for measurement or calculation of 
creatinine clearance
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
27
Approved , Date: 14 February 2018Applicable Section(s) Description of Change(s)
9.1.4 , Follow -up 
PhaseClarified reasons to stop disease evaluations and timing of visits after PD
9.2.1.2 , Myeloma 
Protein MeasurementsRevised testing of quantitative IgD and IgE to only subjects with IgD or IgE myeloma.
9.2.1.7 , Assessment 
of Lytic DiseaseDeleted text regarding use of radionucleotide scan as it is no longer relevant
11.11 , Data 
Monitoring 
CommitteeCorrected IDMC to consist of 2 clinicians and 1 statistician
11.4, PK Analyses
11.6, PK/PD AnalysesRemoved redundancy between sections and consolidated into Section 11.6
Attachment 3 Deleted attachment for measuring creatinine clearance
Rationale: In response to PMDA comments, additional safety monitoring for Japanese subjects is added via an 
Attachment (and cross -references to the amendment in main text).
Synopsis (Safety 
Evaluations) During Cycle 1 at Japanese sites, an enhanced reporting, monitori ng, and review of pre -
specified safety events that occur for Japanese subjects inArm B will be performed until a 
minimum of 3 subjects in Arm B have completed Cycle 1.
12.4. Reporting, 
Monitoring, and 
Revie w of Safety 
Events in Japanese 
Subjects in Arm B; 
Attachment 7Section and attachment added to describe the enhanced reporting, monitoring, and review 
of pre- specified safety events for Japanese subjects in Arm B (min imum of 3 subjects).
Rationale: Minor errors w ere no ted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
28
Approved , Date: 14 February 2018SYNOPSIS
A Phase 3, Randomized, Controlled, Open -label Study of VELCADE (Bortezomib) Melphalan -
Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with 
Previously Untreated Multiple Myeloma who are Ineligible for High -dose Therapy
Daratumumab is a human IgG1 ĸ monoclonal antibody (mAb) that binds with high affinity to a unique 
epitope on CD38, a transmembrane glycoprotein. It is a targeted immunotherapy directed towards tumor 
cells that express high levels of CD38, such as plasma cells from patients with multiple myeloma. This 
target is distinct from those of other approved agents for multiple myeloma therapy .
OBJECTIVE SAND HYPOTHESIS
Primary Objective
The primary objective is to determine if the addition of daratumumab to VMP will prolong PFS compared 
with VMP.
Secondary Objective s
Thesecondary objectives are:
 To determine if the addition of daratumumab to VMP will improve clinical outcome as measured by:
 Time to disease progression (TTP)
 CR rate
 Minimal residual disease ( MRD )negativity rate
 PFS2 (defined as time from randomization to progression on the next line of therapy or death, 
whichever comes first) 
 Time to next treatment
 Overall response rate (partial response [PR] or better )
 Stringent CR (sCR) rate
 Verygood partial response (VGPR) or better rate
 Time to response
 Duration of response
 Overall survival
 To assess patient -reported outcomes and heath economic/resource utilization
 Todetermine the pharmacokinetics and immunogenicity of daratumumab
 To assess the safety and tolerability of daratumumab when administered in combination with VMP
 To evaluate clinical efficacy of daratumumab when added to VMP in high risk molecular subgroups
Exploratory Objective s
 To explore biomarkers predictive of response and resistance to therapy
 To assess durability of MRD negativity
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
29
Approved , Date: 14 February 2018Hypothesis
The hypothesis of the study  is that d aratumumab continued until disease progression, in combination with 
9 cycles of VMP, will improve PFS compared with 9 cycles of VMP alone.
OVERVIEW OF STUDY DESIGN
This is a randomized, open- label, parallel -group, controlled, multicenter study in subjects at least 18 years 
of age with previously untreated multiple myeloma who are ineligible for high dose therapy. A target of 
up to 700 subjects will be enrolled in this study with 350 subjects planned per treatment arm.
Subject participation will include a Screening Phase, a Treatment Phase, and a Follow -up Phase. The 
Screening Phase will be up to 21 days before randomization. All subjects will receive up to 9 cycles of the 
VMP  regimen (1 cycle = 6 weeks) with or without daratumumab.
The Treatment Phase will e xtend from Day 1 of Cycle 1 to discontinuation of all study treatment . Eligible 
subjects will be stratified by International Staging System (I vs II vs III based on central laboratory results 
at Screening ), region (Europe vs Other) , and age(<75 vs ≥75) andthen randomized in a 1:1 ratio. 
Subjects in both treatment arms will receive 1.3mg/m2VELCADE by subcutaneous injection (SC) twice 
weekly (Weeks 1, 2, 4, and 5) in Cycle 1 followed by once weekly (Weeks 1, 2, 4, and 5) in Cycles 2 to 9. 
Melphalan PO at 9 mg/m2and prednisone PO at 60mg/m2will be self-administered on Day 1-4 of each 
VELCA DE cycle. For subjects randomized to the Treatment Arm B, 20mg of dexamethasone will 
substitute for the planned dose of prednisone on Day 1 of each cycle. In this setting, dexamethasone will 
be utilized as the treatment dose of steroid for that particular day, as well as the required pre-medication 
prior to daratumumab infusion. Daratumumab 16 mg/kg will be administered to subjects in Treatment 
Arm B by IV infusion once every week for 6weeks (Cycle 1; 1 VELCADE cycle); then once every 
3weeks for 16addit ional doses (Cycles 2-9). Measures to prevent infusion -related reactions (IRRs) will 
include pre-infusion medication with dexamethasone, paracetamol, and antihistamine before each 
daratumumab infusion.
Assessment of tumor response and disease progression will be conducted in accordance with the 
International Myeloma Working Group (IMWG) response criteria. An assessment of MRD will be 
conducted on bone marrow samples. Safety evaluations will include AE monitoring, physical 
examinations, electrocardiogram (ECG) monitoring, clinical laboratory parameters (hematology and 
chemistry), vital sign measurements, and Eastern Cooperative Oncology Group (ECOG) performance 
status. Blood samples will be drawn for assessment of pharmacokinetic sand immunogenicity .
After co mpletion of the VMP cycles, subjects in Arm A will enter the Follow -up Phase and should not be 
started on subsequent anti-myeloma therapy without confirmed disease progression . Subjects in Arm B 
will continue to receive daratumumab every 4 weeks until docu mented progression, unacceptable toxicity , 
or the study ends (see below for definition). Subjects who need to discontinue treatment with any one 
component of study treatment (VELCADE, melphalan, prednisone, or daratumumab) may continue to 
receive treatment with the other components of study treatment, as assigned. Upon discontinuation of 
daratumumab, subjects in Arm B will also enter the Follow -up Phase and should not be started on 
subsequent anti -myeloma therapy without confirmed disease progression .
In the Follow -up Phase ,subjects who discontinue treatment before disease progression must continue to 
have disease evaluations according to the T ime and Events Schedule until confirmed PD (see Section 8.4, 
Subsequent Therapies ), subsequent anti-myeloma treatment, death, withdrawal of consent, lost to 
follow -up, or the end of the study . After disease progression is documented, follow -up will be obtained at 
least every 16 weeks .Subsequent anti-myeloma treatment , PFS2 (per investigator judgment), second 
primary malignancies, and survival will also be recorded.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
30
Approved , Date: 14 February 2018Two interim analyses are planned. The first interim analysis, with a purpose to evaluate safety, will be 
performed after a total of approximately 100 subjects have been treated for at least 2 cycles or 
discontinued the study treatment. The second interim analysis, with a purpose to evaluate cumulative 
interim safety and efficacy data, will be performed when approximate ly 216 PFS events have been 
accumulated. Investigators will be informed when each interim analysis is to occur .As the superiority of 
daratumumab combined with VMP over VMP alone with respect to PFS was established at the second 
interim analysis, the inter im PFS analysis will serve as the primary PFS analysis, which otherwise was to 
occur when approximately 360 PFS events had been observed. As planned in the original protocol, two 
interim OS analyses will be performed at the time of the interim PFS (216 events) and the primary PFS 
(360 events) prior to the final OS analysis at 330 deaths. The second interim OS will occur when 200 
deaths (60% of all planned deaths) have been accumulated which about the same time of the primary PFS 
analysis as if it would have occurred. All available data prior to that time will be included in each of the 
respective analyses. An Independent Data Monitoring Committee (IDMC) will be commissioned for this 
study to review efficacy and safety results at the 2planned interim analyses and to perform periodic 
review s of safety data .
The end of the study will occur when 330 subjects have died, or 5 years after the last subject is 
randomized, whichever comes first. The sponsor will ensure that subjects benefiting from treatment with 
daratumumab will be able to continue treatment after the end of the study .
As a result of the positive second interim analysis, that established the superiority of daratumumab 
combined with VMP  over VMP  alone with respect to the primary endpoint (PFS), and consistent with the 
IDMC’ s recommendation, the sponsor will ensure that access to daratumumab is provided for subjects 
randomized to Arm A (VMP) who have sponsor -confirmed disease progression (see Section 8.4, 
Subsequent Therapies).
SUBJECT POPULATION
Key eligibility criteria include the following: subjects who are 18 years of age(or legal age of consent) , 
have a confirmed diagnosis of symptomatic multiple myeloma satisfying the calcium elevation, renal 
insufficiency, anemia, and bone abnormalities (CRAB) diagnostic criteria ;monoclonal plasma cells (PCs)
in the bone marrow ≥10% or presence of a biopsy proven plasmacytomas ;and measurable secretory 
disease, asassessed by the central laboratory; an Eastern Cooperative Oncology Group (ECOG) 
performance status score of 0, 1, or 2, must be newly diagnosed and not considered candidates for high-
dose chemotherapy with stem cell transplantation .
DOSAGE AND ADMINISTRAT ION
Daratumumab (16 mg/kg) will be administered to subjects in Arm B by IV infusion initially once every 
week for 6weeks (Cycle 1; 1 VELCADE cycle); then once every 3 weeks for an additional 16 doses 
(Cycles 2-9); then once every 4 weeks thereafter (post -VMP Treatment Phase), until documented 
progression, unacceptable toxicity, or study end.
Subjects will receive 1.3 mg/m2VELCADE as a SC injection twice weekly (Weeks 1, 2, 4, and 5) for one 
6-week cycle (Cycle 1; 8 doses per cycle) followed by once weekly (Weeks 1, 2, 4, and 5) administrations 
for eight 6 -week cycles (Cycles 2 to 9; 4 doses per cycle).
Melphalan will be administered at 9 mg/m2and prednisone will be administered at 60 mg/m2on Day 1 to 
4 of each VELCADE cycle. Both melphalan and prednisone will be administered orally. For subjects 
randomized to the Treatment Arm B, 20mg dexamethasone will substitute for the planned dose of 
prednisone on Day 1 of each cycle. In this setting, dexamethasone will be utilized as the treatment dose of 
steroid fo r that particular day, as well as the required pre -medication prior to daratumumab infusion.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
31
Approved , Date: 14 February 2018EFFICACY EVALUATIONS/ENDPOINTS
Disease evaluations must be performed every 3 weeks during the first year, every 4 weeks during the 
second year, and every 8 weeks thereafter until disease progression (or other reasons as per Section 10of 
the protocol ). Awindow of ±7days is allowed. If treatment has been delayed for any reason, the disease 
evaluations must be performed according to the original schedule, regardless of any changes to the dosing 
regimen.
The primary endpoint is PFS, which is defined as the duration from the date of randomization to either 
progressive disease or death, whichever comes first. Disease progression will be determined according to 
the IMWG criteria (Durie 2006, Rajkumar 2011)8,37.
The secondary efficacy endpoints include:
 Time to disease progression (TTP) is defined as the time from  the date of randomization to the date 
of first documented evidence of PD, as defined in the IMWG criteria. For subjects who have not 
progressed, data will be censored at the date of the disease evaluation before the start of any 
subsequent anti -myeloma therapy.
 CR rate, defined as the percentage of subjects achieving CR, as defined by:
 Negative immunofixation of serum and urine, and
 Disappearance of any soft tissue plasmacytomas, and
 <5% PCs in bone marrow
 For those subjects with negative or low SPEP (≤0.2 g/L) and suspected daratumumab 
interference on immunofixation, a reflex assay using anti-idiotype antibody will be utilized to
confirm daratumumab interference and rule out false positive immunofixation. Subjects who 
have confirmed daratumumab interference, but meet all other clinical criteria for CR or sCR, 
will be considered CR/sCR.
 MRD negativity rate, defined as the proportion of subjects who have negative MRD at any time 
point after the date of randomization .
 Progression- free Survival on Next line of Therapy (PFS2), defined as the time from randomization to 
progression on the next line of treatment or death, whichever comes first. Disease progression will be 
based on investigator judgment. Subjects who are still alive and not yet progressed on the next line 
of treatment will be censored on the last date of follow -up.
 Time to next treatment, defined as the time from randomization to the start of the next -line treatment.
 Overall response rate (ORR), defined as the proportion of subjects who achieve PRor better
according to the IMWG criteria, during or after the study treatment.
 sCR rate, defined as the percentage of subjects achieving CR in addition to having a normal FLC 
ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 
2-4color flow cytometry .
 Proportion of subjects who achieve VGPR or better, defined as the proportion of subjects achieving 
VGPR and CR (including sCR) according to the IMWG criteria during or after the study treatment at 
the time of data cutoff.
 Time to response, defined as the time between randomization and the first efficacy evaluation that
the subject has met all criteria for PR or better. For subjects without response, data will be censored 
either at the date of progressive disease or, in the absence of progressive disease, at the last disease 
evaluation before the start of subsequent anti -myeloma therapy.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
32
Approved , Date: 14 February 2018 Duration of response, calculated from the date of initial documentation of a response (CR or PR) to 
the date of first documented evidence of progressive disease, as defined in the IMWG criteria. For 
subjects who have not progressed, data will be censored at the last disease evaluation before the start 
of any subsequent anti -myeloma therapy.
 OS, measured from the date of randomization to the date of the subject’s death. If the subject is alive 
or the vital status is unknown, then the subjec t’s data will be censored at the date the subject was last 
known to be alive.
 Impact of D- VMP compared to VMP on patient -reported perception of global health.
 Clinical efficacy of D -VMP in high risk molecular subgroups compared to VMP alone.
Exploratory en dpoints include:
 Biomarkers pre dictive ofresponse or resistanceto da ratumumab
 Durability of MRD negat ivity
PHARMACOKINETIC AND IMMUNOGENICITY EVALUATIONS
Samples to assess both the serum concentration (pharmacokinetics) of daratumumab and the generation of 
antibodies to daratumumab (immunogenicity) will be obtained from all subjects in the D-VMP group 
according to the Tim e and Events Schedule. In the Follow -up Phase, for all subjects in Arm B (D-VMP) , 
samples are tobe collected 8 weeks after the last dose of daratumumab, regardless of whether there has 
been confirmed disease progression. At specified time points , venous blood samples (5mL per sample) 
will be collected and the serum will be divided into 3 aliquots (1 aliquot for pharmacokinetic analysis, 
1aliquot for immunogenicity assessment [when appropriate], and 1 aliquot as a back -up).
BIOMARKER EVALUATIONS
Bone marrow aspirates will be collected at screening and following treatment as outlined in the Time and 
Events Schedule. Baseline bone marrow aspirate samples will be subjected to DNA and RNA sequencing 
in order to classify subjects into high-risk molecular subgroups and to establish the myeloma clone for 
MRD monitoring.
In addition to planned bone marrow aspirate assessments, a whole blood samp lewill be collected from 
subjects as outlined in the Time and Events Schedule for processing to plasma and PBMCs.
SAFETY EVALUATIONS
Safety will be measured by adverse events, laboratory test results, ECGs, vital sign measurements, 
physical examination findings, and assessment of ECOG performance status score.
During Cycle 1at Japanese sites, an enhanced reporting, monitoring, and review of pre- specified safety 
events that occur for Japanese subjects inArm B will be performed until a minimum of 3 subject s in Arm 
Bhave completed Cycle 1.
STATISTICAL METHODS
The sample size calculation is performed based on the assumption that the median PFS for the VMP 
group in this study is estimated to be 21months. Assuming that the addition of daratumumab can reduce 
the risk of the disease progression or death by 27.6%, ie, assuming the hazard ratio (VMP vs. D- VMP) of 
0.724, which translates into a median PFS of 29 months for the D-VMP group, a total of 360 PFS events 
is needed to achieve a power of 85% to detect this hazard ratio with a log-rank test (two-sided 
alpha =0.05). With a 20-month accrual period and an additional 21-month follow -up, the total sample 
size needed for the study is approximately 700 (350/treatment group) subjects. The sample size 
calculation ha s taken into consideration an annual dropout rate of 5%.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
33
Approved , Date: 14 February 2018Long- term survival follow -up will continue until 330 deaths have been observed. Therefore, this study 
will achieve more than 80% power to detect a 27% reduction in the risk of death (hazard ratio=0.7 3) with 
a log -rank test (two- sided alpha=0.05).
Response to study treatment and progressive disease will be evaluated by a validated computer algorithm.
For the primary endpoint of PFS, the primary analysis will consist of a stratified log-rank test for the 
comparison of the PFS distribution between the 2 treatment groups. The Kaplan -Meier method will be 
used to estimate the distribution of overall PFS for each treatment. The treatment effect (hazard ratio) and 
its two-sided 95% confidence intervals are to be estimated using a stratified Cox regression model with 
treatment as the sole explanatory variable.
Details of the 2 planned interim analyses are provided in Synopsis, Overview of Study Design. After each 
interim review, the IDMC will make recommendation s regarding the continuation of the study . In 
addition, the IDMC may also review cumulative safety data every 6 months besides the 2interim 
analyses. The IDMC will no longer review study data after the database lock for the primary analysis has 
been compl eted.
As the superiority of daratumumab combined with VMP over VMP alone with respect to PFS was 
established at the second interim analysis , theinterim PFS analysis will serve as the primary PFS 
analysis, which otherwise was to occur when approximately 360 PFS events had been observed. The date 
established for the primary PFS analysis (12 June 2017 ) will serve as the primary clinical cutoff date,
after which subject monitoring will be conducted according to Section 9.1.5 of the protocol. After the OS 
interim analysis (ie, when 200 deaths have occurred) subject monitoring will be conducted according to 
Section 9.1.6 .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
34
Approved , Date: 14 February 2018TIME A ND EVENTS SCHE DULE
NotesScreening 
PhaseTreatment 
PhaseFollow -up 
Phase 
within 21 days 
before 
randomizationCycle 1 -9
VMP Treatment 
(6wk cycles), 
Arm A and
Arm BCycle 10+
Dara Treatment 
(4wk cycles),
Arm B ONLYEOT
30 days 
after last 
dose Prior to PD After PD 
(Q16wks
±2 weeks )
Study treatment should be initiated within 72 hours after randomization. The start of each cycle may occur ±3 days of the scheduled day in order to accommodate the schedule of the site or subject. After 
EOT, subjects in both treatment arms prior to PD will continue to return for disease evaluations. After PD is documented, sub jects wi ll be followed for survival ,PFS2, second primary malignancy, and 
subsequent anti -myeloma therapy. After the primary clinical cutoff date (12 June 2017 ), subject monitoring will be conducted as per Section 9.1.5 . After the OS interim analysis, subject monitoring will be 
conducted according to Section 9.1.6 .
Procedures
Informed consent ICF must be signed before any study related procedures
Eligibility criteria X
Demography/
Medical History X
Height X
Chest X -ray(or full 
chest CT scan)Acceptable for screening if performed as part of SOC within 
42 days before randomization X
SpirometryFEV1 measured for subjects with COPD ; acceptable for 
screening if performed as part of SOC within 42 days before 
randomization X
ECOG Prior to any other study procedures planned for the same day XQ3mo in year 1 (ie, every 12 weeks from C1D1 ), thereafter Q6mo (ie, every 24 weeks thereafter)
until PD, post PD Wk8, Wk16 (window ±14 days)
12-lead ECGAcceptable for screening if performed as part of SOC within 
42 days before randomization XC3D1, C 6D1
(±7 days) X
Physical exam including neurological exam X Symptom and disease directed exam as clinically indicated
Vital signs, weight X Please see following table for details X
Blood type and 
Indirect 
Antiglobulin TestABO, Rh, and IAT to be assessed locally . Results will b e 
included on wallet card for subjects in Arm B. C1D1, Arm B only
Wallet Card To be given to all subjects (in Arm A and in Arm B) C1D1
Laboratory Assessments
Pregnancy testFor women of childbearing potential only, serum or urine 
pregnancy test within 14days of randomization. X additional serum or urine pregnancy tests as clinically indicated
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
35
Approved , Date: 14 February 2018NotesScreening 
PhaseTreatment 
PhaseFollow -up 
Phase 
within 21 days 
before 
randomizationCycle 1 -9
VMP Treatment 
(6wk cycles), 
Arm A and
Arm BCycle 10+
Dara Treatment 
(4wk cycles),
Arm B ONLYEOT
30 days 
after last 
dose Prior to PD After PD 
(Q16wks
±2 weeks )
HematologyAcceptable for screening to meet CRAB criteria if performed 
as part of SOC within 42 days before randomization, but 
must also be performed within 21 days before randomization 
for other eligibility requirements. X Please see following table for details X
Serum chemistryAcceptable for screening to meet CRAB criteria if performed 
as part of SOC within 42 days before randomization, but 
must also be performed within 21 days before randomization 
for other eligibility requirements. X Please see following table for details X
Daratumumab PK Arm B only. On dara infusion days, 1 sample is to be 
collected before the start of infusion (up to 2 hours before the 
start of the infusion) and 1 sample is to be collected after the 
end of infusion (up to 2 hours after the end of infusion). 
Samples to be sent to cen tral laboratory. C1D1, C3D1, C6D1
Arm B ONLYX
Arm B 
ONLY8 wks after last dara dose
Arm B ONLY
Daratumumab 
immunogenicity Arm B only. No additional sample needed; will be taken from 
PK sample. If an infusion reaction occurs, obtain 
unscheduled blood sample as soon as possible. C1D1 predose 
Arm B ONLYX
Arm B 
ONLY8 wks after last dara dose
Arm B ONLY
Whole blood Plasma and PBMC biomarker assessments C1D1 predose X
Disease Evaluations: Every effort should be made to conduct disease evaluations as per schedule (window ±7 days , ePRO window ±14 days ). Refer to Section 9.2for details on efficacy evaluations
SPEP an d IFE, 24 -
hour UPEP and 
IFESample to be sent to central laboratory . Randomization 
based on central laboratory values. After Cycle 1, IFE only 
when endogenous M -protein is 0 or nonquantifiable. XQ3wk in year 1, Q4wk in year 2, thereafter Q8wk until PD . Not required on C1D1 
if screening values were obtained from samples collected within the prior 14 days
Serum FLCFLC to confirm CR and sCR. In addition, for su bjects with 
light chain myeloma, perform according to schedule. Sample 
to be sent to central laboratory. XQ3wk in year 1, Q4wk in year 2, thereafter Q8wk until PD . Not required on C1D1 
if screening values were obtained from samples collected within the prior 14 days
Calcium , albuminSample to be sent to central laboratory . ISS staging based 
on central laboratory value. XQ3wk in year 1, Q4wk in year 2, thereafter Q8wk until PD . Not required on C1D1 
if screening values were obtained from samples collected within the prior 14 days
β2-microglobulinSample to be sent to central laboratory . ISS staging based 
on central laboratory value X
Bone marrow 
aspirate/biopsyFor screening (up to 42 days before randomization) fresh 
aspirate or biopsy preferred . If not available, obtain non-
decalcified sli des (bone marrow aspirate, touch preparation 
or clot selection) or FFPE block (clot section only, no bone 
marrow biopsy) . Fresh biopsy or aspirate or both required to 
confirm CR/sCR. Samples for biomarker analysis to be sent 
to central laboratory.X(Refer to 
Section 9.2.1.5
for required local 
bone marrow 
testing )To confirm CR/sCR, assess MRD, and evaluate PD (if feasible ).For subjects with 
CR/sCR, an additional bone marrow aspirate will be obtained 12, 18, 24 and 30 
months (+2 months) after first dose. A portion of all bone marrow aspirates may 
be used for other biomarker assessments (see Section 9.2.1.5 and Table 10)
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
36
Approved , Date: 14 February 2018NotesScreening 
PhaseTreatment 
PhaseFollow -up 
Phase 
within 21 days 
before 
randomizationCycle 1 -9
VMP Treatment 
(6wk cycles), 
Arm A and
Arm BCycle 10+
Dara Treatment 
(4wk cycles),
Arm B ONLYEOT
30 days 
after last 
dose Prior to PD After PD 
(Q16wks
±2 weeks )
Quantitative Ig See Section 9.2.1.2 XC3D1, C5D1, 
C7D1, C9D1Every 4 months until 
PD
Arm B ONLY XEvery 3 months 
in Year 1, then 
every 4 months 
after Year 1 until 
PD
Lytic disease 
assessmentAcceptable for s creening if performed as part of SOC within 
42 days before randomization X As clinically indicated, using the same methodology as used at screening
Extramedullary 
plasmacytomasSubjects with history of plasmacytoma ; acceptable for 
screening if performed as part of SOC within 42 days before 
randomization XIf applicable, by physical exam Q6wks, by radiologic exam (if required) Q12wks, 
using the same methodology as used at screening . For subjects with history of 
plasmacytoma assessed by physical exam, repeat assessment on C1D1 if not 
done within 14 days prior to randomization .
PROEORTC -QLQ -30, EQ -5D-5L, collected using an electronic 
device (ePRO) XQ3mo in year 1 (ie, every 12 weeks from C1D1) , thereafter Q6mo (ie, every 24 weeks thereafter)
until PD, post PD Wk8, Wk16 (window ±14 days) ; preferably to be completed prior to any other 
study procedures at that study visit
Follow -up
Survival, PFS 2, second primary malignancy, subsequent anti-myeloma therapy Q16wk
Ongoing Subject Review
Adverse Events See Section 12for detailed instructions. continuous from the time of signing of ICF until 30 days after last dose of last study drug
Concomitant 
Medications See Section 8for detailed instructions. continuous from the time of signing of ICF until 30 days after last dose of last study drug
Abbreviations to the Time and Events Schedule s:
AE=adverse event; Arm A=VMP alone for nine 6 -week cycles; Arm B=VMP + daratumumab for nine 6 -week cycles, then daratumumab monotherapy until PD; C=cycle; COPD=chronic 
obstructive pulmonary disease; CR=complete response; CRAB=calcium elevation, renal insufficiency, anemia, a nd bone abnormalities ; D=day; Dara=daratumumab; 
ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; EOT=End-of-Treatment; FEV 1=Forced Expiratory Volume (in 1 second); FFPE=formalin -fixed paraffin embedded; 
FLC=free light chain; hr=hour; ICF=informed consent form; IFE=immunofixation ;Ig=immunoglobulin; ISS=International Staging System; MRD=minimal residual disease ; MRI=magnetic 
resonance imaging; OS=overall survival; PBMC =peripheral blood mononuclear cell ; PD=disease progression; PFS2 =time from randomization to progression on the next line of therapy or 
death, whichever comes first; PK=pharmacokinetics; PRO=patient -reported outcomes; Q(3)(6)mo=every (3)(6) months; Q(3)(4)(8)(16)wk=every (3)(4)(8)(16) weeks; Q(2)(3)cycle=every 
(2)(3) cycles; SAE=serious adverse event; SC=subcutaneous; sCR=stringent complete response; SIPPM =Site Investigational Product Procedures Manual (or equivalent document); 
SOC=standard of care; SPEP=serum M -protein quantitation by electrophoresis; UPEP=urine M -protein quantitation by electrophoresis; VMP=VELCADE -melphalan -prednisone; 
Wk=week.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
37
Approved , Date: 14 February 2018TIME A NDEVENTS SCHEDULE FOR STUDY TRE ATMENT, CYCLE 1 (VMP TREA TMENT PHA SE)
NotesWeek 
1Week 
2Week 3Week 
4Week 
5Week 6
D1 D2 D3 D4 D8 D11 D15 D22 D25 D29 D32 D36
Study trea tment should be administered in the following order: prednisone, daratumumab, VELCADE, and melphalan. Cycles are based on the administration of VELCADE. The start of each cycle may occur 
±3 days of the scheduled day in order to accommodate the schedule of the site or subject
HematologyLocal lab. Required for subjects in both treatment arms. For 
C1D1 , no need to repeat tests if done within past 5 days. 
Testing may be performed up to 2 days before other 
treatment days. Results of hematology tests must be 
evaluated before administration of treatment .Perform at 
additional time points, as clini cally indicated.X X X X X X
Clinical ChemistryX X
WeightIf weight changes by more than 10% from baseline, the dose 
of all study treatments willbe re- calculatedX
Vital SignsVital signs (blood pressure, heart rate, temperature) 
measured in sitting position for subjects in both treatment 
arms. Additionally, for Arm B only, o n Cycle 1 Day 1 before 
the start of dara infusion; at 0.5, 1, 1.5, 2, 3.5 hr after start of 
infusion; at end of infusion; 0.5,1 hr after endofinfusion. For 
all other infusions, vital si gns measured before start and at 
end of dara infusion.X X X X X X
Diary review Accountability/exposure check X
Pre-infusion Medications, Arm B only
Dexamethasone Administer approximately 1 hour before dara infusion. PO 
pre-infusion medications may be administered within 3 hours 
before the infusion.
Dexamethasone 20 mg IV or PO. Substitutions for 
dexamethasone allowed, see Attachment 6. 
An antihistamine (diphenhydramine 25 -50 mg IV or PO, or 
equivalent H1 blocker) , see Attachment 5
Paracetamol (acetaminophen) 650 -1000 mg IV or PO
Leukotriene inhibitor, montelukast 10 mg PO or equivalent, 
optional, C1D1X X X X X X
Antihi stamine X X X X X X
Paracetamol X X X X X X
Leukotriene Inhibitor
(optional)X
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
38
Approved , Date: 14 February 2018NotesWeek 
1Week 
2Week 3Week 
4Week 
5Week 6
D1 D2 D3 D4 D8 D11 D15 D22 D25 D29 D32 D36
Study Treatment , Arm A and Arm B
PrednisoneDispense on Day 1 for self -administration. Prednisone taken 
on Day 1 in Arm A only (dexamethasone will be given on 
Day1 in Arm B) , taken on Day 2 -4 in both Arms.X X X X
VELCADEAdminister by SC injection. Dose may be delayed up to 
48hrs, however subsequent doses m ust be adjusted to 
account for delay as all VELCADE doses should be at least 
72 hrs apart. Doses that need to be withheld are skipped and 
will not be made up later in the cycle. Individual doses within a 
cycle have a ±1 day windowX X X X X X X X
Melphalan Dispense on Day 1 for self -administration. X X X X
Study Treatment, Arm B only
DaratumumabRefer to SIPPM for recommendations on daratumumab 
infusion rate. Skip if infusion cannot be given within 3days.
Individual doses within a cycle have a ±1 day window.X X X X X X
TIME A NDEVENTS SCHEDULE FOR STUDY TREATMENT, CYCLE 2 TO 9 (VMP TREA TMENT PHA SE)
NotesWeek 
1Week 
2Week 
3Week 
4Week 
5Week 
6
D1 D2 D3 D4 D8 D11 D15 D22 D25 D29 D32 D36
Study treatment should be administered in the following order: prednisone, daratumumab, VELCADE, and melphalan. Cycles are based on the administration of VELCADE. The start of each cycle 
may occur ±3 days of the scheduled day in order to accommodate the schedule of the site or subject
HematologyLocal lab. Required for subjects in both treatment arms. 
Testing may be performed up to 2 days before treatment 
day. Results of hematology tests must be evaluated before 
administration of treatment .Perform at additional time
points, as clini cally indicated.X X
Clinical 
ChemistryX X
WeightIf weight changes by more than 10% from baseline, the 
dose of all study treatments willbe re -calculatedX
Vital SignsVital signs (blood pressure, heart rate, temperature ) 
measured in sitting position for subjects in both treatment 
arms. Additionally, for Arm B, vital signs before start and at 
end of dara infusion.X X
Diary review Accountability/exposure check X
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
39
Approved , Date: 14 February 2018NotesWeek 
1Week 
2Week 
3Week 
4Week 
5Week 
6
D1 D2 D3 D4 D8 D11 D15 D22 D25 D29 D32 D36
Pre-infusion Medications, Arm B only
Dexamethasone Administer approximately 1 hour before dara infusion. PO 
pre-infusion medications may be administered within 3 
hours before the infusion.
 Dexamethasone 2 0 mg IV or PO . Substitutions for 
dexamethasone allowed, see Attachment 6. 
 An anti histamine (diphenhydramine 25-50 mg IV or 
PO, or equivalent H1 blocker ), see Attachment 5
 Paracetamol (acetaminophen) 650- 1000 mg IV or POX X
Antihistamine X X
Paracetamol X X
Study Treatment , Arm A and Arm B
PrednisoneDispense on Day 1 for self -administration. Prednisone taken 
on Day 1 in Arm A only (dexamethasone will be given on 
Day 1 in Arm B) , taken on Day 2 -4 in both Arms.X X X X
VELCADEAdminister by SC injection. Dose may be delayed up to 
48hrs, however subsequent doses should be adjusted to 
account for delay as all VELCADE doses must be at least 
72 hrs apart. Doses that need to be withheld are skipped 
and will not be made up later in the cycle. Individual doses 
within a cycle have a ±1 day window.X X X X
Melphalan Dispense on Day 1 for self -admini stration. X X X X
Study Treatment , Arm B only
DaratumumabRefer to SIPPM for recommendations on daratumumab 
infusion rate. Skip if infusion cannot be given within 1 wk.
Individual doses within a cycle have a ± 1 day window.X X
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
40
Approved , Date: 14 February 2018TIME A NDEVENTS SCHEDULE FOR STUDY TREATMENT, CYCLE 10+ (DARA TRE ATMENT PHA SE, ARM B ONLY )
Notes Day 1every 4 weeks
The start of each cycle may occur ±3 days of the scheduled day in order to accommodate the schedule of the site or subject.
HematologyLocal lab. Testing may be performed up to 2 days before treatment 
day. Results of hematology tests must be evaluated before each 
infusion .Perform at additional time points, as clini cally indicated.
AST and ALT every 3 cycles.X
Clinical ChemistryX
WeightIf weight changes by more than 10% from baseline, the dose of all 
study treatments willbe re- calculatedX
Vital SignsVital signs (blood pressure, heart rate, temperature ) measured in 
sitting position before start and at end of daratumumab infusion.X
Pre-infusion Medications, Arm B only
DexamethasoneAdminister approximately 1 hour before dara infusion. PO 
pre-infusion medications may be administered within 3 hours 
before the infusion
 Dexamethasone 2 0 mg IV or PO . Substitutions for 
dexamethasone allowed , see Attachment 6. 
 An antihistamine (diphenhydramine 25 -50 mg IV or PO, or 
equivalent H1 blocker ), see Attachment 5
 Paracetamol (acetaminophen) 650- 1000 mg IV or POX
Antihistamine X
Paracetamol X
Study Treatment , Arm B only
DaratumumabRefer to SIPPM for recommendations on daratumumab infusion 
rate. Skip if infusion cannot be given within 2 wks.X
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
41
Approved , Date: 14 February 2018ABBREVIA TIONS
ADCC antibody -dependent cell -mediated cytotoxicity
ADCP antibody -dependent cellular phagocytosis
AE adverse event
ALT alanine aminotransferase
ASCT autologous stem cell transplantation
AST aspartate aminotransferase
BM-MNC bone marrow  mononuclear cell
BSA body surface area
BUN blood urea nitrogen
CDC complement -dependent cytotoxicity
CKD -EPI chronic kidney disease epidemiology collaboration
CL total systemic clearance
Cmax maximum observed concentration
Cmin minimum observed concentration
COPD chronic obstructive pulmonary disease
CR complete response
CRAB calcium elevation, renal insufficiency, anemia, and bone abnormalities
CrCl creatinine clearance
CT computed tomography
dara daratumumab 
DLCO diffusing capacity of the lung for carbon monoxide
DLT dose limiting toxicity
DTT dithiothreitol
D-VMP daratumumab plus VELCADE -melphalan -prednisone
EBMT European Group for Blood and Marrow  Transplantation
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
eDC electronic data capture
EU European Union
FEV1 forced expiratory volume (in 1 second)
FFPE formalin fixed paraffin embedded
FISH fluorescence in situ hybridization
FLC free light chain
GCP Good Clinical Practice
G-CSF granulocyte colony stimulating factor
HIV human immunodeficiency virus
HR hazard ratio
IAT indirect antiglobulin test (also known as indirect Coombs test)
ICF informed consent form
ICH International Conference on Harmonisation
ICMJE International Commit tee of Medical Journal Editors
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IFE immunofixation
Ig immunoglobu lin
IHC immunohistochemistry
IMiD immunomodulatory agent
IMWG International Myeloma W orking Group
IRB Institutional Review Board
IRR infusion -related reaction
ISS International Staging System
IV intravenous
IWRS interactive web response system
LDH lactic acid dehydrogenase
LVEF left ventricular ejection fraction
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
42
Approved , Date: 14 February 2018mAb monoclonal antibody
MDRD Modification ofDiet in Renal Disease
MedDRA Medical Dictionary for Regulatory Activities
MP melphalan -prednisone
MPT melphalan -prednisone- thalidomide
MRD minimal residual disease
MRI magnetic resonance imaging
MRU medical resource utilization
MTD maximum tolerated dose
NCI CTCAE National Cancer Institute Common T erminology Criteria for Adverse Events
NGS next generation sequencing
NK natural killer
OR overall response
ORR overall response rate
OS overall survival
PBMC peripheral blood mononuclear cell
PC plasma cell
PD disease progression
PFS progression -free survival
PFS2 time from randomization to progression on the next line of therapy or death, whichever comes first
PI proteasome inhibitor
PK pharmacokinetic s
PO per oral
PQC Product Quality Complaint
PR partial response
PRO patient -reported outcome(s)
QD once daily
QIg quantitative immunoglobulins
RBC red blood cell
Rd lenalidomide plus low -dose dexamethasone
SAE serious adverse event
SC subcutaneous injection
sCR stringent complete response
SCT stem cell transplantation
SIPPM Site Investigational Product Procedures Manual (or equivalent document)
SPEP serum M -protein quantitation by electrophoresis
TTP time to progression
ULN upper limit of normal
UPEP urine M -protein quantitation by electrophoresis
US United States
V volume of distribution
VD VELCADE -dexamethasone
VGPR very good partial response
VISTA “VELCADE as Initial Standard Therapy in multiple myeloma” study
VMP VELCADE -melphalan -prednisone
VMPT VELCADE -melphalan -prednisone -thalidomide
VP VELCADE -prednisone
VT VELCADE -thalidomide
VTD VELCADE -thalidomide -dexamethasone
VTP VELCADE -thalidomide -prednisone
WHO World Health Organization
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
43
Approved , Date: 14 February 20181. INTRODUCTION
1.1. Background
1.1.1. Multiple My eloma
Multiple myeloma is a malignant disorder of the plasma cells, characterized by uncontrolled and 
progressive proliferation of a plasma cell clone. The disease leads to progressive morbidity  and 
eventual mortalit y by lowering resistance to infection and causing significant skeletal destruction 
(with bone pain, pathological fractures, and hypercalcemia), anemia, renal failure, neurological 
complications and hy perviscosity  syndrome.
The majorit y of patients with multiple myeloma produce a monoclonal protein, also called 
paraprotein, M-protein or M-component, which is an immunoglobulin (Ig) or a fragment of one 
that has lost its function (Kyle 2009 , Palumbo 2011).19,33Normal immunoglobulin levels are 
compromised, leading to susceptibility  of infections. The proliferating multiple myeloma cells 
displace the normal bone marrow leading to dysfunction in normal hematopoietic tissue and 
destruction of the normal bone marrow architecture, which is reflected by clinical findings such 
as anemia, neurologic symptoms , and bone resorption seen as diffuse osteoporosis or lytic 
lesions shown in radiographs ( Kyle 2003).18Furthermore, hypercalcemia, renal insufficiency or 
failure, and detectable monoclonal protein in the serum or urine are frequently  seen (Palumbo 
2011).33A small minority of patients with multipl e my eloma are non- secretory .
At the time of diagnosis, multiple myeloma is a heterogeneous disease, with a course that varies 
on the basis of both disease -and host -related factors (eg, age, renal function, stage, chromosomal 
abnormalities). Multiple myeloma causes significant morbidity  and mortality . It accounts for 
approximately  1% of all malignancies and 13% of hematologic cancers. Approximately  
50,000 patients per year are diagnosed with multiple myeloma in the EU and US, and 
30,000 patients per year die due to multiple my eloma ( ACS 2013, Ferlay  2010).1,11
1.1.2. Treatment Options for Multiple My eloma
Treatment choices for multiple myeloma vary with age, performance status, comorbidity , the 
aggressiveness of the disease, and related prognostic factors (Palumbo 2011).33Newly  diagnosed 
patients with multiple myeloma are typically  categorized into 2 subpopulations usually  defined 
by their age and suitability  for the subsequent approach to treatment. Younger patients will 
typicall y receive an induction regimen followed by consolidation treatment with high-dose 
chemotherap y and autologous stem cell transplantation (ASCT ). For those not considered 
suitable for high-dose chemotherap y and ASCT, longer -term treatment with multi- agent 
combinations including alkylators, high-dose steroids, and nove l agents are currentl y considered 
as standards of care.
The availability  of different efficacious multi- agent regimens has provided clinicians with the 
opportunity  of tailoring treatment for each patient. Selection is based on patients' comorbidities 
and biologic age, while at the same time, taking into account the expected toxicity  profiles of 
each treatment regimen (Gay  2011).12
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
44
Approved , Date: 14 February 20181.1.3. Transplant -ineligib le Population
In general, patients over the age of 65 or with significant comorbidities are usually  not 
considered eligible for more intensive forms of first line therapy , and as a result the treatment 
approach often favors longer, less-intensive/toxic treatments (Gay 2011).12Treatment 
traditionally  consists of systemic chemotherap y, with adjunctive use of radiation or surgery  in 
selected cases associated with extramedullary  disease (NCCN 2013, Palumbo 2009, Smith 
2005).30,36,40For many  years, the oral combination melphalan -prednisone (MP) was considered 
the standard of care for patients with multiple myeloma who were not eligible for ASCT (Gay 
2011 ).12The advent of immunomodulatory  agents (IMiD)and proteasome inhibit ors(PI)has led 
to a multiplicity  of new treatment options for newly  diagnosed patients not considered suitable 
for transplant based therapy . In Europe, the standard of care are combinations such as melphalan -
prednisone -thalidomide (MPT) (Fayers 2011)10, or VEL CADE -melphalan -prednisone (VMP )
(San Miguel 2008).39VELCADE in combination with melphalan and prednisone are approved in 
this setting within numerous countries worldwide including the European Union and the US.
1.1.4. Treatment U ntil Progression in T ransplant -ineligible Patients
There is growing evidence that continued treatment of multiple myeloma can prolong the period 
of remission; however, long-term treatment with current therapies is often compromised through 
unacceptable toxicity .
The VMP regime n is typically  given for up to a year; the VISTA study  (VEL CADE as Initial 
Standard Therap y in multiple myeloma [VISTA]) demonstrated that complete responses 
continued to occur in the later cycles (Cycles5-9) (Harousseau 2010 ).14Furthermore, the study 
demonstrated that the longer patients were on treatment, the better the outcomes.
VEL CADE, given to disease progression, has been investigated in combination with other agents 
in the transplant -ineligible population. In a study  of 178 elderl y untreated patients who were 
initially  treated with an induction combination regimen comprising either VMP or 
VEL CADE -thalidomide -prednisone (VTP ), patients were treated until progression with either 
VEL CADE -thalidomide (VT) or VELCADE -prednisone (VP). Progression- free survival or OS 
was not significantl y different between the 2 treatment groups, but both resulted in median PFS 
of 32 (VP) to 39 (VT) months and a 5 -year OS over 50% in both arms (Mateos 2012).27
In another randomized comparison of VEL CADE -melphalan -prednisone -thalidomide (VMPT )
followed by continuous VT as maintenance, or VMP with no additional continuous therapy  in 
511previously  untreated patients who were not eligible for transplant (aged 65years or older), 
the arm with VMPT induction followed by the continuous VT therapy  showed superiority  over 
the VMP alone arm. The 3 -year estimates of PFS were 56% in patients receiving VMPT -VT and 
41% in those receiving VMP (p=0.008) (Palumbo 2010).35
Further justification for continuous treatment until progression was demonstrated in a large, 
randomized Phase 3 study  (MM- 020/IFM 07-01) comparing 2 active -treatment arms consisting 
of different durations of lenalidomide plus low -dose dexamethasone ( Rd)to a third active control 
arm of MPT in subjects newly  diagnosed with multiple myeloma (Facon 2013).9In this study , 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
45
Approved , Date: 14 February 20181,623 subjec ts who were ineligible for ASCT were randomized to receive continuous Rd until 
disease progression (Arm A); Rd for eighteen 28 -day cycles (72 weeks) (Arm B); or MPT for up 
to twelve 42-day cycles (72 weeks) (Arm C). The primary  endpoint of the study  is PFS
(Arm A vs Arm C). Secondary  endpoints included OS, response rate, quality  of life and safet y. 
Continuous treatment with Rd significantly  improved the primary  endpoint of PFS compared 
with MPT. After a median follow -up of 37 months, the trial met the prima ry endpoint, 
demonstrating a 28% reduction in risk of progression or death (HR=0.72; p=0.00006). The 
preplanned interim analy sis of OS demonstrated a 22% reduction in risk of death in favor of 
Arm A vs Arm C (HR=0.78, p=0.01685); however, the pre-specified boundary  (p<0.0096) was 
not crossed. All other secondary  endpoints (ORR [PR or better], OR, and PFS2) consistently  
showed improvement in favor of Arm A vs. Arm C. The safet y profile of Rd was manageable, 
with reduced hematologic second primary  malignancie s compared with MPT.
1.2. Daratumumab
Daratumumab is a human IgG1 ĸ monoclonal antibody  (mAb) that binds with high affinity  to a 
unique epitope on CD38, a transmembrane glycoprotein. It is a targeted immunotherapy  directed 
towards tumor cells that express high levels of CD38, such as plasma cells from patients with 
multiple myeloma. This target is distinct from those of other approved agents for multiple 
myeloma therap y.
For the most comprehensive nonclinical and clinical information as well as Reference Safet y 
Information regarding daratumumab, refer to the latest version of the Investigator's Brochure 
(IBDaratumumab 2013).16
1.2.1. Nonclinical Studies
Based on preclinical data, daratumumab may utilize multiple effector cell functions, resulting in 
immune mediated killing of tumor cells. In ex vivo experiments utilizing human bone marrow 
stromal cells co-cultured with primary  multiple myeloma cells, complement -dependent 
cytotoxicity  (CDC) occurs rapidl y and demonstrates maximal myeloma cell killing by 
daratumumab within 1 hour of antibody -mediated activation of the comple ment proteins (de 
Weers 2011).6Daratumumab- induced antibody -dependent cell-mediated cytotoxicity  (ADCC) is 
slower in its action, with maximal ADCC by daratumumab observed at 4 hours in vitro (de 
Weers 2011).6Daratumumab has also been shown to induce antibody -dependent cellular 
phagocy tosis (ADCP) in the presence of macrophages within 4 hours in vitro (Overdijk 2013).32
The precise role of some or all of these effector functions in reducing tumor burden in patients is 
unknown.
In toxicology  studies in cynomolgus monkey s and chimpanzees, the major observed toxicities 
were cytokine release syndrome and thrombocy topenia along with a minor decrease in red blood 
parameters. Cytokine release was seen only following the first dose and was markedly  reduced 
following implementation of a 10-mg predose of daratumumab. The effect on platelets and red 
cells was reversible.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
46
Approved , Date: 14 February 2018Preclinical evidence to support combining VMP with daratumumab is based on results of ex vivo 
flow cytometry -based assay  platform, in which the addition of daratumumab to VMP 
significantl y increased the treatment effect by almost doubling the bone marrow mononuclear 
cells l ysis levels (van derVeer 2011a ).42
In study  GMB3003 -070, the potential benefit of combining daratumumab with multi -drug 
chemotherap y regimens was evaluated in fresh tumor cells fro m subjects with multiple my eloma 
(data on file). Lysis of primary  tumor cells was measured directl y in bone marrow mononuclear 
cell (BM -MNC) isolates obtained from subjects with multiple myeloma. Synergistic tumor cell 
lysis was demonstrated when daratumum ab was combined with lenalidomide and/or VEL CADE, 
even in samples from subjects that were refractory  to lenalidomide and VEL CADE treatment. 
Treatment of BM-MNC with lenalidomide or VEL CADE resulted in 10% and 18% lysis, 
respectivel y. A combination of lenal idomide and VEL CADE resulted in 25% ly sis of BM -MNC. 
When daratumumab was added to either lenalidomide or VEL CADE, a 2 -fold increase in lysis 
was observed compared with lenalidomide or VELCADE alone. When daratumumab was added 
to combinations of dexamethas one, lenalidomide and VEL CADE or to VEL CADE, prednisone, 
and melphalan , the cell lysis was significantl y increased (p<0.001) compared with the triple 
combination alone (no daratumumab) (van derVeer 2011 a).42Refer to Figure 1and Figure 2.
Figure 1: Daratum umab-Enhanced Multiple Myelom a Cell Killing by Key Multiple Myelom a 
Chemotherapeutic Agents
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
47
Approved , Date: 14 February 2018Figure 2: Dose -dependent Lysis of Multiple Myelom a cells in Triple Chem otherapy Treatm ents
1.2.2. Clinical Studies
1.2.2.1. Single -Agent Daratumumab Studies (GEN501 and MMY2002)
Two single -agent studies with daratumumab are ongoing (Studies GEN501 and MMY2002 ), as 
described in Table 1.
Among the 32 subjects treated in Part 1 of Study GEN501, the maximum tolerated dose (MTD) 
was not reached following intravenous (IV) infusions up to 24mg/kg. Two subjects experienced 
dose- limiting toxicities (DLTs) in the lower dose cohorts (a subject in the 0.1-mg/kg group had 
Grade 3 anemia and Grade 4 thrombocy topenia, and a subject in the 1.0-mg/kg group had 
Grade 3 aspartate aminotransferase increased). 
Among the 51 subjects treated in Part 2 of Study GEN501, serious adverse events (SAEs) were 
reported in 37% of subjects (43% of subjects in the 8-mg/kg group and 29% of subjects in the 
16mg/kg -group). The most frequentl y reported SAEs were pneumonia (6% subjects), and 
pyrexia (4% of subje cts).
Among the 34 subjects treated in Stage 1 of Study MMY2002, SAEs were reported in 27% of 
subjects (33% of subjects in the 8 mg-kg group, and 19% of subjects in the 16mg/kg -group). 
The most frequentl y reported SAE was renal failure acute (6% of subjec ts).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
48
Approved , Date: 14 February 2018Table 1: Daratum umab Single -Agent Studies GEN501 and MMY2002
Study Number Study Design Number of subjects Treated/
Treat ment Regimen
GEN501 Open -label, Phase 1/2, first-in -human, 
single -agent study in subjects with 
multiple myeloma whose disease is 
relapsed or refractory to at least 2 prior 
lines of therapies
Population was heavily treated with prior 
treatment, including ASCT, 
chemotherapy based regimens, IMiDs, 
and PIsPart 1
n=32 total treated with daratumumab weekly
0.005-1 mg/kg (n=17)
2 mg/kg (n=3)
4 mg/kg (n=3)
8 mg/kg (n=3)
16 mg/kg (n=3)
24 mg/kg (n=3)
Part 2
n=51 total treated
8 mg/kg (n=30)
Weekly for 8 weeks, 
followed by q2w for an 
additional 16 weeks, and 
monthly thereafter16 mg/kg (n=21)
First dose, followed by a 3 -
week resting period, followed 
by weekly doses for 7 weeks, 
then q2w for an additional 14 
weeks, and monthly 
thereafter
MMY2002 Open -label, multicenter, 2 -stage, Phase 2 
study of daratumumab for the treatment 
of subjects with multiple myeloma who 
have received at least 3 prior lines of 
therapy including a PI and an IMiD or 
whose disease is double refractory to 
both a PI and an IMiDn=34 total treated in Stage 1
8 mg/kg (n=18)
q4w16 mg/kg (n=16)
qw for 8 weeks, then q2w for 
another 16 weeks, and then 
q4w thereafter
ASCT =autologous stem cell transplantation; I MiD=immunomodulatory agent; PI=proteasome inhibitor; q2w=every 2 weeks; 
q4w=every 4 weeks
1.2.2.2. Combination Daratumumab Studies
One study  of daratumumab in combination with lenalidomide and dexamethasone 
(Study GEN503), and one study  of daratumumab in combination with various backbone 
treatment regimens (Study  MMY1001) are ongoing (Table 2).
Based on preliminary  efficacy  data, 15 of 20 subjects treated in Study  GEN503 have achieved a 
PR or better following treatment with daratumumab in combination with lenalidomide and 
dexamethasone.
The safet y profile observed in Study GEN503 is consistent with historical safety  data for 
lenalidomide and dexamethasone. Doses ranged from 2 mg/kg to 16 mg/kg daratumumab, in 
combination with the approved doses of lenalidomide (25mg daily Days 1-21 of 28 days) and 
dexamethasone (40 mg weekl y). No dose-limiting toxicity  (DLT) drug-related safet y signals 
have been observed in this heavily  pre-treated population of subjects with advanced multiple 
myeloma. The Part 2 daratumumab dose was determined to be 16 mg/kg . Across all dose cohorts
in Part 1 and in the 16 mg/kg expansion cohort for Part 2, the most frequently  reported Grade 3 
or higher AE was neutropenia (6 subjects), which is a known toxicity  of lenalidomide. Eight 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
49
Approved , Date: 14 February 2018serious adverse events (SAEs) have been reported. All SAEs were assessed by  the investigator as 
not related to daratumumab. Four subjects experienced infusion-related reactions during the first 
infusion of daratumumab . These events were determined by the investigator to be related to 
daratumumab. In allinstances, daratumumab was interrupted temporarily  and restarted without 
complication or further incident.
In Study  MMY1001, 5subjects have been enrolled to the VMP plus daratumumab cohort as of 
21May 2014. The same dose and schedule used in MMY1001 will be utilized in the present 
study . Emerging safet y data will be communicated as appropriate.
Table 2: Daratum umab Combina tion Studies GEN503 and MMY1001
Study Number Study Desig n Treatm ent RegimenStatus/Estim ated 
Start Date
Number of 
subjects 
Treated/Planned
GEN503Open -label, Phase 1/2 multicenter, dose -
escalating study investigating the safety of 
daratumumab in combination with 
lenalidomide and dexamethasone in subjects 
with relapsed or refractory multiple myelomaPhase 1: 
2-16 mg/kg daratumumab, in 
combination with lenalidomide 
(25mg daily Days 1 -21 of 28 
days) and dexamethasone (40 mg 
weekly)Phase 1: Ongoing 
(n=13 subjects 
treated)
2 mg/kg (n=3)
4 mg/kg (n=3)
8 mg/kg (n =4)
16 mg/kg (n=3)
Phase 2: 
16 mg/kg daratumumab, in 
combination with lenalidomide 
(25mg daily Days 1 -21 of 28 
days) and dexamethasone (40 mg 
weekly)Phase 2:
n=18 subjects treated 
approximately 30 
subjects planned
MMY1001 Open -label, non-randomized, multicenter, 
Phase 1b study to evaluate the safety, 
tolerability, and dose regimen of 
daratumumab in combination with various 
backbone treatment regimens for multiple 
myeloma in either newly diagnosed or those 
who have received at least 2 p rior therapies, 
depending on backbone treatment regimenDaratumumab 16 mg/kg 
(initially, with possibility to de -
escalate, if necessary)
The backbone regimens to be 
combined with daratumumab 
include VELCADE -
dexa methasone (VD), VMP, 
VTD, and Pom -dexn=18 subjects treated
VTD (n=6 )
VMP (n=5 )
Vd (n=1)
Pom-dex (n=6 )
approximately 48 
subjects planned; 12 
per cohort
Pom-dex=pomalidomide -dexamethasone; VMP -VELCADE -melphalan -prednisone; VTD=VELCADE -thalidomide-
dexamethasone
Phase 3 combination studies include study  MMY3003 comparing daratumumab, lenalidomide, 
and dexamethasone with Rd and study  MMY3004 comparing daratumum ab, VEL CADE, and 
dexamethasone with Vd. Both ongoing studies are in patients with relapsed or refractory  multipl e 
myeloma.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
50
Approved , Date: 14 February 20181.3. Overall Rationale for the Study
Multiple myeloma remains incurable with standard chemotherap y, despite the availability  of 
multi agent therap y. Strategies directed at improving and maintaining response for longer periods 
of time and new treatmen t options directed at alternative mechanisms are also urgentl y needed 
for patients with multiple my eloma.
The clinical utility  of adding VELCADE to melphalan and prednisone (VMP) for the treatment 
of patients 65 years or older was investigated in the VISTA study  (San Miguel 2008 ).39The 
study  demonstrated significant improvements in both time to progression and overall survival
compared to MP alone. In terms of response rate, 30% of patients in the VMP group had a 
comple te response versus only 4% in the MPgroup (p<0.001). Median time to progression was 
24.0 months in the VMP group compared to 16.6 months in the MPgroup (HR=0.48, p<0.001). 
Median time to subsequent myeloma therapy  was 20.8 months in the MPgroup and was not 
reached in the VMP group (p<0.001). After a median follow -up of 16.3 months, 45 patients 
(13%) in the VMP group and 76 patients (22%) in the MPgroup had died (hazard ratio in the 
VMP cohort=0.61, p=0.008); median survival was not reached in either group.As a result, VMP 
is now established as a standard of care in numerous countries worldwide.
Recent studies have indicated that multiple drug combinations are superior over single -or 
double -agent combinations in treating multiple myeloma (van der Veer 2011a).42In particular, 
VEL CADE -based treatment regimens have demonstrated significant improvements in response, 
progression- free survival (PFS), an d overall survival (OS) compared with non-VEL CADE -based 
therap y, both in newly  diagnosed transplant ineligible patients and those suitable for induction 
and transplant (Sonneveld 2013, Dimopoulos 2009).41,7
Daratumumab’s immediate and effective cell mediated (and potentiall y direct) cytotoxic effects 
against multiple myeloma cells, combined with the observed remarkable synergy  with 
VEL CADE (even in samples from patients who are refractory  to VEL CADE), may potentiall y 
improve the clinical outcome for patients with multiple myeloma when combined with a 
VEL CADE -based combination regimens (van der Veer 2011a ).42This study  will explore the 
efficacy  and safety  of the combination of darat umumab and VMP in subjects who are not 
eligible for ASCT.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
51
Approved , Date: 14 February 20182. OBJECTIVE SAND HYPOTHESIS
2.1. Objectives
Primary Objective
The primary  objective is to determine if the addition of daratumumab to VMP will prolong PFS 
compared with VMP . 
Secondary Objectives
The secon dary objectives are:
To determine if the addition of daratumumab to VMP will improve clinical outcome as 
measured b y:
Time to disease progression (TTP)
CR rate
Minimal residual disease ( MRD )negativity  rate
PFS2 (defined as time from randomization to progression on the next line of therap y or 
death, whichever comes first)
Time to next treatment
Overall response rate (partial response [PR] or better )
Stringent CR (sCR) rate
Very good partial response ( VGPR )or better rate
Time to response
Duration of re sponse
Overall survival
To assess patient -reported outcomes and heath economic/resource utilization
To determine the pharmacokinetics and immunogenicity  of daratumumab
To assess the safety  and tolerability  of daratumumab when administered in combination wi th 
VMP
To evaluate clinical efficacy  of daratumumab when added to VMP in high risk molecular 
subgroups .
Exploratory Objective
To explore biomarkers predictive of response and resistance to therap y.
To assess durability  of MRD negativity
2.2. Hypothesis
The hypothesis of the study  is that daratumumab continued until disease progression, in 
combination with 9cycles of VMP, will improve PFS compared with 9 cycles of VMP alone.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
52
Approved , Date: 14 February 20183. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a randomized, open -label, parallel -group, controlled, multicenter study  in subjects at least 
18 years of age with previously  untreated multiple myeloma who areineligible for high dose 
therap y. A target of up to 700subjects will be enrolled in this study  with 350 subjects planned 
per treatment arm .A diagram of the stud y design is provided in Figure 3.
Figure 3: Schematic Overview of the Study
Dara=daratumumab; PD=disease progression; Q4wks=every  4 weeks; Q16wks=every  16 weeks; 
VMP=VEL CADE -melphalan -prednisone
Subject participation will include a Screening Phase, a Treatment Phase, and a Follow -up Phase. 
The Screening Phase will be up to 21days before randomization .  All subjects will receive  up to 
9 cycles of the VMP  regimen (1 cy cle = 6 weeks) with or without daratumumab.
The T reatment Phase will extend from Day  1 of Cy cle 1 to discontinuation of all study  treatment . 
Eligible subjects will be stratified by  International Staging System (I vs II vs III), region (Europe 
vs Other) , and age(<75 vs ≥75) and then randomized in a 1:1 ratio. Subjects in both treatment 
arms will receive 1.3mg/m2VEL CADE by subcutaneous injection ( SC)twice weekl y (Weeks 1, 
2, 4, and 5) in Cycle 1 followed by once weekly  (Weeks 1, 2, 4, and 5) in Cycles 2 to 9. 
Melphalan POat 9 mg/m2and prednisone PO at 60mg/m2will be self-administered on Day 1-4 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
53
Approved , Date: 14 February 2018of each VELCADE cycle. For subjects randomized to the Treatment Arm B, 20 mg of 
dexamethasone will substitute for the planned dose of prednisone on Day  1 of each cycle. In this 
setting, dexamethasone willbe utilized as the treatment dose of steroid for that particular day, as 
well as the required pre -medication prior to daratumumab infusion. Daratumumab 16 mg/kg will 
be administered to subjects in Treatment Arm Bby IVinfusion once every  week for 6 weeks
(Cycle1; 1 VELCADE cycle); then once every  3 weeks for 16 additional doses (Cycles2-9). 
Measures to prevent infusion related reactions (IRRs) will include pre-infusion medication with 
dexamethasone, paracetamol, and antihistamine before each daratumumab infusion.
After completion of the VMP cycles, subjects in Arm A will enter the Follow -up Phase and 
should not be started on subsequent anti-myeloma therapy  without confirmed disease 
progression. Subjects in Arm B will continue to receive daratumumab every 4 weeks until 
documented progression, unacceptable toxicity , or the study  ends (see below for definition). 
Subjects who need to discontinue treatment with any one component of study  treatment 
(VEL CADE, melphalan, prednisone, or daratumumab) may continue to receive treatment with 
the other components of study  treatment, as assigned. Upon discontinuation of daratumumab, 
subjects in Arm B will also enter the Follow -up Phase and should not be started on subsequent 
anti-myeloma therap y without confirmed disease progression.
In the Follow -up Phase ,subjects who discontinue treatment before disease progression must 
continue to have disease evaluations according to the T ime and Events Schedule until confirmed 
PD (see Section 8.4, Subsequent Therapies) , subsequent anti-myeloma treatment, death, 
withdrawal of consent, lost to follow -up, or the end of the study . After disease progression is 
documented, follow -up will be obtained at least every  16 weeks. Subsequent anti-myeloma
treatment , PFS2 (per investigator judgment), second primary  malignancies, and survival will also 
be recorded.
Two interim analy ses are planned. The first interim analy sis, with a purpose to evaluate safet y, 
will be performed after a total of approximately  100 subjects have been treated for at least 
2cycles or discontinued the study  treatment. The second interim analy sis, with a purpose to 
evaluat e cumulative interim safet y and efficacy  data, will be performed when approximately 
216PFS events have been accumulated. Asthe superiority  of daratumumab combined with VMP  
over VMP  alone with respect to PFS was established atthe second interim analysis,theinterim 
PFS analysis will serve as the primary  PFS analy sis, which otherwise was tooccur when 
approximately  360PFS events hadbeen observed. The date established for the primary  PFS 
analysis(12June 2017) will serve as theprimary clinical cutof f date, after which subject 
monitoring will be conducted according to Section 9.1.5 of the protocol .As planned in the 
original protocol, two interim OS analy ses will be performed at the time of the interim PFS (216 
events) and the primary  PFS (360 events) prior to the final OS anal ysis at 330 deaths. T he second 
interim OS will occur when 200 deaths (60% of all planned deaths) have been accumulated 
which is about the same time of the primary  PFS analysis as if it would have occurred .After the 
OS interim analysis,subject monitoring will be conducted according to Section 9.1.6 .
Investigators will be informed when each interim analysis isto occur . All available data prior to 
thattime will be included in each of the respective anal yses.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
54
Approved , Date: 14 February 2018The end of the study  will occur when 330 subjects have died, or 5 years after the last subject is 
randomized, whichever comes first. The sponsor will ensure that subjects benefiting from 
treatment with daratumumab will be able to continue treatment after t he end of the study .
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study  to 
review efficacy  and safety  results at the2planned interim analy ses. After the interim review, 
they will make recommendations regarding the continu ation of the study . In addition, the IDMC 
may also review cumulative safet y data every  6 months besides the two interim analyses.The 
IDMC will no longer review study  data after the database lock for the primary  analysishas been 
completed.
As a result of the positive second interim analysis,that established the superiority  of 
daratumumab combined with VMP  over VMP  alone with respect to the primary  endpoint (PFS) , 
and consistent with the IDMC’ s recommendation, the sponsor will ensure that access to 
daratum umab is provided for subjects randomized to Arm A (VMP )who have sponsor -confirmed 
disease progression (seeSection 8.4,Subsequent Therapies) .
Assessment of tumor response and disease progression will be conducted in accordance with the 
International Myeloma Working Group (IMWG) response criteria. An assessme nt of MRD will 
be conducted on bone marrow samples. Safety  evaluations will include AE monitoring, physical 
examinations, electrocardiogram (ECG) monitoring, clinical laboratory  parameters (hematology 
and chemistry ), vital sign measurements, and Eastern Cooperative Oncology  Group (ECOG) 
performance status. Blood samples will be drawn for assessment of pharmacokinetic sand 
immunogenicit y.
3.2. Study Design Rationale
Choice of VELCADE Schedule
The most common side effect of VELCADE therapy  is peripheral neuropathy . In an effort to 
manage this toxicity , a number of clinical investigators have made minor adaptations to the 
VEL CADE schedule in order to reduce the incidence and severity  of this AE, with the intention 
of keeping patients on therap y longer; thus ensuring that patients receive appropriate intensity 
and duration of treatment with corresponding positive effects on the length of remission. A study  
comparing 2 regimens, VMP versus VMPT, as up-front therap y for patients >65years, showed 
that the weekly  infusio n of VEL CADE significantly  reduced the incidence of Grade 3-4 
peripheral neuropath y (18% in the biweekly  vs 9% in the weekly  schedule for the VMPT arm, 
and 12% in the biweekly  vs 3% in the weekly  schedule for the VMP arm) (Table 3) without 
adversel y influencing outcome (Palumbo 2008 ).34The once -weekl y schedule of VEL CADE 
resulted in a reduced discontinuation rate and prolonged the time on therapy : in both groups, 
patients received a median of 9 cycles, andthe median cumulative delivered dose of VELCADE 
was similar, 40.1 mg/m2for twice -weekl y and 39.4 mg/m2for once-weekl y regimens -
corresponding to a dose intensity  of 59% for twice -weekl y and 84% for once -weekl y regimens 
(Bringhen 2010 ).2
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
55
Approved , Date: 14 February 2018Table 3: Complete responses, progression -free survival and peripheral neuropathy in all patients and in 
those who received weekly infusion of VELCADE 
VMPT (n=152) VMP group (n=152)
All Patients
(n=152)Subgroup with 
VELCADE weekly 
infusion (n=90)All Patients
(n=152)Subgroup with 
VELCADE weekly 
infusion (n=90)
CR rate (%) 31 28 16 10
2 year PFS (%) 84 87 76 78
Grade 3 -4 peripheral 
neuropathy (%)18 9 12 3
Source: (Palumbo 2008)34
Similarly , the beneficial impact of a weekl y administration schedule of VEL CADE was also 
shown in a Spanish multicenter study  comparing VMP with VELCADE- thalidomide -prednisone 
(VTP). This study showed that VEL CADE -based regimens that use an intensive dosing of 
VEL CADE twice -per-week in the first cyclefollowed by less intensive weekl y dosing, are not 
only well-tolerated, but are also an active approach for elderl y populations, with similar efficacy 
for VMP and VTP ( Mateos 2010).26
In a recent paper, Mateos et al evaluated the safety  and efficacy  of 4different VMP regimens
(Mateos 2014).25The VISTA study  was compared to the GIMEMA MM-03-05 study  (both 
once -and twice -weekly  Velcade groups) and the GEM2005MAS65 study  (once -weekl y 
Velcade, 6cycles). The median cumulative dose of VEL CADE was notably  higher in patients 
receiving twice -weekl y VEL CADE. Overall response rate for VMP treatment was similar 
between all the regimens and averaged between 74 % to 87%. Overall survival was similar across 
all studies, however PFS was slightly  longer in the GEM2005MAS65 study  likely secondary  to 
extended VEL CADE usage for up to 3 years (38 months vs 21-25 months). Although the 
efficacy  was similar, Mateos and colleagues reported that the risk of peripheral neuropathy  and 
discontinuation due to AEs was much higher in the studies that utilized twice -weekl y 
VEL CADE vs once -weekly  VELCADE. For example, the rate of Grade 3/Grade 4 peripheral 
neuropath y was 13% in VISTA and 14% in the twice -weekl y GIMEMA study , but was 2% to 
7% in the once -weekly  VELCADE studies. The authors concluded that regimens that 
predominantly  use once -weekl y VELCADE result in high efficacy , comparable to response rates 
seen in VISTA, with improved safety  and tolerability .
This study  will incorporate twice -week lydosing of VELCADE in the first cycle, to obtain rapid 
reduction in plasma cell tumor burden , followed by once-weekl y dosing in subsequent cyclesfor 
improved tolerability . The 54-week treatment duration is based on the accepted duration of 
treatment with melphalan -prednisone. Note that for ease of reading, the VMP “lite” regimen is 
referred to as “VMP” throughout the protocol.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
56
Approved , Date: 14 February 2018Rationale for VELCADE Subcutaneous Administration
VEL CADE is approved in the US and the EU for both IV and SC routes of administration for all 
labeled indications. In this study , VELCADE will be administered subcutaneously . In clinical 
studies, SC administration has been shown to be non- inferior to the standard IV route of delivery  
and appears to have an improved systemic s afety profile, notably  resulting in significantl y lower 
rates of peripheral neuropathy , an important side effect of VELCADE (Moreau 2011).29
Further more, SC administration is a useful alternative to IV administration, particularly  for 
patients with poor venous access or with an increased risk of side effects and also affords greater 
flexibility  for the site and convenience for the patient.
Therefore, in this study , subjects will receive 1.3 mg/m2VEL CADE as a SC injection twice 
weekl y (Weeks 1, 2, 4, and 5) for one 6-week cycle (Cycle 1; 8 doses per cycle) followed by 
once weekly  (Weeks 1, 2, 4, and 5) administrations for eight 6 week cycles (Cycles 2 to 9; 
4doses per cy cle).
Rationale for Daratumumab Dose
CD38, the target for daratumumab, is expressed on NK cells and clinical data has shown NK cell 
suppression to be a marker of on target drug activity . Clinical pharmacokinetic data have shown 
the 16 m g/kg dose to be the lowest dose that results in nearly  complete target suppression at all 
time points. This dose and schedule continuously  suppressed NK cells throughout dosing. 
Daratumumab maximal target suppression is presented in Figure 4.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
57
Approved , Date: 14 February 2018Figure 4: Daratum umab Maxim al Target Suppression 
8mg/kg: Observed trough concentration 
values below  predicted 90% suppression 
throughout dosing
16mg/kg: Observed trough concentration 
values at 90% suppression throughout 
dosing
The ORR appeared higher for the 16mg/kg dose compared with the 8mg/kg dose, based on 
early preliminary  data from Part 2 of Study  GEN501 and from Study  MMY2002 (both ongoing 
studies) as of a cutoff date of 24 January  2014. In Study  GEN501, the ORRs (ie, PR or greater) 
were 11% and 40% for the 8mg/kg (n=28) and 16mg/kg (n=15) dose regimens, respectivel y. 
For Study MMY2002, the unconfirmed ORRs for the 8 mg/kg and 16 mg/kg dose regimens were 
similar to those observed in GEN501. In addition, VGPRs were observed for 7 of 30subjects 
treated with the 16mg/kg dose in the 2 studies. VGPR had not been observed at lower dose 
levels. These preliminary  data support that full target saturation at the 16mg/kg dose is needed 
to achieve higher and deeper response rates. 
Rationale for DNA and Biomarker Collection
Biomarker samples will be collected to evaluate the depth of clinical response to daratumumab 
through evaluation of MRD, using DNA sequencing of immunoglobulin genes, and to determine 
response rates in specific molecular subgroups of multiple myeloma, using DNA/RNA 
sequencing of MM cells to allow for assessment of high–risk genomics such as deletion 17p, 
t(4;14), t(14;20), t(14;16), deletion13, GEP signatures such as UAMS -70, and mutations in p53, 
BRAF, FGFR, IGH, PI3K, or other molecular subty pes associated with disease progression.
Other biomarker goals include evaluation of potential mechanisms of resistance, inter -indivi dual 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
58
Approved , Date: 14 February 2018variability  in clinical outcomes or identification of population subgroups that respond differentl y 
to treatment.
4. SUBJECT POPULA TION
Screening for eligible subjects will be performed within 2 1days before randomization .
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator must consult with the appropriate sponsor repre sentative and resolve any issues 
before enrolling a subject in the study .Waivers are not allowed.
For a discussion of the statistical considerations of subject selection, refer to Section 11.2, 
Sample Size Determination.
4.1. Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study . 
1. Subject must b e at least 18 years of age (or the legal age of consent in the jurisdiction in 
which the study  is taking place) .
2. Cri terion modified per Amendment 1
2.1.Criterion modified per Amendment 2
2.2 Subject must have documented multiple myeloma satisfy ing the calcium elevation, 
renal insufficiency, anemia, and bone abnormalities (CRAB) diagnostic criteria 
(seeAttachment 1), monoclonal plasma cells in the bone marrow ≥10% or presence of a 
biopsy  proven plasmacytomas, and measurable secretory  disease , as assessed by the 
central laboratory ,and defined by  any of the following:
IgG myeloma: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine 
M-protein level ≥200 mg/24 hours; or
IgA, IgM, IgD, or IgEmultiple my elom a: serum M-protein level ≥0.5 g/dL or urine 
M-protein level ≥200 mg/24 hours; or
Light chain multiple myeloma without measurable disease in the serum or urine : 
Serum immunoglobulin free light chain ≥10mg/dL and abnormal serum 
immunoglobulin kappa lambda f ree light chain ratio.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
59
Approved , Date: 14 February 20183. Newl y diagnosed andnot considered candidate for high-dose chemotherapy  with SCT 
due to:
Being age ≥65 y ears, Or
In subjects <65 years: presence of important comorbid condition(s) likely to have a 
negative impact on tolerability  of high dose chemotherap y with stem cell 
transplantation. Sponsor review of these comorbid conditions and approval is 
required before randomization.
4. Subject must have an ECOG performance status score of 0, 1, or 2 (Attachment 2 )
5. Cri terion modified per Amendment 1
5.1 Subject must have pretreatment clinical laboratory  values meeting the following 
criteria during the Screening Phase:
a)hemoglobin 7.5g/dL ( mmol/L ; prior red blood cell [RBC] transfusion or 
recombinant human ery thropoietin use is permitted);
b) absolute neutrophil count (ANC) 1.0 x 109/L(G-CSF use is permitted);
c)AST ≤2.5 x upper limit of normal (ULN);
d)ALT≤2.5 xULN;
e)total bilirubin ≤1.5 xULN, except in subjects with congenital bilirubinemia, 
such as Gilbert syndrome ,then direct bilirubin ≤1.5 xULN;
f)creatinine clearance 40mL/min, may  be calculated or measured according to 
local practice (if calculated, MDRD or CKD -EPIformulae preferred, see 
Section 9.1.2 )
g)corrected serum calcium ≤14mg/dL ( ≤3.5 mmol/L); or free ionized calcium 
≤6.5 mg/dL ( ≤1.6 mmol/L) (Attachment 3 );
h)platelet count 70 x 109/L for subjects in whom <50% of bone marrow 
nucleated cells are plasma cells; otherwise platelet count >50 × 109/L
(transfusions are not permitted to achieve this minimum platelet count) .
6. Women of childbearing potential must commit to either abstain continuously  from 
heterosexual sexual intercourse or to use 2 methods of reliable birth control 
simultaneously . This includes one highly  effective form of contraception (tubal
ligation, intrauterine device , hormonal [birth control pills, injections, hormonal patches, 
vaginal rings or implants] or partner’s vasectomy ) and one additional effective 
contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). 
Contraception must begin prior to dosing. Reliable contraception is indicated even 
where there has been a history  of infertilit y, unless due to hysterectomy or bilateral 
oophorectom y
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
60
Approved , Date: 14 February 20187. Cri terion modified per Amendment 1
7.1 A woman of childbearing potential must have a negative serum or urine pregnancy 
test at screening within 14days prior to randomization.
8. Each subject (ortheir legall y acceptable representative) must sign an informed consent 
form (ICF) indicating that he or she understands the purpose of and procedures required 
for the study  and are willing to participate in the study .Subject must be willing and able 
to adhere to the prohibitions and restrictions specified in this protocol, as referenced in 
the ICF.
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study . 
1. Subject has a diagnosis of primary  amyloidosis, monoclonal gammopath y of 
undetermined significance , or smoldering multiple myeloma . Monoclonal gammopath y
of undetermined significance is defined by presence of serum M-protein <3 g/dL; 
absence of lytic bone lesions, anemia, hypercalcemia, and renal insuf ficiency  related to 
the M-protein; and (if determined) proportion of plasma cells in the bone marrow of 
10% or less (Kyle 2003).18Smoldering multiple myeloma is defined as asymptomatic 
multiple myeloma with absence of related organ or tissue impairment or end-organ 
damage (Ky le 2003, Ky le 2007).18,20
2. Subject has a diagnosis of Waldenström’ s disease, or other conditions in which IgM 
M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone 
lesions.
3. Subject has prior or current systemic therapy  or SCT for multiple myeloma, with the 
exception of an emergency  use of a short course ( equivalent of dexamethasone 
40mg/day  for a maximum 4 day s) of corticosteroids before treatment.
4. Subject has peripheral neuropathy  or neuropathic pain Grade 2 or higher , as defined by 
the National Cancer Institute Common Terminology  Criteria for Adverse Events 
(NCI CTCAE) V ersion 4.
5. Subject has a history  of malignancy  (other than multiple myeloma) within 3 years 
before the date of randomization (exceptions are squamous and basal cell carcinomas of 
the skin and carcinoma in situ of the cervix, or malignancy  that in the opinion of the 
investigator , with concurrence with the sponsor's medical monitor , is considered cured 
with minimal risk of recurrence within 3 y ears) .
6. Subject has had radiation therap y within 14days of randomization.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
61
Approved , Date: 14 February 20187. Subject has had plasmapheresis within 28 days of randomization.
8. Subject is exhibiting clinical signs of meningeal involvement of multiple my eloma.
9. Cri terion modified per Amendment 1
9.1a)Subject has known chronic obstructive pulmonary disease (COPD) with a Forced 
Expirato ry Volume in 1 second (FEV1) < 50% of predicted normal. Note that 
FEV1 testing is required for subjects suspected of having COPD and subjects 
must be excluded if FEV1 <5 0% of predicted normal
9.1b) Subject has had known moderate or sever e persistent asthma within the last 
2years (see Attachment 4), or currentl y has uncontrolled asthma of any 
classification .(Note that subjects who currently  have controlled intermittent 
asthma or controlled mild persistent asthma are allowed in the study ).
10. Cri terion modified per Amendment 1
10.1 Subject is known to be seropositive for human immunod eficiency  virus (HIV), 
known to have hepatitis B surface antigen positivity , or known to have a history  of 
hepatitis C.
11. Subject has any concurrent medical or psychiatric condition or disease (eg, active 
systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary  disease ) 
that is likely  to interfere with the study  procedures or results, or that in the opinion of 
the investigator, would constitute a hazard for participating in this study .
12. Cri terion modified per Amendment 1
12.1 Criterion modified per Amendment 2
12.2 Subject has clinically significant cardiac disease, including:
myocardial infarction within 1 year before randomization , or an unstable or 
uncontrolled disease/condition related to or affecting cardiac function (eg, unstable 
angina, congestive heart failure, New York Heart Association Class III-IV)
uncontrolled cardiac arrhy thmia or clinically  significant ECG abnormalities
screening 12- lead ECG showing a baseline corrected QT interval (QTc) >470 msec
13. Subject has known allergies, hypersensitivity , or intolerance toboron or mannitol, 
corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to 
respective package inserts orInvestigator's Brochure), or known sensitivity  to 
mammalian -derive d products.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
62
Approved , Date: 14 February 201814. Subject has plasma cell leukemia (according to WHO criterion : ≥20% of cells in the 
peripheral blood with an absolute plasma cell count of ≥2×109/L) or POEMS syndrome 
(poly neuropathy , organomegaly , endocrinopathy , monoclonal protein, and skin 
changes).
15. Subject is known or suspected of not being able to comply  with the study  protocol 
(eg,because of alcoholism, drug dependency , or psychological disorder). Subject has 
any condition for which, in the opinion of the investigator, particip ation would not be in 
the best interest of the subject (eg, compromise the well-being) or that could prevent, 
limit, or confound the protocol-specified assessments . Subject is taking any prohibited 
medications as per Section 8.3.
16. Criterion Modified per Amendment 2
16.1 Subject is a woman who is pregnant, or breast- feeding, or planning to become 
pregnant while enrolled in this study  or within 3 months after the last dose of any 
component of the treatment regimen. Or, subject is a man who plans to father a child 
while enrolled in this study  or within 3months after the last dose of any component of 
the treatment regimen.
17. Cri terion modified per Amendment 1
17.1 Subject has had major surgery within 2 weeks before randomization or has not
fully recovered from surgery , or has surgery  planned during the time the subject is 
expected to participate in the study . Kyphoplasty or vertebroplasty  arenot considered 
major surgery .Note: subjects with planned surgical procedures to be conducted under 
local anesthesia may  participate.
18. Subject has received an investigational drug (including investigational vaccines) or used 
an invasive investigationa l medical device within 4 weeks before randomization or is 
currentl y enrolled in an interventional investigational study.
19. Incidence of gastrointestinal disease that may significantly  alter the absorption of oral 
drugs.
NOTE: Investigators should ensu re that all study enrollment criteria have been met at 
screening. If a subject's status changes (including laboratory results or receipt of additional 
medical records ) after screening but before the first dose of study treatment is given such 
that he or shenolonger meet sall eligibility criteri a, then the subject should be excluded 
from participation in the study .Section 17.4 describes the required documentation to support 
meeting the enrollment criteria .Subjects who fail to meet the inclusion and exclusion criteria 
(ie,screen failures) may be rescreened once iftheir condition changes. Rescreening must be 
discussed with and approved by the sponsor on a case-by-case basis. Subjects who are 
determined to be eligible for rescreening must sign a new ICF and will then be assigned a new 
screening number.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
63
Approved , Date: 14 February 20184.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  to be eligible for participation. For restrictions related 
to concomitant medications, please refer to Sect ion 8.3.
1. For women of childbearing potential, adequate contraception as specified in Section 4.1
must continue during the Treatment Phase, during any dose interruptions, and for 
3months after the last dose of daratumumab. In addition, women must not donate ova 
during the stud y and for 3 months after the last dose of daratumumab.
2. A man who is sexually  active with a woman of childbearing potential must alway s use a 
latex or synthetic condom during the study  and for 3 months after discontinuing  
daratumumab. All men must not donate sperm during the study  andfor 3 months after 
the last dose of daratumumab .
3. Typically , IV contrast is NOT used in computed tomography  (CT) scanning of subjects 
with secretory  multiple myeloma because of the risk to the kidney . If administration of 
IV contrast is necessary , then adequate precautions including hy dration are indicated.
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Eligible subjects will be stratified by International Staging System (I vs II vs IIIbased on central 
laboratory  results at Screening, see Attachment 9), region (Europe vs Other) , and age(<75 vs 
≥75)and then randomized to treatment in a 1:1 ratio to either Treatment Arm A (VMP alone ) or 
Treatment Arm B (daratumumab+VMP [D-VMP]). The method of randomization is randomly  
permuted blocks .An interactive web based randomization system (IWRS) will be used. Each 
subject will be assigned a unique subject number.
Blinding
As this is an open study , blinding procedures are not applicable.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
64
Approved , Date: 14 February 20186. DOSA GE A ND A DMINISTR ATION
In this protocol, the term “study  drug” refers to daratumumab only, and “study  treatment” refers 
to daratumumab , VEL CADE, melphalan, and prednisone . Daratumumab is to be administered as 
described in the Time and Events Schedule. On dosing days where the combination products are 
given with daratumumab (ie, Arm B only),the study  drug and chemotherap y should be 
administered in the following order:
prednisone, daratumumab, VEL CADE, and melphalan
Detailed information on the composition of the study  treatments can be found in the Site 
Investigational Product Procedures Manual (SIPPM) or equivalent document . The administration 
schedule is provided in the Time and Events schedule. Cycles are based on the administration of 
VEL CADE and will be approximately  42 day s (6 weeks) in duration. 
In Cycles 2-9, b efore initiating a new cycle of therap y, subjects should meet the following 
criteria:
Platelet count ≥70 x 1 09/L
ANC ≥1.0 x 109/L
Non-hematological toxicities resolved to Grade 1 or baseline
The start of each cycle may occur within ±3 days of the scheduled day in order to accommodate 
the schedule of the site or subject. If the start of a cycle is delay ed, Day 1 of subsequent cycles 
should be adjusted accordingl y to maintain the 42-day cycle duration. In Cycles 1 through 9, 
weekl y or every -three -week daratumumab infusions may be given within ±1 day of the 
scheduled day in order to accommodate the schedule of the site or subject. Additionally , weekl y 
or twice weekl y VELCADE doses may be given within ±1 day of the scheduled day in order to 
accommodate the schedule of the site or subject. Changes to within -cycle dosing should not 
impact Day  1 of the next cy cle.
Subjec ts are to receive VMP for a maximum of 9 cycles. For subjects randomized into Treatment 
Arm B, daratumumab will be given according to the Time and Events Schedule until disease 
progression, unacceptable toxicity , or other reasons as listed in the Section 10.2.
A schematic of stud y treatment administration is provided in Figure 5.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
65
Approved , Date: 14 February 2018Figure 5: Study Treatment Administration
6.1. Daratumumab (Arm B Only)
6.1.1. Daratumumab Preparation
The infusion solution will be prepared on the day of the planned infusion. Detailed instructions
for preparation and administration of daratumumab will be supplied in the Site Investigational 
Product Procedures Manual ( SIPPM )or equivalent document .
6.1.2. Daratu mumab A dministration
Daratumumab (16 mg/kg) will be administered to subjects in Arm B by  IV infusion initially  once 
every  week for 6weeks (Cycle 1; 1 VEL CADE cycle); then once every  3  w eeks for an 
additional 16 doses (Cycles 2-9); then once every  4  w eeks thereafter (post -VMP Treatment 
Phase), until documented progression, unacceptable toxicity , or study  end.After the end of the 
study , the sponsor will ensure that subjects benefiting from treatment with daratumumab will be 
able to continue treatment.
A daratumumab infusion will be skipped if it cannot be administered within the prescribed time 
window as outlined in Table 4. Each subject’s dose will be calculated based on the subject’s 
weight rounded to the nearest kilogram. There is no cap on the absolute dose allowed, as long as 
the dose does not exceed 16mg/kg. If a subject’s weight changes by more than 10% from 
baseline, the dose of daratumumab willbe re-calculated. For recommendations on daratumumab 
infusion rate, please refer to the SIPPM or equivalent document . D1
D32 D11
VELCADE
1.3 mg/m2SC
(ALL SUBJECTS )D8 D29
Follow -upD1 D22DARATUMUMAB
16 mg/kg IV
(ARM B ONLY)
Cycle 10+ 
(4 week cycles)D15 D1 D1 D22
Follow -upD22 D8 D1
Cycle 1 
(6 week cycle)Cycles 2-9 
(6 week cycles)D29 D36
MELPHALAN 9 mg/m2PO 
PREDNISONE 60 mg/m2 PO 
(ALL SUBJECTS) D1-D4
Follow -upD1-D4D4D8
D25D29 D22
Cycle 1 
(6 week cycle)Cycles 2-9 
(6 week cycles)
Cycle 1 
(6 week cycle)Cycles 2-9 
(6 week cycles)
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
66
Approved , Date: 14 February 2018As noted in the Time and Events Schedule, vital signs should bemonitored extensively  on 
Cycle1 Day  1 before, during, and after the first infusion of daratumumab. For all other infusions, 
vital signs should be measured before the start of infusion and at the end of the infusion. If a 
subject experiences any significant medical event, then the investigator should assess whether 
the subject should stay overnight for observation.
6.1.3. Guidelines for Prevention of Infusion Reactions
6.1.3.1. Pre-infusion Medication 
Pre-infusion medications for subjects receiving daratumumab will be administered as described 
in the Time and Events Schedules. On daratumumab infusion days, subjects will receive the 
following medications prior to infusion:
Paracetamol (acetaminophen ) 650-1000 mg IV or POapproximately  1 hour or less prior to 
daratumumab infusion
An antihistamine (diphenhy dramine 25-50 mg IV or PO, or equivalent H1 block er; see 
Attachment 5 ) approximately  1hour prior to daratumumab infusion.
Dexamethasone 20 mg IV or PO, approximately 1 hour or less prior to daratumumab 
infusion. Substitutions for dexamethasone are allowed, please refer toAttachment 6.On 
days when subjects receive this dose of dexamethasone in the clinic, prednisone will not be 
self-administered at home.
Leukotriene Inhibitor (optional) on Cycle 1 Day 1: montelukast 10 mg PO, or equivalent, 
approximately  1 hour or less before the daratumumab infusion
If necessary , all PO pre-infusion medications may be administered outside of the clinic on the 
day of the infusion, provided they  are taken within 3 hours before the infusion.
6.1.3.2. Post -Infusion Medica tion
For subjects with higher risk of respiratory  complications (eg, subjects with mild asthma, or 
subjects with COPD who have a FEV 1<80%), the following post-infusion medications should 
be considered:
Antihistamine (diphenhydramine or equivalent) 
Leukotriene inhibitor (montelukast or equivalent)
Short -acting β2 adrenergic receptor agonist such as salbutamol aerosol 
Control medications for lung disease (eg, inhaled corticosteroids ± long -acting β2 adrenergic 
receptor agonists for subjects with asth ma; long -acting bronchodilators such as tiotropium or 
salmeterol ± inhaled corticosteroids for subjects with COPD)
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
67
Approved , Date: 14 February 2018In addition, these at-risk subjects may be hospitalized for monitoring for up to 2 nights after an 
infusion. If subjects are hospitalized, then their FEV 1should be measured before discharge. If 
these subjects are not hospitalized, then a follow up telephone call should be made to monitor 
their condition within 48 hours after all infusions. If the subject has not experienced a significant 
medic al event but is hospitalized overnight only for observation, then the hospitalization should 
not be reported as a serious adverse event. Investigators may prescribe bronchodilators, 
antihistamines, and corticosteroids that are deemed necessary  to provide adequate supportive 
care in the event a bronchospasm occurs after subjects are released from the hospital/clinic. If an 
at-risk subject experiences no major infusion-related reactions, then these post-infusion 
medications may  be discontinued after 4 full do ses at the investigator’s discretion.
6.1.4. Management of Infusion- related Reactions
Subjects in Arm B should be carefully  observed during daratumumab infusions. Trained study  
staff at the clinic should be prepared to intervene in case of any infusion -related reactions 
occurring, and resources necessary  for resuscitation (eg, agents such as epinephrine and 
aerosolized bronchodilator, also medical equipment such as oxygen tanks, anda defibrillator) 
must be available. Attention to staffing should be considered when multiple subjects will be 
dosed at the same time.
If an infusion- related reaction develops, then the infusion should be temporarily  interrupted. 
Subjects who experience adverse events during the infusion must be treated according to the 
investigator’s judgment and best clinical practice. The following guidelines may  apply :
Subjects should be treated with acetaminophen, antihistamine, or corticosteroids. 
Intravenous saline may be indicated. For bronchospasm, urticaria, or dyspnea, subjects may 
require antihistamines, oxygen, corticosteroids, or bronchodilators. For hypotension, 
subjects may  require vasopressors.
In the event of a life-threatening infusion-related reaction (which may include pulmonary  or 
cardiac events), or anaphy lactic reaction, daratumum ab should be discontinued and no 
additional daratumumab should be administered to the subject. Aggressive symptomatic 
treatment should be applied.
If an infusion is paused, then a longer -than-anticipated infusion time may occur. Overnight stays 
at the hospital because of slow infusion times should not be reported as a serious adverse event.
However, if the underl ying cause of the delay ed infusion time is an adverse event or serious 
adverse event, then that should be reported as such .
6.1.4.1. Infusion -Related Events of Grade 1 or Grade 2
If the investigator assesses an adverse event to be related to the daratumumab infusion, then the 
infusion should be paused. When the subject’s condition is stable, the infusion may be restarted 
at the investigator’s discretion. Upon restart, the infusion rate should be half of that used before 
the interruption. Subsequently , the infusion rate may  be increased at the investigator’s discretion. 
If the subject experiences a Grade 2 or higher event of laryngeal edema or a Grade 2 or higher 
event of bronchospasm that does not respond to systemic therapy  and does not resolve within 
6hours from the onset, then the subject must be withdrawn from treatment.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
68
Approved , Date: 14 February 20186.1.4.2. Infusion -Related Reactions of Grade 3 or Higher
For infusion-related adverse events that are Grade 4, the infusion should be stopped and 
treatment with daratumumab will be discontinued for that subject.
For infusion-related adverse events that are Grade 3, the daratumumab infusion must be stopped, 
and the subject must be observed carefully  until the resolution of the adverse event or until the 
intensity  of the event decreases to Grade 1, at which point the infusion may be restarted at the 
investigator’s discretion . Upon restart, the infusion rate should be half of that used before the 
interr uption. Subsequently , the infusion rate may  be increased at the investigator’s discretion.
If the intensity  of the adverse event returns to Grade 3 after restart of the infusion, then the 
procedure described in this section may be repeated at the investiga tor’s discretion. Should the 
intensity  of the adverse event increase to Grade 3 for a third time, then treatment with 
daratumumab will be discontinued for that subject.
6.2. VELCA DE, Melphalan, and Prednisone (Arm A  and Arm B)
The sponsor will provide VELCADE to the sites, if required . Sites will use commerciall y 
available melphalan and prednisone for administration in this study  unless otherwise 
communicated to the site. Before administering, refer to the currently  approved package inserts 
for complete prescribing information. 
6.2.1. Dose C alculation of VELCA DE, Melphalan, and Prednisone
The amount (in mg) of VEL CADE, melphalan , and prednisone to be administered will be 
determined by body surface area (BSA), which will be calculated according to a standard 
nomogram (Attachment 7).The total calculated dose may be rounded to the nearest decimal 
point (eg, a calculated dose of 2.47 m g can be rounded to 2.5 mg). There is no cap on the 
absolute dose allowed, as long as the dose is based on the subject’s BSA. If a subject’s weight 
changes by more than 10% from baseline, the dose of VEL CADE, melphalan, and prednisone 
willbe re -calculated.
6.2.2. VELCA DE Administration
Subjects will receive 1.3 mg/m2VEL CADE as a SC injection twice weekly (Weeks 1, 2, 4, and 
5) for one 6-week cycle (Cycle 1; 8 doses per cycle) followed by once weekl y (Weeks 1, 2, 4, 
and 5) administrations for eight 6 -week cy cles (Cy cles 2 to 9; 4 doses per cy cle). 
On treatment days when both VEL CADE and daratumumab are administered, VEL CADE must 
be administer ed after the daratumumab infusion. VEL CADE will be supplied in sterile, single -
use vials containing 3.5 mg of VEL CADE. Each vial is for single -use administration. 
VEL CADE dosingmay be delay ed up to 48 hours, however subsequent doses must be adjusted 
to account for the delay .Note that there should be at least 72 hours between doses of 
VEL CADE. Skipped doses of VELCADE will not be made up later in the cycle.Individual 
doses within a cy cle have a ±1 day  window.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
69
Approved , Date: 14 February 2018For subjects with unacceptable toxicity  at the local injection site despite dose modifications or 
change in injection concentration , VELCADE can be administered intravenously  as a 3 to 5 sec 
bolus injection. Please refer to local prescribing information for further details on either SC or 
IVadministration.
6.2.3. Melphalan and Prednisone A dministration
Melphalan will be administered at 9 mg/m2and prednisone will be administered at 60 mg/m2on 
Day 1  to 4 of each VELCADE cycle. Both melphalan and prednisone will be administered 
orally . For subjects randomized to the Treatment Arm B, 20 mg dexamethasone will substitute 
for the planned dose of prednisone on Day  1 of each cy cle. In this setting, dexamethasone will be 
utilized as the treatment dose of steroid for that particular day, as well as the required pre-
medication prior to daratumumab infusion. Prednisolone may be substituted for prednisone in 
countries where prednisone is not available. Melphalan and prednisone doses may be reduced, or 
the treatment schedule may be modified for the management of the study  treatment-related 
toxicities.
In exceptional circumstances, a subject may not tolerate sudden corticosteroid withdrawal at the 
end of 4 days of prednisone treatment. In such an instance, a tapering regimen of prednisone 
(30mg/m2on Day 5, 20 mg/m2on Day 6, 10 mg/m2on Day 7, then stop) can be prescribed to 
the subject after sponsor review . Under no circumstances will melphalan administration be 
prolonged bey ond 4 day s.
Breaking or dividing melphalan or prednisone tablets is strongly  discouraged; the total calculated 
dose should be rounded to the closest dose that can be administered using the tablets available . 
Prednisone tablets are to be taken with or immediately  after a meal or snack, preferably  in the 
morni ng.
If subjects develop renal and/or hepatic impairment, please follow recommendations given in 
Table 8.
6.3. Dose Delay s and Dose Modification
Subjects who need to discontinue treatment with any one component of study  treatment 
(VEL CADE, melphalan, prednisone, or daratumumab) may continue to receive treatment with 
the other components of study  treatment, as assigned.
6.3.1. Daratumumab Dose Modification
Dose modification of daratumumab is not permitted ;dose delay  is the primary  method for 
managing daratumumab -related toxicities. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
70
Approved , Date: 14 February 20186.3.1.1. Daratumumab -Related Toxicity  Management
Refer to Section 6.1.3 for details on management of infusion- related reactions. Only if any of 
the following criteria are met and the event cannot be ascribed toother components of the 
chemotherapy regimen, the daratumumab infusion must be held to allow for recovery from 
toxicity. The criteria for a dose delay  are:
Grade 4 hematologic toxicity
Grade 3 thrombocy topenia with bleeding
Febrile neutropenia 
Neutropenia with infection, of an y grade
Grade 3 or higher non -hematologic toxicities with the following exceptions : 
Grade 3 nausea that re sponds to antiemetic treatment within 7 day s
Grade 3 vomiting th at responds to antiemetic treatment within 7 day s
Grade 3 diarrhea that responds to antidiarrheal treatment within 7 day s
Grade 3 fatigue that was present at baseline or that lasts for <7days after the last 
administration of daratumumab
Grade 3 asthenia that was present at baseline or that lasts for <7days after the last 
administration of daratumumab
Other than on Day 1  o f a cycle, if a daratumumab infusion does not commence within the 
pre-specified window (Table 4) of the scheduled administration date, then the dose will be 
considered a missed dose. Administration may  resume at the next planned dosing date. A missed 
dose will not be made up.
Table 4: Daratum umab-Related Toxicity Managem ent
Frequency Dose Miss Dosing Re-start
Cycle 1 Weekly 
(q1wk)>3 days next planned weekly dosing date
Cycle 2-9 Every 3 weeks
(q3wks)>1 w eek next planned every -third -week dosing date
Post VMP Every 4 weeks 
(q4wks)>2weeks next planned every -fourth -week dosing date
If the daratumumab infusion cannot be given on Day  1 of a cy cle, the start of the cy cle should be 
delay ed. Day 1  o f a cycle should not be skipped. If a dose is delay ed, then subsequent 
pharmacokinetic and pharmacod ynamic assessments should be performed based on the actual 
administration daysof daratumumab, not on the original scheduled administration day.A 
maximum delay  of 4 weeks is allowed in Cycle 1 to Cycle 9. Any adverse event deemed to be 
related to daratumumab that requires a dose hold of more than 4weeks will result in permanent 
discontinuation of daratumumab. After Cycle 9, any adverse event deemed to be related to 
daratumumab that requires a dose hold of 2 consecutive planned doses will result in permanent 
discontinuation of daratumumab .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
71
Approved , Date: 14 February 20186.3.1.2. Daratumumab Interruption or Missed Doses
A daratumumab dose that is held for more than the permitted time (Table 4)from the per-
protocol administration date for any reason other than toxicities suspected to be related to 
daratumumab should be brought tothe attention of the Sponsor at the earliest possible time. 
Subjects whose dose was delay ed formore than 4 weeks (Cycle 1 to Cycle 9) or 2 consecutive 
planned doses (after Cycle 9) should have study drug discontinued, unless, upon consultation 
with the sponsor and the review of safet y and efficacy , continuation is agreed upon.
6.3.2. Dose Reductions (VELC ADE, Melphalan, and Prednisone)
VEL CADE will be reduced or discontinued according to the guidelines presented inTable 5.In 
addition to the VELCADE dose modification guidelines presented in Section 6.3.3 , Table 8, if 
several VELCADE doses in a cycle are withheld due to VELCADE -related toxicity  (≥3 doses 
during twice weekl y administration or ≥2 doses during weekl y administration), VEL CADE dose 
should be reduced by 1 dose level. Once reduced due to toxicity , doses of VEL CADE, 
melphalan, or prednisone should not be re-escalated ,with the exception of melphala n 
re-escalation following recovery  of renal function ( Table 8).
Table 5: Dose Reduction for VELCADE
Starting Dose First Dose Reduction Second Dose Reduction Third Dose Reduction
VELCADE 1.3 mg/m2VELCADE 1.0 mg/m2VELCADE 0.7 mg/m2Discontinue VELCADE
Melphalan will be reduced or discontinued according to the guidelines presented in Table 6 .
Table 6: Dose Reduction for Melphalan
Starting Dose First Dose Reduction Second Dose Reduction Third Dose Reduction
9 mg/m2QD on Days 1 -4 6.75 mg/m2QD on Days 1 -44.5 mg/m2QD on Days 1 -4Discontinue melphalan
QD=every day
Prednisone will be reduced or discontinued according to the guidelines presented in Table 7 .
Table 7: Dose Reduction for Prednisone
Starting Dose First Dose Reduction Second Dose Reduction Third Dose Reduction
60 mg/m2QD on Days 1 -4 45 mg/m2QD on Days 1 -430 mg/m2QD on Days 1 -4Discontinue prednisone
QD=every day
6.3.3. Dose Modification Guid elines for VELCA DE, Melphalan, and 
Prednisone Related Toxicities
Dose modification guidelines for VELCADE, melphalan, and prednisone are provided in
Table 8.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
72
Approved , Date: 14 February 2018Table 8: Dose m odification Guidelines for VELCADE, Melphalan, and Prednisone 
Body SystemNCI-CTC Adverse Event and or 
Sym ptom and CategoryVELCADE Melphalan Prednisone
Allergic reactionsAllergic reaction or hypersensitivity
Grade 2 OR 3Hold all therapy.
If the toxicity resolves to Grade 1, restart VMP . Reduce by 1 dose -level the suspected medication(s) AND implement 
appropriate anti-allergic prophylaxis therapy.
If the reaction was anaphylactic in nature, do not resume VMP .
NOTE: If the reaction was cutaneous in nature, refer to the cutaneous category below.
Allergic reaction or hypersensitivity
Grade 4Discontinue VMP .
ConstitutionalFluid Retention (ie, edema) >Grade 3 
(limiting function and unresponsive to 
therapy or anasarca)Administer diuretics as 
needed, and decrease 
dexamethasone or prednisone 
dose by 1 dose -level; if 
edema persists despite above 
measures, decrease dose 
another dose -level.
Discontinue prednisone and 
do not resume if symptoms 
persist despite second 
reduction.
Fatiguea
Grade 3 (ie, severe fatigue 
interfering with activities of daily 
living)Reduce VELCADE by 1 dose-level.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
73
Approved , Date: 14 February 2018Table 8: Dose m odification Guidelines for VELCADE, Melphalan, and Prednisone 
Body SystemNCI-CTC Adverse Event and or 
Sym ptom and CategoryVELCADE Melphalan Prednisone
CutaneousNon-blistering rash
Grade 2Hold VELCADE therapies. Begin treatment with 
antihistamines and/or low -dose steroids as per 
institutional practice.
If the toxicity resolves to Grade 1, restart at 1 dose 
reduced level of VELCADE
Non-blistering rash
Grade 3 or 4 Hold VELCADE therapies. Begin treatment with 
antihistamines and/or low -dose steroids as per 
institutional practice.
If the toxicity resolves to Grade 1, restart 
VELCADE (only) at 1 dose reduced level and 
continue antih istamines and/or low -dose steroids as 
per institutional practice. 
If toxicity recurs despite above measure, discontinue 
VELCADE permanently, as appropriate. 
Desquamating (blistering) rash -
any grade or erythema multiform 
Grade 3Discontinue VELCADE permanently.
Hold other therapies. Begin treatment with antihistamines and/or low -dose steroids as per institutional practice.
If the toxicity resolves to Grade 1, restart other medications. 
GastrointestinalConstipationb
Grade 3Hold.
Upon recovery to Grade 1, restart VELCADE at 1 
dose-reduced level.
Diarrheac
Grade 3Hold VELCADE and consider loperamide therapy.
Upon recovery to Grade 1, restart VELCADE at 
1dose-reduced level.
Dyspepsia, gastric or duodenal ulcer, 
gastritis Grade 1 -2 (requiring medical 
management)Treat with histamine -2 
blockers, sucralfate, or 
omeprazole. 
If symptoms persist despite 
above measures, decrease 
prednisone dose by 1 
dose-level.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
74
Approved , Date: 14 February 2018Table 8: Dose m odification Guidelines for VELCADE, Melphalan, and Prednisone 
Body SystemNCI-CTC Adverse Event and or 
Sym ptom and CategoryVELCADE Melphalan Prednisone
Dyspepsia, gastric or duodenal ulcer, 
gastritis Grade 3 (requiring 
hospitalization or surgery)Hold prednisone and consider 
treatment with histamine -2 
blockers, sucralfate, or 
omeprazole.
Restart prednisone 1 dose 
reduction level if symptoms 
are adequately controlled. 
If symptoms persist despite 
above measures, discontinue 
prednisone and do not 
resume.
HematologicalNeutropenia
Grade 3 (without complications)No dose reduction required of VELCADE. Consider 
treatment with G-CSF.Continue melphalan dosing and 
add G -CSF support.
Grade 3 neutropenia associated with 
fever ( ≥38.5°C) or any Grade 4 
neutropeniaHold therapy with all drugs until recovery to baseline OR Grade 2.
Upon recovery, restart melphalan at 1 dose reduced level. Maintain VELCADE at current 
dose and consider G -CSF suppor t.
If recurrence is seen, reduce VELCADE by 1 dose-level.
Thrombocytopenia
Grade 3 (without complications)No dose reduction required for VELCADE. Reduce melphalan by 
1dose-level
Platelet count ≤ 30 x 109/Lor ANC 
≤0.75 x 109/Lon a VELCADE dosing 
day ( See Section 6for minimum 
criteria for dosing on Day 1 of a cycle )Withhold VELCADE therapy.
Platelet count <25,000/ L (ie, Grade 
4) or Grade 3 thrombocytopenia with 
bleedingHold therapy with all drugs until recovery to baseline OR Grade 2.
Upon recovery, restart melphalan and VELCADE at 1 dose reduced level. If recurrence is 
seen, reduce melphalan by 1 further dose-level.
Infection Herpes Zo sterdactivation or 
reactivation
ANY gradeHold ALL therapies until lesions are dry. If not already underway, begin antiviral treatment
Once the infection is resolved all medications can be restarted without a dose reduction; however, continued antiviral 
prophylaxis is required.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
75
Approved , Date: 14 February 2018Table 8: Dose m odification Guidelines for VELCADE, Melphalan, and Prednisone 
Body SystemNCI-CTC Adverse Event and or 
Sym ptom and CategoryVELCADE Melphalan Prednisone
Musculoskeletal Muscle weakness >Grade 2 
(symptomatic and interfering with 
function +/- interfering with activities 
of daily living)Decrease prednisone dose by 
1 dose -level. If weakness 
persists despite above 
measures, decrease dose by 
1further dose-level. If 
symptoms stillpersist, 
discontinue and do not 
resume if symptoms persist.
Metabolic Hyperglycemia
Grade 3Treatment with insulin or oral 
hypoglycemics. If 
uncontrolled despite above 
measures, decrease dose by 1 
dose-level until levels are 
satisfactory.
Neurologicale
Peripheral Neuropathy (Sensory or Motor) and/or Neuropathic PainGrade 1 
(paresthesias and/or 
loss of reflexes) 
without pain or loss 
of functionNo action required.
Grade 1 with pain 
or Grade 2 
(interfering with 
function but not 
with activities of 
daily living)Reduce V ELCADE by 1 dose -level or change 
schedule to once weekly
Grade 2 with pain 
or Grade 3 
(interfering with 
activities of daily 
living)Hold VELCADE until toxicity resolves to < Grade 2. 
When toxicity resolves, reinitiate with a reduction 
by 1 dose -level and change VELCADE treatment 
schedule to once per weekf
Grade 4 (permanent 
sensory loss that 
interferes with 
function) and/or 
severe autonomic 
neuropathyDiscontinue VELCADE permanently.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
76
Approved , Date: 14 February 2018Table 8: Dose m odification Guidelines for VELCADE, Melphalan, and Prednisone 
Body SystemNCI-CTC Adverse Event and or 
Sym ptom and CategoryVELCADE Melphalan Prednisone
Neuro -
psychological Confusion or mood alteration >Grade 
2 (interfering with function 
+/-interfering with activities of daily 
living)Hold prednisone until 
symptoms resolve. 
Restart with 1 dose -level 
reduction. 
If symptoms persist despite 
above measures, discontinue 
prednisone and do not 
resume.
ThromboembolicVenous and /or pulmonary thrombo -
embolism Grade 3 [Deep vein 
thrombosis or cardiac thrombosis 
intervention indicate; eg: 
anticoagulation, lysis, filter, invasive 
procedure.]Stop until toxicity resolves 
and, if not already given, start 
anticoagulation therapy.
Restart prednisone at full 
dose af ter adequate 
anticoagulation,
Renal 
ImpairmentIf a subject develops renal 
function impairment with a serum 
creatinine >2 mg/dL 
(>176.8 mcmol/L) but less than 
Grade 3, the melphalan dose must 
be reduced to 4.5 mg/m2, while 
VELCADE and prednisone can 
be continued at the current dose. 
On recovery of renal function, 
melphalan can be re escalated to 
the previous dose.
Other toxicities Any reported 
Grade 3Determine drug attribution of the toxicity and hold the therapy(ies) as appropriate.
If toxicity resolves to Grade 1, resume therapy with 1 level of dose reduction for suspect drug .
a Determine if fatigue is possibly not medication-related but due to an underlying cause (eg, infection, progression of disease, diarrhea, anemia, depression) and treat these 
symptoms/causes as appropriate.
b  Prior to dose reduction of medications, consider/eliminate other po ssible causes of constipation. 
cPrior to dose reduction of medications, consider/eliminate other possible causes (ie, bacterial or viral infections) of diarrhea.
d  In the event that a subject is already receiving antiviral treatment at the time of the Herpes Zoster activation, consider sw itching to or adding another antiviral agent.
eThe neurotoxicity -directed questio nnaire is a useful tool for determining the presence and intensity of neuropathic pain and/or peripheral neuropathy from the subject’s perspective. 
Neuropathic symptoms are more prominent than abnormalities on the clinical examination. After the subject co mpletes the neurotoxicity directed questionnaire, the questionnaire should 
be reviewed to assist with the evaluation of the onset and intensity of peripheral neuropathy and other neurotoxicities that may require int ervention or dose modification.
f  If therapy is continued as twice weekly, VELCADE treatment should be continued at once weekly dosing.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
77
Approved , Date: 14 February 20187. TREA TMENT COMPLIA NCE
Study  drug (daratumumab) and VEL CADE will be administered by qualified site staff, and the 
details of each administration will be recorded in the electronic case report form (eCRF). 
Subjects will be provided with a treatment diary which will be used to assess compliance with 
melphalan and prednisone treatment. Additional details are provided in the SIPPM or equivalent 
document .
8. CONCOMITA NT THERA PY
Throughout the study , investigators may prescribe any concomitant medications or treatments 
deemed necessary  to provide adequate supportive care except for those listed in Section 8.3. The 
sponsor must be notified in advance (or as soon as possible thereafter) of any instances in which 
prohibited therapies are administered .
Routine systemic use of the following concomitant medications will be collect ed in the eCRF 
and recorded in the source documents beginning with signing of the ICF to 30 days after the last 
dose of the last study  treatment or until the start of subsequent anti-myeloma treatment, if earlier: 
growth factors, transfusions, anti- infecti ves (antibacterials, antivirals, and antimy cotics), steroids, 
anti-arrhythmics and other cardiac supportive therapy , anti- epileptics, centrally  acting ps ychiatric 
medication, anti-histamines and other medications targeting post-infusion systemic reactions,
bisphosphonates, and any anti-myeloma therapy  (including radiation). Concomitant medications 
to manage AEs and SAEs will be recorded as per Section 12.3.1 . 
8.1. Recom mended Therapies
8.1.1. Bisphosphonate Therapy
Bisphosphonate therapy is recommended to be continued per treatment guidelines (NCCN 
2013).30Commercially  available IV bisphosphonates (pamidronate and zoledronic acid) are 
preferred when available, and should be used according to the manufacturer’s recommendations, 
as described in the prescribing information, for subjects with osteoly tic or osteopenic 
myeloma tous bone disease. Oral bisphosphonates may be used as alternatives if IV 
bisphosphonates are not available at the stud y site.
Subjects who are currently  using bisphosphonate therap y when they enter the study  should 
continue the same treatment. If clinicall y indicated, subjects may  initiate bisphosphonate therap y 
as soon as possible during Screening and no later than the end of Cycle 1. After Cycle 1, 
investigators should not prescribe bisphosphonate s to subjects who have not received them 
before, unless approved by the sponsor after confirming that the subject does not have disease 
progression at the time of bisphosphonate initiation.
8.1.2. Therapy  for Tumor Lysis Syndrome
Subjects should be monitored for symptoms of tumor lysis syndrome. Management of tumor 
lysis syndrome, including dehydration and abnormal laboratory  test results such as 
hyperkalemia, hyperuricemia, and hypocalcemia, are highly  recommended. It is also 
recommended that high-risk subjects, ie, those with a high tumor burden, be treated 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
78
Approved , Date: 14 February 2018prophylacticall y in accordance with local standards (eg, rehydration; diuretics; allopurinol 
300mg dail y and medicatio n to increase urate excretion).
8.1.3. Prophy laxis for Pneumocy stis carinii
Pneumocy stis carinii pneumonia proph ylaxis should be considered, as per institutional 
guidelines.
8.1.4. Prophy laxis for Herpes Zoster Reactivation
Prophy laxis for herpes zoster reactivation is recommended during the Treatment Phase, as per 
institutional guidelines.
8.1.5. Prevention of Hemorrhagic Cy stitis
Melphalan may cause hemorrhagic cystitis, especiall y in patients who have marginal renal 
function and/or dehydration. Measures to prevent hemorrhagic cystitis include IV hydration and 
the administration of Mesna. These measures are permitted therapies during the course of the 
study  and may be used per inst itutional policy . Urine alkalini zation is not recommended.
8.2. Permitted Therapies
Subjects are to receive full supportive care during the study . The following medications and 
supportive therapies are examples of support therapies that may  be used during the stud y:
Colony  stimulating factors, ery thropoietin, and transfusion of platelets and red cells
Loperamide is recommended for the treatment of diarrhea, starting at the time of the first 
watery  stool. The loperamide dose and regimen is according to institutional guidelines. 
Prophy lactic loperamide is not recommended.
It is important to prevent constipation (eg, adequate hydration, high-fiber diet, and stool 
softeners if needed)
Adequate h ydration is recommended for prevention of my eloma -related kidney  disease
Prophy lactic antiemetics, with the exception of corticosteroids
8.3. Prohibited Therapies
Concomitant administration of any other antineoplastic therap y for the intention of treating 
multiple myeloma is prohibited prior to confirmation of disease progression, including 
medications that target CD38, as well as medications used for other indications that have 
anti-myeloma properties ( for example, interferon and clarithrom ycin [Ghosh 2013]13).
Continuation of the study drug and components of the VMPregimen during or after emergency 
orthopedic surgery  or radiotherap y for conditions related to multiple my eloma mayoccur only in 
the absence of disease progression and after review by the sponsor. Such emergency  
radiotherap y may consist of localized radiotherapy  for pain control or for stabilization of an 
extensive bone lesion at high risk of pathologic fracture or damage to surrounding tissues in a 
subject in whom delay  of systemic therapy  is not appropriate. Such radiotherapy  is to occur 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
79
Approved , Date: 14 February 2018within the first 2 cycles of treatment and the absence of evidence of disease progression is to be 
reviewed b y the sponsor.
Concomitant administration of investigational agents is prohibited. Administration of 
commerciall y available agents with activity  against or under investigation for multiple my eloma, 
including systemic corticosteroids (>10 mg prednisone per day or equivalent) (other than those 
given for infusion-related reactions as described in Section 6.1.3.2 ) should be avoided. 
Nonsteroidal anti-inflammatory  agents should be used with caution in order to prevent 
myeloma -related kidney  disease. Typicall y, IV contrast is NOT used in computed tomograph y 
(CT) scanning of the subjects with secretory  multiple my eloma because of the risk to the kidney . 
If administration of IV contrast is necessary , then adequate precautions including hydration are 
indicated. The sponsor must be notified in advance (or as soon as possible thereafter) of any 
instances in which prohibited therapies are administered.
Concomitant administration of strong CYP3A4 inducers is prohibited with the use of 
VEL CADE. Administration of strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir) should be 
avoided and is not recommended in patients receiving VELCADE. If a strong CYP3A4 inhibitor 
must be given in comb ination with VEL CADE, monitor patients for signs of VEL CADE toxicity  
and consider a VEL CADE dose reduction. For an ongoing list of CYP3A inhibitors and 
inducers, see http://medicine.iupui.edu/flockhart/.
8.4. Subsequent Therapies
After completion or discontinua tion of study therap y subjects should continue efficacy  
evaluations per the Time and Events Schedule until PD. Subsequent anti -myeloma therapy
cannot be started before disease progression is established per the IMWG criteria 
(Section 9.2.1.1 ,Response Categories) orprior to sponsor confirmation of PD.
After sponsor confirmation of PD, choice of subsequent therapy  is at the discretion of the 
investig ator. Subjects randomized to Arm A (VMP) may have the option to receive daratumumab 
provided by the sponsor (in any subsequent line of therap y)if recommended by the investigator . 
Eligibility  for and administration of daratumumab must be in accordance with local prescribing 
information and local regulations . Subjects in Arm A (VMP) who receive daratumumab post 
progressive disease through the sponsor will remain in the Follow -up phase of study . SAEs 
(including second primary  malignancies) must be reported for these subjects until 30 days after 
daratumumab is discontinued. The option for sponsor provision of daratumumab will not be 
implemented in Japan or in countries where dara tumumab is not approved.
All subsequent therap y for multiple myeloma (including start and end date, best response, and 
date of progression to the subsequent therapy ) should be documented in the appropriate section 
of the eCRF .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
80
Approved , Date: 14 February 20189. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , 
pharmacokinetic, immunogenicity , biomarker, patient -reported outcomes, and safety 
measurements applicable to this study .
All visit-specific PRO assessments should preferably  be conducted/completed before any tests, 
procedures, or other consultations for that visit to prevent influencing subject perceptions. Refer 
to Section 9.6for details.
Blood collections for pharmacokinetic assessments should be kept as close to the specified time 
as possible. Other measurements may  be done earlier than specified time points if needed. Actual 
dates and times of assessments will be recorded in the source documentation.
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by the 
investigator or required by local regulation, to establish the absence of pregnancy  at any time 
during the subject's participat ion in the study .
The total blood volume for the study  is estimated at approximately  45mL during screening and 
480mL during VMP treatment in the first year. In the post-VMP treatment phase, blood 
sampling for subjects in Arm B will be approximately  305 m L per year on treatment . In the 
Follow -up Phase, subjects prior to PD will have approximately  120 mL  blood drawn per yearfor 
serum disease evaluations. This includes laboratory  assessments associated with safet y, efficacy , 
and pharmacokinetic evaluations, as well as scientific research samples. Repeat or unscheduled 
samples may  be taken for safet y reasons or for technical issues with the samples.
9.1.2. Screening Phase
The signed ICF must be obtained before any study -specific procedures are performed. The 
Screeni ng Phase begins when the first screening assessment is conducted (that was not 
performed as part of the subject’s standard of care) . During the Screening Phase, eligibility 
criteria will be reviewed and a complete clinical evaluation will be performed as specified in 
Time and Events Schedule. Screening procedures will be performed within 21days before 
randomization; however, results of tests such as skeletal survey , radiologic tests (eg, magnetic 
resonance imaging [MRI]) to document baseline size of known or suspected extramedullary  
plasmacy tomas; ECG; chest X-rays(or full chest CT scan) ; or bone marrow aspirate/biops y) 
performed up to 6 weeks (42 days) before randomization as routine standard of care for the 
subject’s disease can be used. If collection ofblood and urine specimens for disease evaluation
(SPEP, UPEP, calcium , and albumin )isperformed within 14 days of Cycle1 Day 1, it doesnot 
need to be repeated on Cy cle 1 Day  1.
Prior to randomization, the Sponsor will review key eligibility  criteria for all subjects. Relevant 
eCRF forms will be completed by site staff for review prior to approval for randomization being 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
81
Approved , Date: 14 February 2018granted by the Sponsor (further details provided as a separate document). Subjects <65 years
must have known presence of important comorbid condition(s) likely  to have a negative effect on 
the tolerability  of high dose chemotherap y with SCT. Documentation of the condition, for 
example diagnosis of concomitant infectious disease, should be provided.
At screening, creatinine clearance may be measured or calculated according to local practice. If 
calculated, formulae according to the modification of diet in renal disease [MDRD, 
Levey 2006]22or chronic kidney  disease epidemiology  collaboration [CKD -EPI, Leve y 2009]23
are preferred. For online calculators, please go to https://www.kidney .org/professionals/KDOQI / 
gfr_calculator . Creatinine clearance will be analyzed locally . 
A negative pregnancy  test for women of childbearing potential must be documented within 
14days before the first dose of any  component of the treatm ent regimen.
All attempts should be made to determine eligibility  of the subject based on the central 
laboratory  results of Screening blood and urine M-protein measurements. In exceptional 
circumstances, the local laboratory  results of blood and urine M-pr otein measurements may be 
used to determine eligibility , but only if the results are clearly  (eg, 25% or more) above the 
thresholds for measurability .
9.1.3. Treatment Phase
Details of the procedures performed during the Treatment Phase are outlined in the Time and 
Events Schedule. Subjects should start study  treatment within 72 hours after randomization. The 
start of each cycle may occur within ±3 days of the scheduled day in order to accommodate the 
schedule of the site or subject. If the start of a cycle is delayed, Day 1  of subsequent cycles 
should be adjusted accordingl y to maintain the 42-day cycle duration. In Cycles 1 through 9, 
weekl y or every -three -week daratumumab infusions may be given within ±1 day of the 
scheduled day in order to accommodate the sched ule of the site or subject. Additionally , weekly 
or twice weekl y VELCADE doses may be given within ±1 day of the scheduled day in order to 
accommodate the schedule of the site or subject. Changes to within -cycle dosing should not 
impact Day  1 of the next c ycle.
Subjects will be closely monitored for adverse events, laboratory  abnormalities, and clinical 
response. Clinical evaluations and laboratory  studies may be repeated more frequentl y, if 
clinically  indicated. If disease progression is diagnosed, then the subject will discontinue study  
treatment , complete the End -of-Treatment Visit, and enter the Follow- up Phase.
End of Treatment Visits
Unless a subject withdraws consent for study  participation or is lost to follow up, an End-of-
Treatment Visit is to occu r within 30 daysafter the last dose all study  treatments. Every  effort 
should be made to conduct the End-of- Treatment Visit before the subject starts subsequent 
treatment. If a subject is unable to return to the site for the End-of- Treatment Visit, then the 
subject should be contacted to collect information on adverse event s that occur up to 30 days 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
82
Approved , Date: 14 February 2018after the last dose of study  treatment. Additional information on reporting of adverse event s is 
presented in Section 12.
9.1.4. Follow -upPhase
The Follow -up Phase will begin once a subject completes the VMP  regimen (Treatment Arm A) 
or completes the daratumumab -VMP  regimen (Treatment Arm B), or discontinues treatment in 
either arm for any reason . Subjects who discontinue treatment before disease progression must 
continue to have disease evaluations according to the Time and Events Schedule (ie, every  3 
weeks in Year1, every  4 weeks in Year 2, and every  8 weeks thereafter) until confirmed PD
(seeSection 8.4, Subsequent Therapies) , subsequent anti-myeloma treatment, death, withdrawal 
of consent, lost to follow -up, or the end of the study .After disease progression is documented, 
follow -up informa tion will be obtained every  16weeks (±2 weeks). Every  16-week follow -up 
contacts , as well as Week 8 post-PD and Week 16 post-PD ECOG and ePRO assessments,
should be scheduled from the date of confirmed progression (ie, the date of the confirmatory 
laborat ory assessment, not the date of confirmation by  the sponsor) . In subjects for whom disease 
progression cannot be documented (eg, received subsequent anti-myeloma treatment or refused 
disease evaluations, but agreed to follow -up contacts), the every -16-week follow -up should be 
scheduled from the date of the End of Treatment Visit. Subsequent anti-myeloma treatment, 
PFS2 (perinvestigator judgment), second primary  malignancies, and survival will also be 
recorded.
If the information is obtained via telephone contact, written documentation of the 
communication must be available for review in the source documents. If the subject has died, the 
date and cause of death will be collec ted and documented in the eCRF.
The end of the study  occurs after 330 subjects have died, or for a maximum of 5 years after the 
last subject is randomized, whichever occurs first.The sponsor will ensure that subjects 
benefiting from treatment with daratumumab will be able to continue treatment after the end of 
the study .
9.1.5. Assessments Fol lowing the Positive Second Interim A nalysis of PFS
Following the positive second interim analy sis of PFS, subjects remaining in the study  will 
continue to be monitored as follows until the next interim analy sis of OS (ie, when 200 deaths 
have occurred):
Subjects who have had disease progression
For subjects whose disease has alread y progressed, every -16-week follow -up contacts should be 
performed to capture:
Survival
Subsequent anti -myeloma therap y
New second primary  malignancies
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
83
Approved , Date: 14 February 2018These data may  be collect ed by telephone. Bey ond the end of the serious adverse event reporting 
period (30 day s after the last dose of study  drug or the start of any subsequent anti -myeloma
treatment, whichever comes first), only  those serious adverse events that are considered to be 
possibly , probabl y, or definitely  related to the study  drug need to be reported.
Subjects who have not had disease progression
For subjects in the randomized portion of the study  who have not experienced disease 
progression, disease assessments will continue to occur every  3 weeks in Year 1, every  4 weeks 
in Year 2,and every  8  w eeks thereafter until disease progression is confirmed by central 
laboratory  examination per the Time and Event Schedule s.
9.1.6. Assessments Following the OS Interim A nalysis
Following the OS interim analy sis (ie, when 200 deaths have occurred), subjects remaining in the 
study  will continue to be monitored as follows until the study  end (ie, when 330 deaths have 
occurred , or 5 y ears after the last subject is randomized, whichever comes first):
For subjects whose disease has alread y progressed at the time of the OS interim analy sis, 
only survival, subsequent anti-myeloma therapy , and all new second primary  malignancy 
information will be collected , which may  be obtained by  telephone conta ct.
For subjects without disease progression at the time of the OS interim analysis, disease 
assessments will continue but will be performed locally  perthe standard of care. Sponsor 
confirmation of disease progression will no longer be required prior to initiation of 
subsequent anti -myeloma therap y.
For subjects in Arm Bwho are continuing to receive study  medication at the time of the OS 
interim analysis, dosing data and safety information will be collected. Safety  information 
will include adverse events during treatment and within 30 days after last dose, concomitant 
medications associated with a serious adverse event, and information on all second primary 
malignancies.
9.2. Efficacy
9.2.1. Evaluations
9.2.1.1. Response Categories
Disease evaluations must be performed every  3weeks during the first year, every  4 weeks during 
the second year, and every  8 weeks thereafter u ntil disease progression (or other reasons as per 
Section 10). A window of±7daysis allowed. If treatment has been delayed for any reason, the 
disease evaluations must be performed according to the original schedule, regardless of any 
changes to the dosing regimen.
Disease evaluations will be performed by a central laboratory  (unless otherwise specified). This 
study  will use the IMWG consensus recommendations for multiple myeloma treatment response 
criteria (Durie 2006 , Kumar 2016, Rajk umar 2011 ).8,17,37For quantitative immunoglobulin, 
M-protein, and immunofixation measurements in serum and 24-hour urine, the investigator will 
use results provided by the central laboratory . Disease progression must be consistently  
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
84
Approved , Date: 14 February 2018documented across clinical study  sites using the criteria in Table 9.Per Table 9, for patients with 
measurable disease by SPEP and/or UPEP at baseline, increases in serum free light chains or the 
FLC ratio alone do not meet criteria for progressive disease.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
85
Approved , Date: 14 February 2018Table 9: International Uniform  Response Criteria Consensus Recommendations
Response Response Criteria
Stringent 
complete
Response (sCR)CR as defined below , plus
Normal FLC ratio, and
Absence of clonal PCs by immunohistochemistry, immunofluorescenceaor 2-to 4-color 
flow cytometry
Com plete 
response (CR)*Negative immunofixation on the serum and urine, and
Disappearance of any soft tissue plasmacytomas, and
<5% PCs in bone marrow
Very  good 
partial
Response 
(VGPR)*Serum and urine M -component detectable by immunofixation but not on electrophoresis, or
≥90% reduction in serum M -protein plus urine M -protein <100 mg/24 hours
Partial response 
(PR)≥50% reduction of serum M -protein and reduction in 24 -hour urinary M -protein by ≥90% 
or to <200 mg/24 hours
If the serum and urine M -protein are not measurable, a decrease of ≥50% in the difference 
betw een involved and uninvolved FLC levels is required in place of the M -protein criteria
If serum and urine M -protei n are not measurable, and serum free light assay is also not 
measurable, ≥50% reduction in bone marrow  PCs is required in place of M -protein, 
provided baseline bone marrow plasma cell percentage was ≥30%
In addition to the above criteria, if present at bas eline, a ≥50% reduction in the size of soft 
tissue plasmacytomas is also required.
Stable disease 
(SD)Not meeting criteria for CR, VGPR, PR, or progressive disease
Progressive 
disease (PD)†Increase of 25% from lowest response value in any one of the following:
Serum M -component (absolute increase must be ≥0.5 g/dL), 
Urine M -component (absolute increase must be ≥200 mg/24 hours), 
Only in subjects without measurable serum and urine M -protein levels: the difference 
betw een involved and uninvolved FLC l evels (absolute increase must be >10 mg/dL)
Only in subjects without measurable serum and urine M -protein levels and without 
measurable disease by FLC levels, bone marrow PC percentage (absolute percentage must 
be ≥10%)
Bone marrow  plasma cell percentage: the absolute percentage must be >10%
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase 
in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcemia (corrected serum calcium >11.5 mg /dL) that can be 
attributed solely to the PC proliferative disorder
EBMT = European Group for Blood and Marrow  Transplantation; FLC = free light chain; PC = plasma cell
All response categories (CR, sCR, VGPR, PR, and PD) require 2 consecutive assessments made at any time before the institution 
of any new therapy; CR, sCR, VGPR, PR, and SD categories also require no known evidence of progressive or new bone 
lesions if radiographic studies were performed. VGPR and CR categories require serum and urine studi es regardless of 
whether disease at baseline was measurable on serum, urine, both, or neither.
Radiographic studies are not required to satisfy these response requirements. Bone marrow assessments need not be confirmed. 
For PD, serum M -component increases of more than or equal to 1 g/dL are sufficient to define relapse if starting M -component 
is ≥5 g/dL.
*Clarifications to IMWG criteria for coding CR and VGPR in subjects in whom the only measurable disease is by serum FLC 
levels: CR in such subjects indicates a normal FLC ratio of 0.26 to 1.65 in addition to CR criteria listed above. VGPR in such 
subjects requires a >90% decrease in the difference between involved and uninvolved FLC levels.
†Clarifications to IMWG criteria for coding PD: Bone marrow criteria for PD are to be used only in subjects without measurable 
disease by M protein and by FLC levels; “25% increase” refers to M protein, FLC, and bone marrow results, and does not refer 
to bone lesions, soft tissue plasmacytomas, or hypercalcemia and the “lo west response value” does not need to be a confirmed 
value. 
aPresence/absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by 
immunohistochemistry or immunofluorescence requires a minimum of 100 plasma cells for an alysis. An abnormal ratio 
reflecting presence of an abnormal clone is kappa/lambda of >4:1 or <1:2.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
86
Approved , Date: 14 February 2018Table 9: International Uniform  Response Criteria Consensus Recommendations
Clinical Relapse
Clinical relapse is defined using the definition of clinical relapse in the IMWG criteria (Durie 2006, Rajkumar 2011).8,37In the 
IMWG criteria, clinical relapse is defined as requiring one or more of the following direct indicators of increasing disease or 
end-organ dysfunction that are considered related to the underlying plasma cell proliferative disorder:
1. Development of new soft tissue plasmacytomas or bone lesions on skeletal survey, magnetic resonance imaging, or other 
imaging
2. Definite increase in the size of existing plasmacytomas or bone lesions. A d efinite increase is defined as a 50% (and at least 
1 cm) increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion
3. Hypercalcemia (>11.5 mg/dL; >2.875mM/L)
4. Decrease in hemoglobin of more than 2 g/dL (1.25 mM) or to less than 10 g/dL
5. Rise in serum creatinine by more than or equal to 2 mg/dL ( ≥177 mM/L)
6. Hyperviscosity
In some subjects, bone pain may be the initial symptom of relapse in the absence of any of the above features. However, bone 
pain withou t imaging confirmation is not adequate to meet these criteria in studies .
For continuation of treatment, the IMWG response will be determined on an ongoing basis by 
the investigator. For data analysis and reporting, however, the sponsor will use a valida ted 
computer algorithm that has been shown to provide consistent review of the data necessary  to 
determine disease progression and response according to the IMWG criteria .
Serum free light chain assay  test results will be analyzed by the central laboratory for the 
assessment of sCR, according to the most recently  published IMWG criteria (Durie 2006 ).8For 
subjects who discontinue study  treatment before disease progression, disease evaluations should 
continue to be performed per the Time and Events Schedule until confirmed disease progression
(see Section 8.4, Subsequent Therapies) , death, the start of a new treatment for multiple 
myeloma, withdrawal of consent for study  participation, lost to follow -up,or the end of study , 
whichever occurs first. Disease evaluations scheduled for treatment days should be collected 
before stud y treatment is administered.
9.2.1.2. Myeloma Protein Measurements in Serum and Urine
Blood and 24-hour urine samples for M-protein measurements will be sent to and analyzed by a 
central laboratory . Onl y 1 serum and one 24 -hour urine sample per time point are required by  the 
central laboratory  to perform the following tests.
All subjects will be evaluated for IgG, IgA, IgM, IgE, and IgD at Screening. During the 
study , subjects with IgD or IgE disease will be evaluated for IgG, IgA, IgM, IgE, and IgD 
and subjects with IgG, IgA, or IgM disease will be evaluated for IgG, IgA, and IgM .
Serum M -protein quantitation by  electrophoresis (SPEP)
Serum immunofixation at Screening and thereafter when a CR is suspected . If daratumumab 
interference is suspected based on SPEP and immunofixation (IFE)results, additional reflex 
IFE testing may  be performed.
Serum free light chain assay will be done at screening, and to confirm CR. In addition, FLC 
will be used to monitor subject s who have light chain only  disease
24-hour urine M -protein quantitation by  electrophoresis (UPEP)
Urine immunofixation at Screening and thereafter when a CR is suspected
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
87
Approved , Date: 14 February 2018Blood and 24-hour urine samples will be collected as specified in the Time and Events Schedule
until the development of confirmed disease progression. Disease progression based on 1 of the 
laboratory  tests alone must be confirmed by arepeat investigation performed at least 1day later. 
Disease evaluations will continue beyond relapse from CR until disease progression is 
confirmed. Serum and urine IFEand serum free light chain assay  will be performed at Screening 
and thereafter when a CR is suspected (when SPEP or UPEP are 0 or nonquantifiable). For 
subjects with light chain multiple myeloma, serum FLCassay  will be performed routinely per
the Time and Events Schedule . Previous studies have demonstrated potential interference of 
therapeutic monoclonal antibodies with detection of endogenous myeloma M-protein on serum 
IFE(McCudden 2010).28For subjects with suspected daratumumab interference on SPEP and/or 
serum IFE, a follow -uptest will be run utilizing anti -idioty pe antibodies against daratu mumab to 
remove antibody  interference. Subjects who meet all other IMWG criteria for CRor sCR,and 
whose positive IFE is confirmed to be daratumumab, will be considered complete responders or 
stringent complete responders .
9.2.1.3. Serum Calcium Corrected for Albumin
Blood samples for calculating serum calcium corrected for albumin will be collected and 
analyzed centrally (as specified in the Time and Events Schedules) until the development of
confirmed disease progression. During the Treatment Phase, developme nt of hypercalcemia 
(corrected serum calcium >11.5 mg/dL or 2.8 mmol/L) can indicate disease progression or 
relapse if it is not attributable to any  other cause (see disease response criteria). Calcium binds to 
albumin and only the unbound (free) calcium is biologicall y active; therefore, the serum calcium 
level must be adjusted for abnormal albumin levels (“corrected serum calcium”). Measurement 
of free ionized calcium is an acceptable alternative to corrected serum calcium for determining 
hypercalcemia. F ree ionized calcium levels greater than the ULN (local laboratory  reference 
ranges) are considered to be hy percalcemic for this study .
9.2.1.4. β2-microglobulin and A lbumin
Blood samples for β2 microglobulin and albumin are to be collected at Screening, and will be
analyzed by the central laboratory .The central laboratory  values will be used to calculate 
International Staging Sy stem ( ISS)stage.
9.2.1.5. Bone Marrow Examination
Bone marrow assessments to be performed locall y and centrally aresummarized in Table 10 .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
88
Approved , Date: 14 February 2018Table 10: Bone Marrow Testing
Local Testing Central Testing
Screening Disease characterization 
(morphology and either 
immunohistochemistry  or 
immunofluorescence or flow 
cytometry ). Cy togenetics by  
conventional kary otype or FISH.MRD and molecular subty ping: a portion 
ofbone marrow aspirates collected at 
screening will be sent to a central 
laboratory .
If a fresh bone marrow aspirate will not be 
performed at screening because a sample is 
available within 42 day s prior to 
randomization, obtain non -decalcified 
slides (bone marrow aspirate, touch 
preparation or clot selection) or FFPE 
block (clot section onl y, no bone marrow 
biopsy ).
CR, sCR For res ponse confirmation, 
additional bone marrow aspirates 
or biopsies (or both) will be 
performed locall y to confirm 
sCR or CR. Response 
characterization (morphology  by 
immunohistochemistry  or 
immunofluorescence or flow 
cytometry ).
For sCR: Detection of 
kappa/l ambda ratio by  2-4 color 
flow cy tometry  is strongly  
preferred. If flow cy tometry  is 
not available at site, either 
immunohistochemistry  or 
immunofluorescence can be 
done, however, kappa/lambda 
ratio from anal ysis of ≥100 
plasma cells is required to 
confirm sCR.
If sCR is not met, repeat local 
testing for sCR with subsequent 
bone marrow examinations will 
be done at the time of the next 
protocol -required bone marrow 
examination .MRD Assessment : 
Aportion of bone marrow aspirate 
collected for confirmation of CR/sCR will 
be sent to the central laboratory for MRD 
assessment .
For subjects with CR/sCR ,an additional 
bone marrow aspirate will be obtained at 
12, 18, 24, and 30 months after first dose 
andsent to the central laboratory  to 
monitor for MRD. For the 12, 18, 24, and 
30-month bone marrow aspirate, subjects 
can have a window of 2 months after each 
time point to complete the bone marrow 
aspiration ( ie, range of 12-14, 18-20, 24-26 
and 30- 32 month s after C1D1).
Disease 
ProgressionNot applicable. If feasible, a bone marrow aspirate is 
requested to be collected from subjects in 
both treatment arms at disease progression 
to evaluate mechanisms of resistance.
CR=complete response; FFPE=formalin -fixed paraffin embedded; FISH=fluo rescence in situ 
hybridization; MRD=minimal residual disease; sCR=stringent complete response
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
89
Approved , Date: 14 February 20189.2.1.6. Minimal Residual Disease A ssessment
Minimal Residual Disease (MRD) assessment by next-generation sequencing (NGS) is a 
relativel y new and effective tool in the assessment of patients with multiple myeloma 
(Ladetto, 2014).21Several studies have demonstrated that MRD status is correlated with PFS and 
OS(Martinez -Lopez, 2014).24In the present study , bone marrow aspirate will be collected for 
MRD analy sis when bone marrow samples areobtained at Screening , confirmation of CR/sCR, 
and subsequent time points after the first dose (see Table 10 ).
9.2.1.7. Assessment of Lytic Disease
A complete skeletal survey  (including skull, entire vertebral column, pelvis, chest, humeri, 
femora, and any other bones for which the investigator suspects involvement by disease) is to be 
performed and evaluated by the local laboratory  by roentgenograph y (or the local standard of 
care imaging, eg, low-dose CT) during the Screening Phase. Please note that the same 
methodology  used at Screening should be used throughout the study  for comparison purposes. 
During the Treatment Phase and before disease progre ssion is confirmed, imaging should be 
performed whenever clinically  indicated based on symptoms, to document response or 
progression. Magnetic resonance imaging (MRI) is anacceptable method for evaluation of bone 
disease, and may  be included as an additio nal assessment at the discretion of the investigator (see 
the disease response criteria in Table 9 ).
Sometimes subjects present with disease progression manifested bysymptoms of pain due to 
bone changes. Therefore, disease progression may be documented, in these cases, by skeletal 
survey  or other radiographs, depending on the symptoms that the subject experiences. If the 
diagnosis of disease progression is obvious by radiographic investigations, then no repeat 
confirmatory  imaging isnecessary . In instances where changes may be subtler, repeat imaging
may be performed in 1 to 3 weeks per investigator discretion.
9.2.1.8. Documentation of Extramedullary  Plasmacytomas
Sites of known extramedullary  plasmacy tomas must be documented during the Screening Phase. 
Clinical examination or MRI  may be used to document extramedullary  sites of disease. 
Computed tomograph y scan evaluations are an acceptable alternative if there is no 
contrai ndication to the use of intravenous contrast . Positron emission tomograph yscan or 
ultrasound tests are not acceptable to document the size of extramedullary  plasmacy tomas.
Extramedullary  plasmacy tomas should be assessed for all subjects with a history  of 
plasmacy tomas or if clinically  indicated at Screening, by clinical examination or radiologic 
imaging. For subjects with a history  of plasmacy tomas assessed by physical examination, 
physical examination should be repeated on Cycle 1 Day 1 if not done within 14 days prior to 
randomization. Assessment of measurable sites of extramedullary  disease will be performed and 
evaluated locall y every 6weeks (by phy sical examination )or every 12 weeks by imaging 
(ifrequired ) for subjects with a history  of plasmacy toma s or as clinically  indicated during 
treatment for other subjects, until confirmed disease progression. For every  subject, the 
methodology  used for evaluation of each disease site should be consistent across all visits. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
90
Approved , Date: 14 February 2018Irradiated or excised lesions will beconsidered not measurable, and will be monitored only for 
disease progression.
To qualify  for PR, the sum of products of the perpendicular diameters of the existing  
extramedullary  plasmacytomas must have decreased by at least 50%, and new plasmacy tomas 
must not have developed (see the disease response criteria inTable 9). To qualify  for disease 
progression, either the sum of products of the perpendicular diameters of the existing  
extramedullary  plasmacy tomas must have increased by at least 50% or a new plasmacy toma 
must have developed. In the cases where not all existing extramedullary plasmacy tomas are 
reported, but the sum of products of the perpendicular diameters of the reported plasmacy tomas 
have increased b y at least 50%, this will also qualify  as disease progression.
9.2.2. Endpoints
Primary Endpoints
The primary  endpoint is PFS, which is defined as the duration from the date of randomization to 
either progressive disea se or death, whichever comes first. Disease progression will be 
determined according to the IMWG criteria (Durie 2006, Rajkumar 2011).8,37For subjects who 
have not progressed and are alive, data will be censored at the last disease evaluation before the 
start of any subsequent anti-myeloma therapy. Relapse from CR by positive immunofixation or 
trace amount of M-protein is not considered to be progressive disease and is not included in the 
PFS calculation.
Asthe superiority  of daratumumab combined with VMP over VMP alone with respect to PFS 
was established atthe second interim analysis, the interim PFS analy sis will serve as the primary 
PFS analy sis, which otherwise was tooccur when approximately  360 PFS events had been 
observed.
Secondary Endpoints
The secondary  efficacy  endpoints include:
Time to disease progression (TTP) is defined as the time from the date of randomization to 
the date of first documented evidence of PD, as defined in the IMWG criteria. For subjects 
who have not progressed, data will be censored at the date of the disease evaluation before 
the start of an y subsequent anti -myeloma therap y.
CR rate, defined as the percentage of subjects achieving CR, as defined by:
Negative immunofixation of serum and urine, and
Disappearance of an y soft tissue plasmacy tomas, and
<5% PCs in bone marrow
For those subjects with negative or low SPEP (≤0.2 g/L)and suspected daratumumab 
interference on immunofixation, a reflex assay  using anti-idiotype antibody  will be 
utilized to confirm daratumumab interference and rule out false positive 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
91
Approved , Date: 14 February 2018immuno fixation. Subjects who have confirmed daratumumab interference, but meet all 
other clinical criteria for CR or sCR, will be considered CR/sCR.
MRD negativity  rate, defined as the proportion of subjects who have negative MRD at any 
time point after the date of randomization .
Progression- free Survival on Next line of Therap y (PFS2), defined as the time from 
randomization to progression on the next line of treatment or death, whichever comes first. 
Disease progression will be based on investigator judgment . Subjects who are still alive and 
not yet progressed on the next line of treatment will be censored on the last date of 
follow -up.
Time to next treatment, defined as the time from randomization to the start of the next-line 
treatment.
Overall response rate (O RR), defined as the proportion of subjects who achieve PR or better , 
according to the IMWG criteria, during or after the study  treatment.
sCR rate, defined as the percentage of subjects achieving CR in addition to having a normal 
FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry , 
immunofluorescence, 2 -4 color flow cy tometry .
Proportion of subjects who achieve VGPR or better, defined as the proportion of subjects 
achieving VGPR and CR (including sCR) according to the IMWG criter ia during or after the 
study  treatment at the time of data cutoff.
Time to response, defined as the time between randomization and the first efficacy 
evaluation that the subject has met all criteria for PR or better. For subjects without 
response, data will be censored either at the date of progressive disease or, in the absence of 
progressive disease, at the last disease evaluation before the start of subsequent anti-
myeloma therap y.
Duration of response, calculated from the date of initial documentation of a response (PRor 
better ) to the date of first documented evidence of progressive disease, as defined in the 
IMWG criteria. For subjects who have not progressed, data will be censored at the last 
disease evaluation before the start of an y subsequent anti -myeloma therap y.
OS, measured from the date of randomization to the date of the subject’s death. If the 
subject is alive or the vital status is unknown, then the subject’s data will be censored at the 
date the subject was last known to be alive.
Impact of D- VMP compared to VMP on patient -reported perception of global health.
Clinical efficacy  of D -VMP in high risk molecular subgroups compared to VMP alone.
Exploratory Endpoints
Biomarkers predictive of response or resistance to daratumumab.
Durability  of MRD negativity .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
92
Approved , Date: 14 February 20189.3. Pharmacokinetics and Immunogenicity
9.3.1. Evaluations
Samples to assess both the serum concentration (pharmacokinetics) of daratumumab and the 
generation of antibodies to daratumumab (immunogenicity ) will be obtained from all subjects in 
the D-VMP group according to the Time and Events Schedule. In the Follow -upPhase , forall 
subjects in Arm B (D- VMP ),samples are tobe collected 8 weeks after the last dose of 
daratumumab, regardless of whether there has been confirmed disease progression. Atspecified 
time points, venous blood samples (5mL per sample) will be collected and the serum will be 
divided into 3 aliquots (1 aliquot for pharmacokinetic analy sis, 1 aliquot for immunogenicity 
assessment [when appropriate], and 1 aliquot as a back -up).
The exact dates and times of blood sampling must be recorded. Refer to the Laboratory  Manual 
or equivalent document for sample collection requirements. Collected samples must be stored 
under the specified and controlled conditions for the temperatures indicated in the laboratory  
manual. 
Samples collected for determining serum concentrations of daratumumab in this study  may be 
retained to address questions about drug characteristics that may  arise at a later time point.
9.3.2. Analytical Procedures
Serum samples will be analy zed to determine concentrations of daratumumab or generation of 
antibodies to daratumumab using validated immunoassay  methods by  or under the supervision of 
the sponsor’s bioanal ytical facility . 
For the immunogenicit y assessments, serum samples will be screened for antibodies binding to 
daratumumab and serum titer will also be determined from confirmed positive samples. Other 
immunogenicit y analyses (eg, assessment of neutralizing capabilities) may be performed to 
further characterize the immu ne responses that are generated.
9.3.3. Pharmacokinetic Parameters
The pharmacokinetic parameters are defined as:
Cmax Maximum observed concentration
Cmin Minimum observed concentration
For daratumumab, the pharmacokinetic evaluations include Cmin and Cmax. If sufficient data 
are available, then other pharmacokinetic parameters may be calculated. If sufficient data are 
available, population pharmacokinetic analysis of serum concentration- time data of 
daratumumab may be performed and may include data from other c linical studies; details will be 
provided in a population pharmacokinetic analy sis plan and results will be presented in a 
separate report.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
93
Approved , Date: 14 February 20189.3.4. Immunogenicity  Assessments (Antibodies to daratumumab )
Serum from venous blood samples collected from D-VMP subjects will be assessed for the 
generation of antibodies to daratumumab (immunogenicity ) according to the Time and Events 
Schedule. In the Follow -up Phase, for all subjects in Arm B (D-VMP), samples are tobe 
collected for immunogenicity assessments 8 weeks after the last dose of daratumumab, 
regardless of whether there has been confirmed disease progression. Daratumumab concentration 
is also evaluated at all immunogenicity  time points to ensure appropriate interpretation of 
immunogenicit y data. When both serum concentration and immunogenicity  analyses are 
specified, they are performed on aliquots from the same blood draw and no additional sampling 
is required. Procedures for sample collection, preparation, identification, storage, and shipment 
will be provided in the Laboratory  Manual or equivalent document. 
A blood sample should be drawn, if possible, for determination of antibodies to daratumumab 
any time an infusion reaction is observed or reported during the study . Daratumumab serum 
concentration will also bedetermined from the same infusion reaction sample for the purpose of 
interpreting immunogenicity  data. These samples will be stored and evaluated if deemed 
necessary . If the infusion reaction results in treatment discontinuation, then subjects should 
unde rgo all scheduled safet y and efficacy  evaluations. Samples collected for the analysis of 
daratumumab immunogenicity /serum concentration may additionally  be used to evaluate safety 
or efficacy  aspects that address concerns arising during or after the study  period or for the 
evaluation of relevant biomarkers b y the sponsor or sponsor’s designee.
9.4. Pharmacokinetic/Pharmacody namic Evaluations
If sufficient data are available, then other pharmacokinetic/pharmacod ynamic modeling may be 
performed, including explorin g the relationship between serum concentrations of daratumumab 
and endpoints of clinical efficacy . If these analy ses are performed, then the details and results 
will be presented in a separate report.
9.5. Biomarkers
Biomarker assessments will focus on two main objectives including evaluating the ability  of 
daratumumab + VMP to reduce minimal residual disease (MRD) in subjects that achieve a 
complete response (compared to VMP alone), and to determine the clinical benefit (ORR, PFS, 
and OS) of daratumumab + VMP in high-risk molecular subty pes(del17p, t(4;14), t(14;16 ), 
specific gene signatures, specific mutations). Bone marrow aspirates will be collected at 
screening and following treatment as outlined in the Time and Events Schedule .  Baseline bone 
marrow aspira te samples will be subjected to DNA and RNA sequencing in order to classify 
subjects into high-risk molecular subgroups and to establish the myeloma clone for MRD 
monitoring. A fresh bone marrow aspirate or biopsy at Screening is required if at all possible ;by 
exception non-decalcified diagnostic tissue (bone marrow aspirate slides or FFPE tissue) may be 
supplied for MRD assessment instead. For subjects who achieve a CRor sCR, bone marrow 
aspirates will be utiliz ed for assessment of MRD by next-generation sequencing (NGS) of 
immunoglobulin heavy  and light chains (Vij 2013 ).43If this methodology  is unavailable, or 
determined to be scientifically  inferior, then alternative methods for MRD assessment may be 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
94
Approved , Date: 14 February 2018utilized. In cases where daratumumab is suspected of interfering with serum IFEand preventing 
clinical CR response calls, subjects with VGPR will also be evaluated for MRD by  NGS.  
In addition to planned bone marrow aspirate assessments, a whole blood sample will be collecte d 
from subjects as outlined in the Time and Events Schedule for processing to plasma and PBMC s. 
These samples may be used to evaluate specific subsets of immune cells such as cytotoxic 
Tcells, regulatory  T cells, MDSCs, and activated NK cells. Cells may  also be used for additional 
phenoty pic and functional profiling. Proteomic analy sis may also be used to evaluate changes in 
cytokines, complement proteins, soluble CD38, soluble CD59, IFNγ, granzy me, perforin, and 
other proteins associated with ADCC/CDC/ADCP to evaluate potential biomarkers of response 
and resistance.
Potential mechanisms of tumor resistance, such as changes in antigen (CD38) expression or 
increased expression in complement inhibitory  proteins (CD46, CD55, and CD59) in multiple 
myeloma cells, may be monitored in subjects if a bone marrow aspirate sample is deemed 
feasible for collection at progressive disease. In addition, changes in expression patterns of genes 
associated with ADCC, CDC, or other mechanisms of action of daratumumab may  be evaluated. 
Biomarker anal yses are dependent upon the avail ability  of appropriate biomarker assay s and may 
be deferred or not performed if, during or at the end of the study , it becomes clear that the 
analysis will have no scientific value, or if there are not enough samples or not enough 
responders to allow for adequate biomarker evaluation. In the event the study  is terminated early 
or shows poor clinical efficacy , completion of biomarker assessments is based on justification 
and intended utility  of the data. Samples for biomarker evaluations will be collected asspecified 
in the Time and Events Schedule.
9.6. Patient -reported Outcomes
It is anticipated that the addition of daratumumab will provide benefits in terms of symptom 
reduction, improved functioning , and improved utilities. To measure functional status, well-
being, and symptoms, the EORTC QLQ-C30 and the EQ-5D- 5Linstruments will be used.Both 
questionnaires will be completed at the time points outlined in the Time and Events Schedule
before any other study  procedures scheduled for the same day.All PRO measure s will be 
completed using an electronic device (ePRO). For more details ,refer to the ePRO user manual .
The EORTC QLQ -C30 includes 30 items resulting in 5 functional scales (physical functioning, 
role functioning, emotional functioning, cognitive functioni ng, and social functioning), 1 Global 
Health Status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single 
items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The 
recall period is 1 week (the past week). The EORTC QLQ-C30 has been widel y used among 
cancer patients. Scores are transformed to a 0 to 100 scale. Administration time is approximately  
11minutes. Reliability , validity , and clinically  meaningful change have been demonstrated in 
patie nts with multiple myeloma (Wislo ff 1996, Wisloff 1997).44,45The focus of the 
PRO assessment will be the global health scale which is designated as a secondary  endpoint. The 
remaining domains are included as exploratory  endpoints.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
95
Approved , Date: 14 February 2018The EQ-5D-5L is a generic measure of health status. For purposes of this study , the EQ-5D- 5L 
will be used to generate utility  scores for use in cost effective analyses. The EQ-5D- 5L is a 
5item questionnaire that assesses 5 domains including mobility , self-care, usual activiti es, 
pain/discomfort and anxiety /depression plus a visual analog scale rating “health today ” with 
anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)
(Herdman 2011) .15The scores for the 5 separate questions are categorical and cannot be 
analyzed as cardinal numbers. However, the scores for the 5 dimensions are used to compute a 
single utility  score ranging from zero (0.0) to 1 (1.0) representing the general health status of the 
individual.
9.7. Medical Resource Utilization
Medical resource utilization (MRU) data, principally  number of hospitalizations, will be derived 
from data collected in the eCRF for all subjects throughout the study .
9.8. Safety  Evaluation s
Safety  will be measured by adverse events, laboratory  test results, ECGs, vital sign 
measurements, physical examination findings, and assessment of ECOG performance status 
score. Any clinicall y relevant changes occurring during the study  must be recorded on the 
Adverse Event section of the eCRF. Any  clinically  significant abnormalities persisting at the end 
of the study /early  withdrawal will be followed by the investigator until resolution or until a 
clinically  stable endpoint is reached.
Based on the previous human experience with daratumumab, in vitro studies, and animal 
toxicological findings, infusion- related reactions/allergic reactions, hemoly sis, and 
thrombocytopenia will be closel y monitored. As a biologic agent, immunogenicity  also will be 
monitored. Any of the safet y monitoring assessments may be performed more frequentl y, and 
adverse events should be evaluated by the investigator according to the standard practice, if 
clinically  indicated.
Details regarding theIndependent Data Monitoring Committee are provided in Section 11.11 .
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule:
Adverse Events
Adverse events (with the exception of progression of multiple myeloma) will be reported by the 
subject (or, when appropriate, by a caregiver, surrogate, or the subject's legall yacceptable 
representative) from the time a signed and datedinformed consent isobtained until 30 days 
following the last dose of study  treatment . Adverse events will be followed by  the investigator as 
specified in Section 12, Adverse Event Reporting.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
96
Approved , Date: 14 February 2018Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  will be collected. The investigator must 
review the laboratory  report, document this review, and record any clinically  relevant changes 
occurring during the study  in the adverse event section of the eCRF. The laboratory  reports must 
be filed with the source documents.
The fo llowing tests will be performed by  the local laboratory :
Hematology  Panel
-hemoglobin -absolute neutrophil count
-white blood cell (WBC) count -platelet count
-absolute ly mphocy te count
Serum Chemistry  Panel
Screening ,Cycles 1-9 and E nd-of-Treatment:
-blood urea nitrogen (BUN) or urea -alkaline phosphatase
-creatinine -lactic acid deh ydrogenase (LDH)
-glucose -uric acid
-aspartate aminotransferase (AST) -total protein
-alanine aminotransferase (ALT) -sodium *
-total bilirubin (direct bilirubin if total 
bilirubin >1.5xUL N)-potassium *
*Sodium and potassium assessment swere added in Protocol Amendment 2, however ,entry  
of sodium and potassium results in the eCRF will be done retrospectivel y from the date of 
subject consent for the duration of the study , if collected as part of routine care .
Cycle 10+:
-creatinine -blood urea nitrogen (BUN) or urea
-sodium -potassium
Cycle 10+, every  third cycle:
-aspartate aminotransferase (AST) -alanine aminotransferase (ALT)
Pregnancy  testing : Serum or urine pregnancy  test for women of childbearing potential only
Calcium and albumin adjusted calcium: These parameters will be part of the efficacy  
evaluations as specified in Section 9.2.1.3 , and will be analy zed by the central laboratory . 
Measurement of calcium and albumin should follow the schedule for disease assessments . 
Measurement of free ionized calcium is an accepta ble alternative to corrected serum calcium 
for determining h ypercalcemia.
Daratumumab Interference with Indirect Antiglobulin Test (IAT) R esults
Daratumumab interferes with the Indirect Antiglobulin Test (IAT), which is a routine 
pre-transfusion test perfo rmed to identify  a patient’s antibodies to minor antigens so that suitable 
donor blood can be given for transfusion. Daratumumab does not interfere with ABO/RhD 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
97
Approved , Date: 14 February 2018typing. CD38 is expressed at very low levels on erythrocy tes. Daratumumab binds to the CD38 
on erythrocy tes,which results in a positive IAT(Indirect Coombs Test) .This positive result 
masks the detection of antibodies to minor antigens and may prevent or delay  blood banks from 
issuing donor blood for transfusion. This effect occurs during daratumu mab treatment and for up 
to 6months after treatment ends. Subjects will receive a patient identification wallet card for the 
study  thatincludes the blood profile (ABO, Rh, and IAT) determined before the first infusion of 
daratumumab along with informatio n on the IAT interference for healthcare providers/blood 
banks. Subjects are tocarry  this card throughout the treatment period and for at least 6 months 
after treatment ends. Blood banks can eliminate the daratumumab IAT interference by treating 
reagent R BCs with dithiothreitol (DTT) (Chapu y2015 , Chapuy 2016 ).5,4
Possible methods for blood banks to provide safe RBCs for transfusion to subjects receiving
daratumumab include:
a)Providing ABO/RhD compatible, phenoty pically  or genoty picall y matched units
b)Providing ABO/RhD compatible, K-negative units after ruling out or identify ing 
alloantibodies using DTT -treated reagent RBCs
Uncrossmatched, ABO/RhD compatible RBC units should be administered if transfusion is 
needed emergentl y as per local blood bank practice.
Despite daratumumab binding to CD38 on erythrocy tes, no indication of clinically  significant 
hemoly sis has been observed in daratumumab studies. For additional details, refer to the 
daratumumab IB.
Pulmonary Function Test
Subjects with known or suspected COPD must have a FEV 1test during screening. Refer to 
Section 6.1.3.2 for details on subjects with higher risk of respiratory  complications.
Electrocardiogram (ECG)
During the collection of ECGs, subjects should be in a quiet setting without distractions 
(eg,television, cell phones). Subjects should rest in a supine position for at least 5minutes 
before ECG collection and should refrain from talking or moving arms or legs. If blood sampling 
or vital sign measurement is scheduled for the same time point as ECG recording, the procedures 
should be performed in the following order: ECG(s), vital signs, blood draw.
Vital Signs (heart rate, temperature, blood pressure) will be performed as specified in the Time 
and Events Schedule. It is recommended that blood pressure (sitting) and heart rate
measurements be preceded by at least 5 minutes of rest in a quiet setting without distractions 
(eg,television, cell phones). Only  vital signs at Screening or associated with an AE will be 
entered in the eCRF; all measurements will be recorded in the source documents.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
98
Approved , Date: 14 February 2018Physical Examination
A complete physical examination (including neurological examination) should be performed 
during the Screening Phase. Height will be measured at screening only; weight will be measured 
regularl y as specified in the Time and Events Schedule. Thereafter, only a symptom and disease 
directed physical examination is required. Abnormalities will be recorded in the appropriate
sections of the eCRF.
Eastern Cooperative Oncology Group (ECOG) Performance Status
When scheduled, ECOG assessments along with PRO questionnaires should be obtained prior to 
any other study  procedures planned for the same day .
9.9. Sample Collection and Handling
If blood samples are collected via an indwelling cannula, an appropriate amount (1 mL) of 
serosanguineous fluid slightl y greater than the dead space volume of the lock will be removed 
from the cannula and discarded before each blood sample is taken. After blood sample 
collection, the cannula will be flushed with 0.9% sodium chloride, United States Pharmacopeia
(or equivalent)/ sodium heparin of 10 U/mL  and charged with a volume equal to the dead space 
volume of the lock. If a mandarin (obturator) is used, blood loss due to discard is not expected.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
A subject will be considered to have completed the study  if he or she has finished all protocol -
specified procedures before the end of the study , has not been lost to follow up, or has not 
withdrawn consent for study  participation before the end of the study .The study  end is defined 
as when 330 deaths have occurred , or 5 years after the last subject is randomized, whichever 
comes first .
Completion of Study Treatment
Subjects in Arm A (VMP) will be considered to have completed the study  treatment if they  have 
received at least 1 dose of study treatment in Cycle 9 and have not discontinued study  treatment 
in Cy cle 9 due to an y of the reasons in Section 10.2 (Discontinuation of Study  Treatment).
Subject s in Arm B (D-VMP) will continue daratumumab monotherapy  until PD or until 
discontinuation due to an AE. As there is no protocol -defined study  treatment period for this
arm, no subjects in Arm B will be considered to complete study  treatment at an y time .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
99
Approved , Date: 14 February 201810.2. Discontinuation of Study Treatment
If a subject's study  treatment must be discontinued before the end of the treatment regimen, this 
will not result in automatic withdrawal of the subject from the study . After treatment 
discontinuation, the subject will move intotheFollow -upPhase .The End -of-Treatment Visit and 
Follow -up visit assessments should continue as specified in the Time and Events Schedule. If 
study  treatment is discontinued for a reason other than disease progression, then disease 
evalua tions will continue to be performed as specified in the Time and Events Schedule .
Subjects who need to discontinue treatment with any one component of study  treatment 
(VEL CADE, melphalan, prednisone, or daratumumab) may continue to receive treatment with 
the other components of study treatment, as assigned.
A subject's study  treatment should bediscontinue d if:
The investigator believes that for safet y reasons (eg,adverse event) it is in the best interest 
of the subject to discontinue study treatment
The s ubject becomes pregnant 
The subject (or the subject’s legall y acceptable representative) withdraws consent for 
administration of study  treatment
The subject initiates treatment with a prohibited medication
The subject received concurrent (non -protocol) treatment for multiple my eloma
The subject experiences unacceptable toxicity , including infusion-related reactions as 
described in Section 6.1.4
Thesubject’s dose of daratumumab is held for more than 4 weeks (Cycle 1 to Cy cle 9), after 
Cycle 9 if the subject misses 2 consecutive planned doses (unless Sponsor approves 
continuation )
The subject experiences disease progression (please see below) . Relaps e from CR is not 
considered as disease progression
A subject who experiences a second primary  malignancy  that can be treated by surgery  alone, 
may continue to receive the assigned study  treatment and should continue to be followed for 
subsequent progression of multiple my eloma .
If any component of VMP requires dose reduction for a third time, only  the component requiring 
dose reduction for a third time should be discontinued (ie, other components of the VMP 
regimen may  continue to be administered).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
100
Approved , Date: 14 February 2018Before subjects discontinue study treatment due to disease progression , sites will document 
disease progression (for example by completing a disease progression form or by contacting the 
IWRS) as soon as possible and within 48 hours. The medical monitor will confirm that treatment 
should be discontinued. After confirmation from the sponsor, study  treatment may be 
discontinued and the subject entered into Follow- up.
The primary  reason for discontinuation of study  treatment is to be recorded in the eCRF.
10.3. Withdrawal F rom the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent for study  participation
Death
The study  investigator or Sponsor, for any reason, stops the study  or stops the subject’s 
participation in the study
Before a subject is considered lost to follow -up, every  reasonable effort must be made by the 
study  site personnel to contact the subject and determine the reason for 
discontinuation/withdrawal. The measures taken to follow up must be documented.
When a subject withdraws from the study , the reason for withdrawal is to be documented in the 
eCRF and in the source document. Study  treatment assigned to the withdrawn subject may  not be 
assigned to another subject. If a subject withdraws from the study  before the end of treatment, 
assessments outlined in the End- of-Treatment Visit should becompleted . If the reason for 
withdrawal from the study is withdrawal of consent then no additional assessments are allowed.
Withdrawal From the Use of Sam ples in Future Research
The subject may withdraw consent for use of samples for future research (refer to 
Section 16.2.5 ). In such a case, samples will be destroy ed after they are no longer needed for the 
clinical study . Details of the sample retention for research are presented in the main I CF.
11. STATISTICA L MET HODS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Sta tistical Analy sis Plan.
11.1. Subject Information
The primary  analysis population will be the intent -to-treat (ITT) population, which will include 
all randomized subjects. Safety  will be evaluated for the population of all treated subjects. The 
pharmacokinetic analyses will be performed on the pharmacokinetic evaluable population. 
Continuous variables will be summarized using descriptive statistics such as mean, standard 
deviation, and range. Categorical variables will be summarized using frequency  tables. For 
time-to-event variables, the Kaplan -Meier method will be used for descriptive summaries.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
101
Approved , Date: 14 February 201811.2. Sample Size Determination
In the VISTA study , the median PFS (as calculated by algorithm), was 18.3 months. The sample 
size calculation is performed based on the assump tion that the median PFS for the VMP group in 
this study  is estimated to be 21months. Assuming that the addition of daratumumab can reduce 
the risk of the disease progression or death by 27.6%, ie, assuming the hazard ratio (VMP vs. 
D-VMP) of 0.724, which translates into a median PFS of 29 months for the D-VMP group, a 
total of 360 PFS events is needed to achieve a power of 85% to detect this hazard ratio with a 
log-rank test (two-sided alpha =0.05). With a 20-month accrual period and an additional 
21-month follow -up, the total sample size needed for the study  is approximately  700 
(350/treatment group) subjects. The sample size calculation has taken into consideration an 
annual dropout rate of 5%.
Long -term survival follow -up will continue until 330deaths have been observed. Therefore, this 
study  will achieve more than 80% power to detect a 27% reduction in the risk of death (hazard 
ratio=0.73) with a log- rank test (two- sided alpha=0.05).
11.3. Efficacy  Analyses
Response to study  treatment and progressive disease will be evaluated by a validated computer 
algorithm. 
Primary Endpoint
For the primary  endpoint of PFS, the primary  analysis will consist of a stratified log -rank test for 
the comparison of the PFS distribution between the 2 treatment groups. The Kapl an-Meier 
method will be used to estimate the distribution of overall PFS for each treatment. The treatment 
effect (hazard ratio) and its two-sided 95% confidence intervals are to be estimated using a 
stratified Cox regression model with treatment as the so le explanatory  variable. 
Secondary Endpoints
Other time-to-event efficacy  endpoints, including TTP, PFS2, OS, and time to next treatment, 
will be analyzed using the same method as for PFS. For overall survival, the final analysis will 
occur after 330 deaths have been observed. Earlier analyses, in which overall survival is 
analyzed, will be considered as interim analyses. Even though the significance of PFS has 
alread y been established at the second interim analy sis, testing of OS will continue as planned 
until a definitive conclusion on OS is reached. The details about testing of OS over time are 
specified in Section 11.10 . The analysis of OSmay be confounded by subjects from Arm A 
receiving daratumumab after their study  treatment was stopped. Exploratory  analysis may be 
performed to adjust for the effect daratumumab exposure may have on OS for the subjects who 
were randomized to Arm A (VMP ).
Compari son between the 2 treatment groups of overall response rates, rate of VGPR or better ,
rate of CR or better, and other binary  endpoints will be conducted using the stratified Cochran 
Mantel Haenszel test. The Mantel -Haenszel odds ratio will be provided along with its two-sided 
95% confidence interval, and will be provided as the measure of treatment effect. Duration of 
response will be provided descriptivel y without formal statistical comparison.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
102
Approved , Date: 14 February 2018Strong control of famil ywise Ty pe I error rate will be control led at a two -sided significance level 
of 0.05 for the major secondary  endpoints, including ORR ,rate of VGPR or better, rate of CRor 
better , MRD negativity  rate, and OS. Asequential hierarchical testing procedure will be used. 
The details of the testing procedure will be pre-specified in a statistical analy sis plan that will be 
finalized prior to any  unblinded efficacy  analy sis.
11.4. Pharmacokinetic A nalyses
Pharmacokinetic analyses will be performed on the pharmacokin etic-evaluable population, 
defined as subjects who have received one dose of daratumumab and at least one post-infusion 
sample. All serum concentrations below the lowest quantifiable concentration or missing data 
will be labeled as such in the concentration data presentation. Concentrations below the lowest 
quantifiable concentration will be treated as zero in the summary  statistics. All subjects and 
samples excluded from the anal ysis will be clearly  documented in the study  report.
Descriptive statistics will be used to summarize daratumumab serum concentrations at each 
sampling time point and pharmacokinetic parameters of daratumumab such as Cmin and Cmax. 
If sufficient data are available, then other pharmacokinetic parameters may be calculated, 
including b ut not limited to CL  and V.
11.5. Immunogenicity  Analyses
The incidence of antibodies to daratumumab will be summarized for all subjects who receive a 
dose of daratumumab and have appropriate samples for detection of antibodies to daratumumab .
11.6. Pharmacokine tic/Pharmacody namic A nalyses
If sufficient data are available, then population pharmacokinetic analy sis of serum 
concentration -time data of daratumumab may be performed using nonlinear mixed -effects 
modeling. The potential population PK analysis may also include PK data from other clinical 
studies. If the population pharmacokinetic analysis is conducted, then details will be given in a 
population pharmacokinetic analysis plan, and the results of the analysis will be presented in a 
separate report.
11.7. Biomarker Analyses
Biomarker studies are designed to identify  markers predictive of response (or resistance) to 
daratumumab. Anal yses will be performed and stratified by clinical covariates or molecular 
subgroups using the appropriate statistical methods (eg, param etric or non-parametric, univariate 
or multivariate, analysis of variance, or survival analysis, depending on the endpoint). 
Correlation of baseline expression levels or changes in expression levels with response or 
time-to-event endpoints will identify  responsive (or resistant) subgroups in addition to genes and 
pathway s attenuated following treatment with daratumumab. In order to remove any 
confounding influence of prognostic factors, any predictive biom arker identified in this study 
could be verified in a prospective clinical stud y with a control treatment arm.
Any biomarker measures will be listed, tabulated, and where appropriate, plotted. Subjects will 
be grouped b y prescribed dose. Complete responders will be utilized to investigate the prognostic 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
103
Approved , Date: 14 February 2018effect of MRD on PFS. MRD analysis will include evaluation of data from other studies to 
determine if decreased MRD is seen with daratumumab + VEL CADE based chemotherap y 
regimen compared with the VEL CADE based chemotherapy  alone. 
Results of biomarker and pharmacod ynamic analy ses may be presented in a separate report. 
Planned analyses are based on the availability  of clinically  valid assay s and may be deferred if 
emerging study  data show no likelihood of providing useful scientific information.
In addition, due to the small sample sizes of high-risk subgroups within the multiple myeloma
patient population, a meta -analysis may be performed across daratumumab Phase 3 studies to 
evaluate clinical efficacy  of daratumumab with standard of care agents in pre-speci fied 
subgroups of multiple myeloma patients. The meta -analysis protocol will pre-specify  the 
objective of the meta -analy sis, the criteria for inclusion and exclusion of studies, the hypotheses 
and endpoints, and statistical methods including a method for investigation of heterogeneity . 
This meta -analy tic approach, supported by  high-quality  data from the individual trials, should be 
able to provide definitive evidence on the effectiveness of daratumumab in the subpopulation of 
multiple myeloma subjects with high-risk molecular abnormalities. In a similar fashion, a meta -
analysis examining MRD negativity  in daratumumab treated patients in frontline, newl y 
diagnosed multiple my eloma (MMY3006, MMY3007, MMY3008) may  also be performed.
11.8. Patient -reported Outcomes
EORTC -QLQ -C30 scores will be evaluated for all domains except “financial problems” among 
patients with at least one post-baseline assessment and 50% completion of the relevant items for 
a domain.  Descriptive analyses followed by mixed model repeated measure s will be used to 
analyze each domain score.  No adjustment for mu ltiple comparisons will be made.
EQ-5D- 5L scores will be summarized at each time point.
11.9. Safety  Analyses
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  adverse events will be coded 
using the Medical Dictionary  for Regulatory  Activities (MedDRA). The severit y assessment for 
an adverse event or serious adverse event should be completed using the NCI  CTCAE Version 4.
All reported adverse events with onset during the treatment phase (ie, treatment -emergent 
adverse events, and adverse events that have worsened since baseline) will be included in the 
analysis. For each adverse event, the percentage of subjects who experience at least 1 occurrence 
of the given event w ill be summarized by  treatment group.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
104
Approved , Date: 14 February 2018Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and for observed values and changes from baseline at each scheduled time point. Changes from 
baseline results will be presented in pre -versus post-treatment cross -tabulations (with classes for 
below , within, and above normal ranges). Frequency  tabulations of the abnormalities will be 
made. A listing of subjects with any laboratory results outside the reference ranges will be 
provided. A listing of subjects with any markedly  abnormal laboratory result s will also be 
provided.
Parameters with predefined NCI CTCAE toxicity  grades will be summarized. Change from 
baseline to the worst toxicity grade experienced by the subject during the study  will be provided 
as shift tables. Worst toxicity  grade during treatment will be presented, according to NCI
CTCAE (version 4).Clinically  relevant changes (i.e. causing a treatment intervention and/or 
need for concomitant therap y) will be also recorded on the adverse event eCRF. All other lab 
abnormalities need not be r ecorded as adverse events.
Electrocardiogram (ECG)
Electrocardiogram data will be summarized by  ECG parameter and listed.
Vital Signs
Descriptive statistics of baseline temperature, pulse/heart rate, and blood pressure (systolic and 
diastolic) values will be summarized .
11.10. Interim A nalysis
Two interim analy ses are planned for this study . The first interim analy sis will be performed 
after a total of approximately  100 subjects have been treated for at least 2 cyclesor discontinued 
the study  treatment. Its purpo se is to evaluate safet y. The second interim analy sis will be 
performed when approximately  216 PFS events, which is 60% of the total planned PFS events, 
have been accumulated. The purpose of this interim analysis is to evaluate cumulative interim 
safet y and efficacy  data. The significance level at this interim analy sis to establish the superiority 
of D-VMP over VMP with regard to PFS will be determined based on the observed number of 
PFS events at the interim analy sis, using the O’Brien -Fleming boundaries a s implemented by  the 
Lan-DeMets alpha spending method. Assuming 216 PFS events are observed, the alpha to be 
spent in this interim analy sis will be 0.00762 (2-sided). If the experimental group (D-VMP) is 
numericall y worse than the control group in terms of PFS (observed hazard ratio >1 favoring the 
control group), then the study  may  be terminated for futility .
As planned in the original protocol, two interim OS analy ses will be performed at the time of the 
interim PFS (216 events) and the primary  PFS (360 events) prior to the final OS analy sis at 
330deaths. As the superiority  of daratumumab combined with VMP over VMP alone with 
respect to PFS was established at the interim PFS analysis, the second interim OS will occur 
when 200deaths (60% of all planned deaths) have been accumulated which is about thesame 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
105
Approved , Date: 14 February 2018time of the primary  PFS analy sis as if it would have occurred. The stopping boundary  for OS 
will be determined using an alpha -spending approach. At the interim PFS analysis,an alpha of 
0.0001 will be spent. For thesecond OS interim and final analyses, the alpha to be spent will be 
determined by a linear alpha spending function based on the observed number of deaths at that 
time, ie, the cumulative alpha to be spent will be the total alpha (0.05) multiplied by the 
proportion of the observed number of deaths out of the total planned number of deaths (330).
11.11. Data Monitoring Committee
An IDMC, consisting of 2clinicians and 1 statistician who are independent experts not otherwise 
participating in the study, will be established to review efficacy  and safet y results at the 2 
planned interim analyses. After the interim review, they will make recommendations regarding 
the continuation of the study . In addition, the IDMC may also review cumulative safet y data 
every  6months besides the two interim analy ses. The IDMC will no longer review study  data 
after the database lock for the primary  analysis has been completed . The details will be provided 
in a separate IDMC charter.
12. ADVERSE EVENT REPORT ING
Timely , accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigation al) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequenc y from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1 , All Adverse Events, for time of last adverse event recording).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
106
Approved , Date: 14 February 2018Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspec ted transmission of any  infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  treatment and the event (eg, death from anaphy laxis), the event 
must be reported as a serious and unexpected suspected adverse reaction even if it is a 
component of the stud y endpoint (eg, all -cause mort ality).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable produ ct reference safety  information. For daratumumab , the expectedness of an 
adverse event will be determined by whether or not it is listed within the Reference Safet y 
Information included in the Investigator's Brochure. 
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel yby the definitions listed in Section 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
107
Approved , Date: 14 February 2018Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by dechallenge). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by an alternative explanation, eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
The severity  assessment for an adverse event or serious adverse event should be completed using 
the NCI CTCAE Version 4. Any adverse event orserious adverse event not listed in the 
NCI CTCAE Version 4 will be graded according to investigator clinical judgment by using the 
standard grades as follows:
Grade 1(Mild) : Awareness of symptoms that are easily tolerated, causing minimal discomfort 
and not interfering with every day activities.
Grade 2 (Moderate) : Sufficient discomfort is present to cause interference with normal activity .
Grade 3(Severe) : Extreme distress, causing significant impairment of functioning or 
incapacitation. Prevents norma l every day activities.
Grade 4: Life-threatening of disabling adverse event
Grade 5: Death related to the adverse event
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
108
Approved , Date: 14 February 2018Overdose of a sponsor study  drug . No MTD has been reached for daratumumab. However, if 
the dose exceeds the maximum tested dose of 24 mg/kg, then it will be considered as 
overdose in this study .
Suspected abuse/misuse of a sponsor study  drug
Inadvertent or accidental exposure to a sponsor study  drug
Medic ation error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serio us adverse event should be recorded on the adverse event page of the 
eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until 30 days after the last dose of 
study  treatment unless the subject withdraws consent for study  participation or starts subsequent 
anti-myeloma therapy . For subjects who have received subsequent treatment with therapeutic 
intent for multiple myeloma during the adverse event reporting period, only adverse event s that 
are considered to be possibly , probabl y, or definitely  related to daratumumab need to be 
reported. Serious adverse events, including those spontaneousl y reported to the investigator 
within 30days after the last dose of study  treatment, must be reported using the Adverse Event 
Form .The sponsor will evaluate any safet y information that is spontaneously reported by an 
investigator bey ond the time frame specified in the protocol.
Disease progression should not be recorded as an adverse event or serious adverse event term; 
instead, signs and symptoms of clinical sequelae resulting from disease progression/lack of 
efficacy  will be reported if they fulfill the serious adverse event definition (refer to 
Section 12.1.1 ). Death should not be recorded as an adverse event or serious adverse event, but 
as the outcome of an adverse event. The adverse event that resulted in the death should be 
reported as a serious adverse event.
Only  clinicall y relevant laboratory  abnormalities (ie, those causing a treatment intervention or 
need for concomitant therapy ) should be recorded on the adverse event eCRF. All other 
laboratory  abnormalities need not be recorded as adverse events.
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol -specific assessments. Anticip ated events will be 
recorded and reported as described in Attachment 10.
All adverse events, regardless of seriousness, severit y, or presumed relationship to study  
treatment , must be recorded using medical terminology  in the source document and the eCRF. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a common 
etiology  (eg, cough, runny  nose, sneezing, sore throat, and head congestion should be reported as 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
109
Approved , Date: 14 February 2018"upper respiratory  infection"). Investigators must record in the eCRF their opinion concerning 
the relationship of the adverse event to study  therap y. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs). For 
anticipated events reported as individual serious adverse events the sponsor will make a 
determination of relatedness in addition to and independent of the investigator’s assessm ent. The 
sponsor will periodicall y evaluate the accumulating data and, when there is sufficient evidence 
and the sponsor has determined there is a reasonable possibility  that the drug caused a serious 
anticipated event, they  will submit a safety  report in narrative format to the investigators (and the 
head of the investigational institute where required) .The sponsor assumes responsibility  for 
appropriate reporting of anticipated events to the regulatory  authorities perrequirements of the 
countries in which the studies are conducted. The investigator (or sponsor where required) must 
report these events to the appropriate Independent Ethics Committee/Institutional Review Board 
(IEC/I RB) that approved the protocol unless otherwise required and documented by the 
IEC/IRB .
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  treatment phase (Arm A) and for at least 6 months after the study  treatment is 
discontinued (Arm B) indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical staf f onl y)
Site number
Subject number
Blood type and indirect antiglobulin test results (as described in Section 9.8for subjects in 
Treatment Arm B)
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact person b ystudy -site personnel within 24 hours of the ir knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax) .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
110
Approved , Date: 14 February 2018All serious adverse events that have not resolved by the end of the study , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in astudy  must be reported as a serious 
adverse event , except hospitalizations for the following:
If the subject is hospitalized overnight due to slow daratumumab infusion, or for observation 
after daratumumab infusion, and in the absence of a significant med ical event
Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underl ying condition for which the hospitalization was planned has not worsened ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospitalization is to be reported as a new serious adverse event.
12.3.3. Pregnancy
All initial reports of pregnancy  in female subjects or partners of male subjects must be reported 
to the sponsor by the study -site personnel within 24 ho urs of their knowledge of the event using 
the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered serious 
adverse events and must be reported using the Serious Adverse Event Form . Any subject who 
becomes pregnant during the study  must promptly discontinue further study  treatment.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Reporting, Monitoring, and Review  of Safety  Events in Japanese Subjects
inArm B (Japanese Sites Only )
There will be enhanced reporting, monitoring, and review of pre-specified safet y events that 
occur during Cycle 1 at Japanese sites, for Japanese subjects in Arm B until a minimum of 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
111
Approved , Date: 14 February 20183Japanese subjects in Arm B have completed Cy cle1. A list of these pre -specified safet y events 
and details regarding the reporting requirements are available in Attachment 8.
12.5. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durabi lity, or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the pr otection of subjects, investigators, 
and the sponsor , and are mandated by regulatory  agencies worldwide. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
If the defec t is combined with a serious adverse event, the study -site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor .
13.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed in theContact Information page(s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of S tudy Drug
Thedaratumumab supplied for this study  is a colorless to yellow liquid and sterile concentrate of 
20 mg/mL  in a vial. It will be manufactured and provided under the responsibility  of the sponsor .
Refer to the Investigator's Brochure for a list of excipients.
14.2. Packaging
Daratumumab is supplied in glass vials containing daratumumab at a concentration of 
20mg/mL .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
112
Approved , Date: 14 February 201814.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory  requirements. Each 
vial will contain a study -speci fic label with a unique identification number.
14.4. Preparation, Handling, and Storage
All study  drug vials must be stored in the original carton at controlled temperatures in a 
refrigerator ranging from 2°C to 8°C and must not be utilized after the expiry  date printed on the 
label. The product must be protected from light and must not be frozen. Daratumumab does not 
contain preservatives; therefore, any unused portion remaining in the vial must be discarded.
Daratumumab will be diluted in a sterile, py rogen -free phy siological saline solution (0.9% NaCl) 
prior to IV administration .Refer to the Investigational Product Preparation Instructions or Site 
Investigational Product Procedures Manual for details regarding dose preparation, storage, and 
handling of dilute d solutions .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The study  drug administered to the subject must be 
documented on the drug accounta bility  form. All study  drug will be stored and disposed of 
according to the sponsor's instructions. Study-site personnel must not combine contents of the 
study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the conta iner label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug must be available for verification by the sponsor's 
study  site monitor during on-site monitoring visits. The return to the sponsor of unused study 
drug, or used returned study  drug for destruction, will be documented on the drug return form. 
When the study  site is an authorized destruction unit and study  drug supplies are destro yed on-
site, this must also be documented on the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accou ntability  purposes. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospital/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Study drug may not be relabeled or reassigned for use by 
other subjects. The investigator agrees neither to dispense the study  drug from, nor store it at, 
any site other than the study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator Brochure for daratumumab
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
113
Approved , Date: 14 February 2018Site I nvestigational Product Procedures Manual
Laboratory  manual
PRO questionnaires on a TrialSlate and user guidelines
eCRF completion guidelines
Sample I CF
Subject diaries
Subject wallet card indicating blood t ypeand indirect antiglobulin test results
Other manuals and guidance documents as needed
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
The primary  safety profile of daratumumab is consistent with infusi on-related reactions; see 
Section 6.1.3 for prevention details. Based on the mode of action of daratumumab, a potential risk 
could be infection; therefore ,the protocol requires the review of hematological laboratory  results  
prior to daratumumab infusion. CD38 is distributed in erythrocy tes and platelets. A significant 
reduction of platelets was reported in an animal study . In a human clinical study  (Study GEN501), 
thrombocy topenia was also reported. However, safety laboratory  monitoring did not show a 
clinicall y meaningful reduction of platelets. Anemia was also reported in Study GEN501. Free 
hemoglobin was mildl y elevated, but other parameters did not support hemol ysis. No bleeding 
events were observed. Routine safety  laboratory  measurement of RBCs and platelets will be 
closel y monitored in this study .
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalty  or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.
The total blood volume for the study  is estimated at approximately  45 mL during screening and 
480mL during VMP treatment in the first year. In the post-VMP treatment phase, blood 
sampling for subjects in Arm B will be approximately  305 mL per year on treatment. In the 
Follow -up Phase, subjects prior to PD will have approximately  120 mL  blood drawn per yearfor 
serum disease evaluations. This isconsidered to bewithin the normal range of a single blood 
donation.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
114
Approved , Date: 14 February 201816.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an internat ional ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (orsponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be prov ided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives f or subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct ), the ICF, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/IRB and the documents being 
approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
115
Approved , Date: 14 February 2018If applicable, new or revised subject recruiting materials approved b y the sponsor
Revision s to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guideline s of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
Furthermore, where required, progress reports/written summaries of the trial status will be 
submitted to the IRB/IEC annually , or more fre quently  if requested .
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution) .
16.2.3. Informed Co nsent
Each subject (or a legally acceptable representative) must give written consent according to local 
requirements after the nature of the study  has been fully  explained. The ICF(s) must be signed 
before performance of any study-related activity . The ICF(s) that is/areused must be approved 
by both the sponsor and by  the reviewing IEC/IRB and be in a language that the subject can read 
and understand. The informed consent should be in accordance with principles that originated in 
the Declaration of Helsin ki, current ICH and GCP guidelines, applicable regulatory  
requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects or their legall y acceptable representatives the aims, 
methods, reasonabl y anticipated benefits, and potential hazards of the study ,and any discomfort 
participation in the study  may entail. Subjects will be informed that their participation is 
voluntary  and that they may withdraw consent to participate at any time. They  will be informed 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
116
Approved , Date: 14 February 2018that choosing not to participate will not affect the care the subject will receive for the treatment 
of his or her disease. Subjects will be told that alternative treatments are available if they refuse 
to take part and that such refusal will not prejudice future treatment. Finally , they will be told 
that the investigator will maintain a subject identification register for the purposes of long-term 
follow up if needed and that their records may be acces sed by health authorities and authorized 
sponsor personnel without violating the confidentiality  of the subject, to the extent permitted by 
the applicable law(s) or regulations. By signing the ICF the subject or legall y acceptable 
representative is authori zing such access , including permission to obtain information ab out his or 
her survival status, and agrees to allow his or her study  physician to recontact the subject for the 
purpose of obtaining consent for additional safet y evaluations, if needed, and su bsequent disease -
related treatments , or to obtain information about his or her survival status.
The subject or legally  acceptable representative will be given sufficient time to read the ICF and 
the opportunity  to ask questions. After this explanation and before entry  into the study , consent 
should be appropriatel y recorded by means of either the subject's or his or her legall y acceptable 
repres entative's personally  dated signature. After having obtained the consent, a copy of the ICF
must be given to the subject.
If the subject or legally  acceptable representative is unable to read or write, an impartial witness 
should be present for the entire informed consent process (which includes reading and explaining 
all written information) and should personally  date and sign the ICFafter the oral consent of the 
subject or le gally acceptable representative is obtained.
When prior consent of the subject is not possible and the subject's legally  acceptable 
representative is not available, enroll ment procedures should be described in the protocol with 
documented approval/favorable opinion by the IEC/I RB to protect the rights, safety , and well-
being of the subject and to ensure compliance with applicable regulatory  requirements. The 
subject or legally acceptable representative must be informed about the study  as soon as possible 
and give consent to continue.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject (or his or her legally acceptable representative)
includes explicit consent for the processing of personal data and for the investigator /institution to 
allow direct access to his or her original medical records (source data/documents) for study -
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
117
Approved , Date: 14 February 2018related monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also 
addresses the transfer of the data to other entities and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into c onsideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  biomarker/ PK/immunogenicity  research is not conducted under standards 
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory  
research data will not be returned to subjects or investigators, unless required by lawor local 
regulations . Privacy  and confidentiality  of data generated in the future on stored samples will be 
protected b y the same standards applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand daratumumab , to 
understand multiple myeloma , to understand differential drug responders, and to develop 
tests/assays related to daratumumab and multiple my eloma .  The research may begin at any time 
during the stud y or the post -study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research ( refer toSection 10.3, Withdrawal From the Study  (Withdrawal From the Use 
of Samples in Future Research) .
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product, unless explicitly  addressed as a specific ethical 
consideration in S ection 16.1, Study -Specific Design Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented witho ut prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
118
Approved , Date: 14 February 2018During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page(s) provide d separatel y). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notificat ion
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Pre -Study  Documentation
Thefollowing documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of i nvestigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, w hich includes the financial agreement
Any other documentation required by  local regulations
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
119
Approved , Date: 14 February 2018The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all sub- inves tigators
Documentation of sub -investigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigato r in the study  file. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by subject identification
and date of birth (as allowed by local regulations) . In cases where the subject is not randomized 
into the study , the date seen and date of birth (as allowed by  local regulations) will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for incl usion in the study .
17.4. Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility , and study identification; study  
discussion and date of signed inform ed consent; dates of visits; results of safety  and efficacy  
parameters as required by the protocol; record of all adverse events and follow -up of adverse 
events; concomitant medication; drug receipt/dispensing/return records; study  treatment
administration information ; and date of study  completion and reason for early discontinuation of 
study  treatment or withdrawal from the stud y, if applicable. 
In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document).
Subject -and investigator -completed scales and assessments designated by the sponsor (EORTC 
QLQ -C30 and EQ-5D- 5L) will be recorded directly  into an electronic device or other tool and 
will be considered source data.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
120
Approved , Date: 14 February 2018The minimum source documentation requirements for Section 4.1,Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify  a need for documented medical history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject intervie w or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format. 
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
study -sitepersonnel from the source documents onto an eCRF, and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor and the study  site. 
The electronic file will be considered to be the e CRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documentation . Data must be entered 
into eCRFs in English. Study site personnel must complete the eCRF as soon as possible after a 
subject visit, and the forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale information or other questionnair es) will be 
completed by the same individual who made the initial baseline determinations whenever 
possible. The investigator must verify that all data entries in the e CRF s are accurate and correct.
All eCRF entries, corrections, and alterations must be made by the investigator or other 
authorized study -site personnel. If necessary , queries will be generated in the eDC tool. The 
investigator or study -site personnel must adjust the e CRF (if applicable) and complete the query .
If corrections to an eCRF are needed after the initial entry  into the eCRF, this can be done in 3 
different way s:
Study site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated b y the eDC tool) .
Study site manager can generate a query  for resolution by  the study -site personnel.
Clinical data manager can generate a query  for resolution by  the study -site personnel.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
121
Approved , Date: 14 February 201817.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by the sponsor, direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base , and 
direct transmission of PRO data to the ePRO vendor database and then to the sponsor’s database . 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .The sponsor will review eCRFs for accuracy  and completeness during 
on-site monitoring visits and after transmission to the sponsor; any  discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study database 
they will be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
122
Approved , Date: 14 February 201817.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site. The first 
post-initiation visit will be made as soon as possi ble after enrollment has begun. At these visits, 
the monitor will compare the data entered into the eCRFs with the hospital or clinic records 
(source documents). The nature and location of all source documents will be identified to ensure 
that all sources of original data required to complete the eCRF are known to the sponsor and 
study -site personnel and are accessible for verification by the sponsor study -site contact. If 
electronic records are maintained at the study site, the method of verification must be discussed 
with the study -site personnel . 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the e CRF are consistent with the original sou rce data. Findings 
from this review of eCRFs and source documents will be discussed with the study -site personnel . 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
17.9. Study Completion/Termination
17.9.1. Study Complet ion
The study  is considered completed after 330 deaths have occurred or 5 years after the last subject 
is randomized, whichever is first. The final data from the study site will be sent to the sponsor
(ordesignee) after completion of the final subject at that study  site, in the time frame specified in 
the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites willbe closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  drug development
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
123
Approved , Date: 14 February 201817.10. On-Site A udits
Representatives ofthe sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the eCRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -site audit visits 
conducted b y the sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of thisstudy  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or shehas
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding daratumumab or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and any data, including exploratory  biomarker research data, generated as 
a result of this study , areconsidered confidential and remain the sole property  of the sponsor. 
The investigator agrees to maintain this information in confidence and use this information only 
to accomplish this study , and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of daratumum ab, and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the s tudy.
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain eCRF data from all study  sites that participated in the study , and direct transmission 
of clinical laboratory  data from a central laboratory  into the sponsor's database. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator for the study . Results of exploratory  
biomarker analyses performed after the Clinical Study  Report has been issued will be reported in 
a separate report and will not require a revision of the Clinical Study  Report. Study  subject 
identifiers will not be used in publication o f results. Any work created in connection with 
performance of the study  and contained in the data that can benefit from copyright protection 
(except any publication by the investigator as provided for below) shall be the propert y of the 
sponsor as author and owner of cop yright in such work.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
124
Approved , Date: 14 February 2018Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors (ICMJE) guidelines, t he sponsor shall have the right to publish such primary 
(multicenter) data and information without approval from the investigator. The investigator has 
the right to publish study site -specific data after the primary  data are published. If an investigator 
wishes to publish information from the study ,a copy  of the manuscript must be provided to the 
sponsor for review at least 60days before submission for publication or presentation. Expedited 
reviews will be arranged for abstracts, poster presentations, or other materials. If requested by 
the sponsor in writing, the investigator will withhold such publication for up to an additional 
60days to allow for filing of a patent application. In the event that issues arise regarding 
scientific integrity  or regulatory  compliance, the sponsor will review these issues with the 
investigator. The sponsor will not mandate modifications to scientific content and does not have 
the right to suppress information. For multicenter study  designs and substudy  approaches, 
secondary  results generally  should not be published before the primary  endpoints of a study  have 
been published. Similarly , investigators w ill recognize the integrity  of a multicenter study by not 
submitting for publication data derived from the individual study  site until the combined results 
from the completed study have been submitted for publication, within 18 months after study  end 
date,or the sponsor confirms there will be no multicenter study  publication. Authorship of 
publications resulting from this study  will be based on the guidelines on authorship, such as 
those described in the ICMJE Recommendations for the Conduct, Reporting, Editing and 
Publication of Scholarly Work in Medical Journals, which state that the named authors must 
have made a significant contribution to the conception or design ofthe work; or the acquisition, 
analysis, or interpretation of the data for the work; and drafted the work or revised it critically  for 
important intellectual content; and given final approval of the version to be published; and 
agreed to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy  or integrity of any  part of the work are appropriatel y investigated and resolved .
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
125
Approved , Date: 14 February 2018REFERENCES
1. American Cancer Society (ACS). Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012. 
Available from: http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/multiple -myeloma- key-
statistics. Accessed on 25 March 2013 .
2. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once- weekly bortezomib in multiple myeloma 
patients. Blood. 2010;116:4745 -4753.
3. Burtis CA, Ashw ood ER. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia; WB Saunders, 1999.
4. Chapu yC, Aguad MD, Nicholson RT , et al. International validation of dithiothreitol (DTT) -based method to 
resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;00:1 -9.
5. Chapuy, C, Nicholson R, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility 
testing. Transfusion. 2015; 55:1545 -1554.
6. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal 
antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;1 86:1840 -
1848.
7. Dim opoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) Is Active 
and Well Tolerated in New ly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal 
Function, and Results in Reversal of Rena l Impairment: Cohort Analysis of the Phase III VISTA Study. J Clin 
Onco. 2009;27:6086 -6093.
8. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. 
Leukemia. 2006;20:1467 –1473. Corrigenda/Erratum in: Leukemi a. 2007;21:1134 -1135.
9. Facon T, Dimopoulos MA, Dispenzieri A, et al. Initial Phase 3 Results Of The First (Frontline Investigation Of 
Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM -020/IFM 07 01) In New ly 
Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT). Blood 
2013;122:21. ASH Annual Meeting Abstract. 
http://bloodjournal.hematologylibrary.org/content/122/21/2.abstract?sid=06133b3d -094e- 452b -aeb2 -
f12d2a83ce53. Accessed on 16 January 2014. 
10. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple 
myeloma: meta -analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 
2011:118;1239 -1247.
11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM. Estimates of w orldwide burden of cancer in 
2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893 -2917.
12. Gay F and Palumbo A. Management of older patients with multiple myeloma. Blood Reviews 2011;25:65 -73.
13. Ghosh N, Tucker N, Zahurak M, et al.  Addition of clarithromycin to lenalidomide and dexamethasone (BiRd) 
is effective in MM after progression on lenalidomide and dexamethasone.  Session 653.  Myeloma: Therapy, 
excluding Transplantation. American Society of Hematology (ASH) 2013 meeti ng.  Abstract 1960.
14. Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in 
newly diagnosed multiple myeloma patients treated w ith non -intensive therapy; analysis of the Phase 3 VISTA 
study of bortezomib plus melphalan -prednisone versus melphalan -prednisone. Blood. 2010;116:3743 -3750.
15. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five -level version of 
the EQ- 5D (EQ -5D-5L). Qual Lif Res. 2011;20:1727 -1736.
16. Investigator's Brochure: JNJ-54767414 (daratumumab) Edition 10. Janssen Research & Development, LLC 
(16 December 2013).
17. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response 
and minimal residual disease assessmen t in multiple myeloma. Lancet Oncol. 2 016;17:e328 -346.
18. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. 
Mayo Clin Proc. 2003;78:21 -33. 
19. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple 
myeloma. Leukemia. 2009;23:3 -9.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
126
Approved , Date: 14 February 201820. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) 
multiple myeloma. N Engl J Med. 2007;356:2582 -2590.
21. Ladetto M, Bruggemann M, Monitello L, et al. Next -generation sequencing and real -time quantitative PCR for 
minimal residual disease detection in B -cell disorders. Leukemia. 2014;1 -9.doi:10.1038/leu.2013.375.
22. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in 
renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247 -254.
23. Levey AS, Stevens LA, Schmid CH, et al. A ne w equation to estimate glomerular filtration rate. Ann Intern 
Med. 2009;15 0(9):604 -612.
24. Martinez -Lopez J, Lahuerta JJ, Pepin F, et al.  Prognostic value of deep sequencing method for minimal 
residual disease detection in multiple myeloma.  Blood, prepublished online March 19, 2014: 10.1182/blood -
2014 -01-55020.
25. Mateos MV, Bringhe n S, Richardson PG, et al. Bortezomib cumulative dose, efficacy, and tolerability with 
three different bortezomib -melphalan -prednisone regimens in previously untreated myeloma patients ineligible 
for high -dose therapy. Haematologica. 2014:Apr 24 [Epub ahea d of print].
26. Mateos MV, Oriol A, Martinez- Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, 
thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and 
thalidomide versus bortezomib and pred nisone in elderly patients with untreated multiple myeloma: a 
randomised trial. Lancet Oncol. 2010;11:934 -941.
27. Mateos MV, Oriol A, Martínez- López J, et al. Maintenance therapy with bortezomib plus thalidomide or 
bortezomib plus prednisone in elderly multip le myeloma patients included in the GEM2005MAS65 trial. 
Blood. 2012;120:2581 -2588.
28. McCudden, CR, Voorhees PM, Hainsworth SA, et al. Interference of monoclonal antibody therapies with serm 
protein electrophoresis tests. Clin Chem. 2010;56:1897 -1904.
29. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in 
patients with relapsed multiple myeloma: a randomised, phase 3, non -inferiority study. Lancet Oncol. 
2011;12:431 -440.
30. National Comprehensive Cancer Netw ork. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines®): Multiple Myeloma, version 2.2013.
31. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology 
Group. Am J Clin Oncol. 1982;5:649 -655.
32. Overdijk MB , Verploegen S, Bogels M, et al. Phagocytosis is a potent mechanism of action for the therapeutic 
human monoclonal antibody daratumumab in lymphoma and multiple myeloma. Submitted to Blood. 
13May 2013. 
33. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046 -1060.
34. Palumbo A, Brighen S, Rossi D, et al. A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, 
Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly 
Diagnosed Myeloma Patient s. Blood. 2008;112:652. ASH Annual Meeting Abstract.
35. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib -Melphalan -Prednisone -Thalidomide Follow ed by   
Maintenance With Bortezomib -Thalidomide Compared With Bortezomib -Melphalan -Prednisone for Initial 
Treatment of Multiple Myeloma: A Randomized Controlled Trial. J Clin Oncol. 2010;28:5101 -5109.
36. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of 
multiple myeloma patients ineligible for standard high -dose chemot herapy with autologous stem cell 
transplantation. Leukemia. 2009;23:1716 -1730.
37. Rajkumar SV, Harousseau J -L, Durie B, et al. Consensus recommendations for the uniform reporting of 
clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691 -4695.
38. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for 
the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538 -e548 .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
127
Approved , Date: 14 February 201839. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomi b plus melphalan and prednisone for initial treatment 
of multiple myeloma. N Engl J Med. 2008;359:906 -917.
40. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma. Br J 
Haem atol. 2005;132:410 -451.
41. Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib -Based Versus Nonbortezomib -Based Induction 
Treatment Before Autologous Stem -Cell Transplantation in Patients With Previously Untreated Multiple 
Myelom a: A Meta -Analysis of Phase III Randomized, Controlled Trials. J Clin Oncol. 2013:31;3279 -3287.
42. van der Veer M, de Weers M, van Kessel B. The therapeutic human CD38 antibody daratumumab improves 
the anti -myeloma effect of newly emerging multi -drug therapies. Blood Cancer Journal. 2011a; 1 e41. 
Doi:10.1038/bcj.2011.42 .
43. Vij R, Mazumder A, Klinger M, et al. Deep sequencing reveals myeloma cells in peripheral blood in majority 
of multiple myeloma patients, Clinical Lymphoma, Myeloma and Leukemia (2013), doi: 
10.1016/j.clml.2013.09.013.
44. Wisloff F, Eika S, Hippe E, et al. Measurement of health -related quality of life in multiple myeloma. Nordic 
Myelom a Study Group. Br J Haematol. 1996;92:604 -613.
45. Wisloff F, Hjorth M. Health -related quality of life assessed before and during chemotherapy predicts for 
survival in multiple myel oma. Nordic Myeloma Study Group. Br J Haematol. 1997;97:29 -37.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
128
Approved , Date: 14 February 2018Attachment 1: Modified IMWG Diagnostic Criteria for Multiple My eloma
Clonal bone marrow plasma cells ≥10% or biops y-proven bon y or extramedullary 
plasmacy tomaaAND an y one or more of the following m yeloma defining events: 
Evidence of end organ damage that can be attributed to the underl ying plasma cell proliferative 
disorder, specificall y:
Hypercalcemia: serum calcium >0.25 mmol/L  (>1 mg/dL) higher than ULN or
>2.75 mmol/L  (>11 mg/dL )
Renal insufficiency : creatinine clearanceb<40mL /min or serum creatinine 
>177 µmol/L  (>2 mg/dL)
Anemia: hemoglobin >2 g/dL below the lower limit of normal or hemoglobin 
<10g/dL
Bone lesions: one or more osteol ytic lesions on skeletal radiograph y, CT, or PET-
CTc
Footnotes:
a)Clonality  should be established by showing /light-chain restriction on flow cytometry , 
immunohistochemistry , or immunofluorescence. Bone marrow plasma cell percentage 
should preferabl y be estimated from a core biopsy  specimen; in case of a disparity  between 
the aspirate and the core biopsy , the highest value should be used. 
b) Measured or estimated by  validated equations.
c)If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required 
to distinguish from solitary  plasmacy toma with minimal marrow involvement.
Reference: Rajkumar 201438
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
129
Approved , Date: 14 February 2018Attachment 2 : ECOG Performance Status Scale
Grade ECOG Performance Status 
0 Fully  active, able to carry  on all pre -disease performance without restriction
1 Restricted in phy sically  strenuous activity  but ambulatory  and able to carry  out 
work of a light or sedentary  nature, eg, light house work, office work
2 Ambulatory  and capable of all self -care but unable to carry  out an y work 
activities. Up and about more than 50% of waking hours
3 Capable of onl y limited self -care, confined to bed or chair more than 50% of 
waking hours
4 Completely  disabled. Cannot carry  on any  self-care. Totall y confined to bed or 
chair
5 Dead
Reference:  Oken 198231
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
130
Approved , Date: 14 February 2018Attachment 3: Serum Calcium Corrected for Albumin
If calcium is expressed in mg/dL and albumin is expressed in g/dL :
Corrected calcium (mg/dL) = 
serum calcium (mg/dL) + 0.8•(4 -serum albumin [g/dL ])
If calcium is expressed in mmol/L  and albumin is expressed in g/L:
Corrected calcium (mmol/L ) = 
serum calcium (mmol/L) + 0.02•(40 -serum albumin [g/L ])
Source: Burtis 19993
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
131
Approved , Date: 14 February 2018Attachment 4: Guideline for A sthma Eligibility  Criteria
Componen ts ofSeverity Classification ofAsthma Severity
IntermittentPersist ent
Mild Moderate Severe
0-4
yrs5-11yrs 12+yrs 0-4yrs 5-11yrs 12+yrs 0-4yrs 5-11yrs 12+yrs 0-4yrs 5-11yrs 12+yrs
Impairment
Normal 
FEV1/FVC :
8-19 yr 85%
20-39 yr
80%
40-59 yr
75%
60-80 yr
70%Symptoms ≤2days/w eek ≤2days/w eek but notdaily Daily Throughout theday
Nighttime 
awakenings 0 ≤2x/month1-2x/
month3-4x/month3-4x/
month>1x/week butnot 
nightly>1x/
monthOften 7x/week
SABA use for 
symptom control 
(not prevention
of EIB)≤ 2days/w eek≤ 2days/w eekbut not daily>2days / 
week but
not dail y,
and
notmore 
than 1x
on
any dayDaily Several time per day
Interference with 
normal activity None Minor limitation Some limitation Extremely limited
Lung function
FEV1
FEV1/FVCN/ANormal FEV1 
between 
exac erbations
>80%
>85%Normal FEV1 
between 
exac erbations
>80%
NormalN/A
>80%
>80%>80% 
NormalN/A
60-80%
75-80%60-80% 
Reduced
5%N/A
<60%
<75%<60% 
Reduced
5%
RiskExacerbatio ns 
requi ring oral 
system ic 
corticosteroids0-1/year≥2 exacerbation s in
6months requiring
oral stero ids or>4 
wheezing 
episodes/1 year
lasting>1 dayand
risk factors for 
persistent asthma≥ 2/year
Relati ve 
annual
risk may
be related
to FEV1.≥ 2/year
Relati ve 
annual
risk may
be related
to FEV1.≥ 2 e xacerbations 
in6months 
requiring oral 
steroids or >4 
wheez ing 
episo des/1 year
lasting >1 day and
risk factors for 
persistent ast hma≥ 2/year
Relati ve 
annual
risk may
be related
to FEV1.≥ 2/year
Relati ve 
annual risk 
may be 
related to 
FEV1.≥ 2 e xacerbations
in
6months 
requiring oral 
steroids or >4 
wheez ing 
episo des/1 year 
lasting >1 day 
and risk factor s 
for persist ent 
asthma≥ 2/year
Relati ve 
annual risk 
may be 
related to 
FEV1.≥ 2/year
Relati ve 
annual
risk
may be
related
toFEV1.
Consider severity andintervalsincelastexacerba tion.Frequ ency a ndseveri ty may f luctuate over time forpatients inanyseveri tycategory.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
132
Approved , Date: 14 February 2018Recommended Step for
Initiating TreatmentStep 1 Step 2Step 3 and 
consider sho rt 
course of oral 
steroidsStep 3: 
medium
dose ICS
and 
consider
short 
course of
oral 
steroidsStep 3 and 
consider 
short 
course of
oral 
steroidsStep 3 and 
consider sho rt 
course of oral 
steroidsStep 3: 
medium
dose ICS
ORStep4 
and
consider 
shortcourse
of oral
steroi dsStep 4 or
5 and
consider 
short 
course
oforal
steroi ds
In2-6 w eeks, evaluate level of asthmacontrol that is ac hieved. 0 -4 years: Ifnoclearbenefit is observed in4-6 w eeks, stop treatme nt and consider alternate diagnos is or
adjusting therap y. 5-11 and12+years: adjust therapy accord ingly.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
133
Approved , Date: 14 February 2018Components of 
ControlClassification of Asthma Control
Well Controlled Not Well Controlled Very Poorly Controlled
0-4 yrs 5-11 yrs 12 + yrs 0-4 yrs 5-11 yrs 12 + yrs 0-4 yrs 5-11 yrs 12 + yrs
Symptoms≤ 2 days /week but not more
than once on each day≤ 2 days/
week> 2 days /week or 
multiple times on ≤2 
days/week> 2 days/
weekThroughout the day
Impairme ntNighttime 
awakenings ≤ 1x/month ≤ 2x/month > 1x/month ≥ 2x/month 1-3x/week > 1x/week ≥ 2x/we ek ≥ 4x/we ek
Interference with 
normal activity None Some limitation Extremely limited
SABA use for symptom control 
(not prevention ofEIB)≤2 days/week >2 days/week Several times per day
Lung function
FEV1or peak flow
FEV1/FVCN/A
>80%
>80%>80%N/A
60-80%
75-80%60-80%N/A
<60%
<75%<60%
Validated q uestionnaires
ATAQ
ACQ
ACT0
≤ 0.75
≥ 201-2
≥ 1.5
16-193-4
N/A
≤ 15
RiskExacerbatio ns requiring oral 
system ic cort icosteroids0-1/year ≥2/year
Consider severity and interval since last exacerbation
Reduction in lung growth/ 
Progressive loss of lung 
functionEvaluation requires long-term follow -up
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
134
Approved , Date: 14 February 2018Recommended A ction for
Treatment•Maintain current step
•Regular foll ow-u p every 1 -6 
months
•Consider step down if well 
controlled for at least 3 m onthsStep up 1 
stepStep up at 
least 1 st ep• Step up1 
step
• Reevalua te
in2-6 
weeks
• Forside 
effects, 
consider 
altern ative 
treatment 
options• Consider short
course of oral steroids
• Step up1-2steps• Consider 
short cour se 
oforal 
steroids
• Step up1-
2 steps
• 
Reevaluate 
in2 weeks
• Forside
effects, 
consider 
altern ative 
treatment 
options•Before step u p:
Reviewadherence to
medicat ion,inhaler 
techni que, and 
environmental co ntrol. If 
alternati ve treatment was 
used, disco ntinue it and u se 
prefe rredtreatment for that 
step.
•Reevaluate the levelof 
asthma contr ol in 2-6
weeks to achieve 
control .
0-4 years: Ifno clear be nefit
isobserved in
4-6 weeks, co nsider
alternative diag noses or 
adjusting therapy.
5-11 years: A djust thera py
accordin gly.
•For side effects, 
consi der alternative 
treatment opt ions.•Before step u p:
Reviewadherence to
medicat ion,inhaler 
techni que, and 
environmental co ntrol. If 
alternati ve treatment was 
used, disco ntinue it and 
use prefe rredtreatment for 
that step.
•Reevaluate the level
of asthma contr ol in 
2-6 w eeks to achieve 
control .
0-4 years: Ifno clear 
benef itisobser ved in
4-6 weeks, co nsider
alternative diag noses or 
adjusting therapy.
5-11 years: A djust thera py
accordin gly.
•Forsideeffects, 
consi der alternative 
treatment opt ions.
American Lung Association of Minnesota
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
135
Approved , Date: 14 February 2018Attachment 5 : Antihistamine M edications
The following antihistamines may be used for daratumumab pre -infusion medication (including, 
but not limited to):
Diphenhy dramine
Cetirizine
Fexofenadine
Loratadine
Clemastine
Dexchlorpheniramine
Promethazine*
* The IV use of promethazine should be avoided. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
136
Approved , Date: 14 February 2018Attachment 6: Conversion Table for Glucocorticosteroid Dose
Generic Name Oral or Intravenous
Dose (mg)
Dexamethasone 0.75
Methy lprednisolone 4
Prednisolone 5
Prednisone 5
Betamethasone 0.6
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
137
Approved , Date: 14 February 2018Attachment 7: Body Surface A rea Nomogram
Body surface area should be calculated according to the following formula:
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
138
Approved , Date: 14 February 2018Attachment 8: Reporting, Monitoring, and Evaluating Safety  Events in Japanese 
Subjects in A rmB(Japanese Sites Only )
Enhanced reporting of specific events (as described below) will be required until a minimum of 
3 Japanese subjects in Arm  B have completed Cycle 1 of treatment.  If these spe cific events (as described 
below) occur in Cycle 1 in ≥2subjects from the first 3 treated subjects in Arm  B, an additional 3 subjects 
in Arm B will be monitored (for a total of 6 subjects).  The events (as described below) that occur during 
Cycle 1 of treatment in Japanese subjects in Arm B will be reported to the sponsor by the investigator or 
study personnel within 24 hours of awareness.
Definitions of Adverse Events in Japanese Subjects in Arm B that are Subject to Evaluation 
by External Safety Monitor (ESM)
Any of the following events considered by the investigator to be related to study treatment
(VELCADE, melphalan, prednisone, or daratumumab) :
Infusion -related reactions
 Any Grade 4 infusion -related reactions occurring within 48 hours of the infusion of daratumumab
 Any Grade 3 infusion -related reactions occurring within 48 hours of the infusion of daratumumab 
that do not resolve with a reduced infusion rate or temporarily stopping (maximum 2 hours) the 
infusion, supportive care, and symptomatic therap y such as administration of steroid and 
antihistamine
Non-hematologic toxicity of Grade 3 or higher with the exception of:
 Grade 3 nausea or Grade 3 vomiting that responds to antiemetic treatment
 Grade 3 diarrhea that responds to antidiarrheal treatment
 Grade 3 fatigue or asthenia present at baseline or lasting for less than 7 days after the last 
administration of daratumumab
Hematologic toxicity, defined as:
 Grade 4 thrombocytopenia (platelet count <25,000/mm3) lasting for more than 7 days, or Grade 3 or
4 thrombocytopenia with bleeding
 Grade 4 neutropenia (ANC <500 cells/mm3) lasting for more than 7 days
 Grade 3 febrile neutropenia (ANC <1000 cells/mm3and a single temperature >38.3°C or a sustained 
temperature >38°C for >1 hour), or sepsis
 Grade 4 anemia
These events should follow the same reporting process as serious adverse events (see Section 12.3.2). 
Receipt of a report of a serious adverse event or any of the events listed above during Cycle 1 of treatment 
will, in turn, trigger enhanced reporting and review as described below.
An External Safety Monitor (ESM) who is a hematologist will evaluat e these events in Japan and will 
review the reported safety data and may request additional information from the sites. If the ESM 
identifies a critical safety signal, he/she may, at his/her discretion, suspend enrollment in Japan until 
Independent Data Monitoring Committee (IDMC) review is comp leted . The IDMC chair will be notified 
of the signal and will review the data. After the review is complete, the IDMC chair will communicate the 
final recommendation to the sponsor.
Japanese sites will be notified when the first 3 subje cts in Arm Bhave completed Cycle 1of treatment. 
However, if the above events occur in Cycle 1 in ≥2 subjects from the first 3 treated subjects in Arm B, an 
additional 3 subjects in Arm Bwill be monitored (for a total of 6 subjects) as described above.  After 
enrollment of a minimum of 3 subjects (and up to 6 subjects, as described above) is complete, enhanced 
reporting, monitoring, and evaluation of the above safety events in Japanese subjects will no longer be 
required.  However, serious adverse events and adverse events of special interest must continue to be 
reported to the sites within 24 hours of awareness, as described in Section 12.3.2.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
139
Approved , Date: 14 February 2018Attachment 9: International Staging Sy stem ( ISS) Staging
International Staging System
Stage Criteria Median Survival (months)
I Serum ß2 microglobulin <3. 5 mg/L, serum 
albumin ≥3.5 g/dL62
II Not I or IIIa44
III Serum ß2 microglobulin ≥5.5 mg/L 29
a There are 2 possibilities for Stage II: 
  1) Serum ß2 microglobulin <3.5 mg/ L but serum albumin <3.5 g/dL, or 
  2) Serum ß2 microglobulin 3.5 to < 5.5 mg/L  irrespective of the serum albumin
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
140
Approved , Date: 14 February 2018Attachment 10 : Anticipated A dverse Eve nts
Anticipated Event
An anticipated event is an adverse event (serious or non-serious) that commonly  occurs as a 
consequence of the underly ing disease or condition under investigation (disease related) or 
background regimen.
For the purposes of this study  the following events will be considered anticipated events: 
Anemia
Bleeding
Bone diseases
Hypercalcemia 
Hyperuricemia
Hyperviscosit y syndrome
Infection
Neutropenia
Renal failure or insufficiency
Thrombocy topenia
Reporting of Anticipated Events
All adverse events will be recorded in the CRF regardless of whether considered to be 
anticipated events and will be reported to the sponsor as described in Section 12.3.1 , All Adverse 
Events. Any anticipated event that meets serious adverse event criteria will be reported to the 
sponsor as described in Section 12.3.2 Serious Adverse Events. These anticipated events are 
exempt from expedited reporting as individual single cases to Health Authorities. However ,if 
based on an aggregate review, it is determined that an anticipated event is possibly  related to 
study  drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC ) will be established to perform reviews of 
pre-specified anticipated events at an aggregate level. The ARC is a safet y committee within the 
sponsor’s organization that is independent of the sponsor’s study  team. The ARC will meet to aid 
in the recommendation to the sponsor’s study  team as to whether there is a reasonable possibility  
that an anticipated event is related to the study  drug.
Statistical Analysis
Details of statistical analy sis of anticipated events, including the frequency  of review and 
threshold to trigger an aggregate analysis of anticipated events will be provided in a separate 
Anticipated Events Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protocol 54767414MMY3007 Amendment 5
141
Approved , Date: 14 February 2018INVESTIGA TOR AGREEME NT
I have read this protocol and agree that it contains all necessary details for carrying out this study. I will 
conduct the study as outlined herein and will complete the study within the time designated.
I will provide copies of the protocol and all pertinent information to all individuals responsible to me who 
assist in the conduct of this study. I will discuss this material with them to ensure that they are fully 
informed regarding the study drug, the conduct of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: Date:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: Date:
(Day Month Year)
Sponsor's Responsible Medical Officer:
Nam e (typed or printed): Ming Qi, MD, PhD
Institution: Janssen Research & Development
Signature: electronic signature appended at the end of the protocol Date:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by the investigator to the sponsor, and a protocol amendment will not be required.
[STUDY_ID_REMOVED]
  
SIGNATURES 
    
Signed by  Date  
 Justification  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Ming Qi
15Feb2018, 05:12:59 AM, UTC
Document Approval
[STUDY_ID_REMOVED]